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ABSTRACT
The aetiological agent of pertussis, Bordetella pertussis, is still a major cause of disease 
today and occurs even in countries that have had vaccination programmess implemented 
since about the 1950s. Several countries have reported increasing levels of pertussis in 
recent years and one possible reason for this is that an antigenic shift has occurred in the 
B. pertussis population since the introduction of pertussis whole-cell vaccines. Changes 
have been described in sequence types of two virulence-related genes, encoding 
pertactin (prnA) and pertussis toxin SI subunit (ptxA), amongst B. pertussis from 
several countries and the United Kingdom (UK). B. pertussis population was expanded 
in this study by investigating other virulence-related genes. An already established 
multilocus sequence typing (MLST) scheme (based on a combination of alleles of ptxA, 
pertussis toxin S3 subunit (ptxC) and tracheal colonisation factor (tcfA) genes) was 
applied to the UK B. pertussis population. The same predominating tcfA allele was 
found in all time periods studied, however, there has been a shift in predominating 
sequence types in the UK population relating to ptxC and prnA types. The 
predominating alleles found in recent isolates were not seen in isolates ft'om the pre­
vaccination era or from the era just after the introduction of whole-cell vaccine. New, 
multilocus virulence gene sequence typing (MVGST) schemes are proposed in this 
study. These include the prnA gene and another polymorphic gene encoding fimbrial 
antigen 2 and these schemes are compared to the MLST scheme. Increasing the number 
of gene targets increased the discriminatory power of the typing scheme. All schemes 
identified sequence types in recent B. pertussis isolates that were not found in the pre­
vaccination era or the era just after the introduction of vaccination. However, no 
increased incidence of pertussis has been described for the UK. It is accepted that 
particular sequence types found within the UK B. pertussis population and other B. 
pertussis populations may not be identical, and that there may be unknown genes that 
are affecting pertussis levels within different countries. Other genes were investigated, 
namely those encoding adenylate cyclase toxin, virulence-activated gene 8, bordetella 
resistance to killing protein A, bordetella autotransporter protein C, outer-membrane 
protein Q, but they showed insufficient variation to be useful for inclusion in the 
MVGST schemes.
A novel conductimetry tool was used to develop a rapid procedure for detecting 
adenylate cyclase (AC) enzymic activity fi'om adenylate cyclase toxin (CyaA)
x v ii
preparations and the optimisation of this assay is described. The conductimetry assay 
was found to be useM for determining the phenotypic phase of Bordetella strains as 
CyaA is expressed only in the vkulent (Bvg^ phase. However, the conductimetry assay 
was not sufficiently sensitive for use as a diagnostic tool. Two recent (1999) isolates of 
B. pertussis were found to be different from other isolates due to the presence of a 6 bp 
insertion between cyaA and its accessory gene cyaC. These isolates were screened for 
differences in AC activity by the conductimetry assay and for differences in 
cytotoxicity. No cleai* differences were found between these two isolates and a 
laboratory strain of B. pertussis laboratory strain, BP338 strain, which was considered 
to be a typical strain and representative of the B. pertussis population. Further studies 
should be carried out to determine if this 6 bp insertion has an effect on the phenotype 
of the strains and their virulence.
Novel plasmid constructs were made containing the cyaA promoter region inserted 
upstream of promoterless reporter genes, namely the lux operon and gfp, and these were 
maintained in Escherichia coli. A plate-mating method was used to transfer the lux 
construct from the donor E. coli strain to the recipient B. pertussis BP338 strain but the 
plasmid was not maintained in B. pertussis possibly due to the HinàlW 
restriction/modification system known to be present in this species.
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1.0 Introduction
1.1 DESCRIPTION OF Bordetella spp.
1.1.1 Definition of the genns Bordetella
Bordetella is a member of the family Alcaligenaceae to which Alcaligenes and 
Achromobacter also belong (von Wintzingerode et al, 2001). Comparison of 16S rRNA 
gene sequences has shown that Bordetella forms a distinct cluster separated from 
Alcaligenes and Achromobacter within the p-Proteobacteria. The Bordetella aie Gram- 
negative, catalase positive, asaccharolytie coccobacilli with a G+C content of 60-69 mol %. 
Bacterial growth is aerobic but one species grows anaerobically under conditions favouring 
(respiratory) nitrate and selenate reduction (von Wintzingerode et al, 2001; see below). 
Seven species are isolated from humans and warm-blooded animals while one species is an 
environmental organism (see below).
1.1.2 Members of the genus Bordetella
The genus Bordetella consists of eight species, of which Bordetella pertussis the causative 
agent of whooping cough (pertussis) is the type species. The first description of the 
characteristic symptoms of pertussis was by de Baillou in 1640 who reported an epidemic in 
Paris in 1578 (Gerlach et al, 2001) but the organism was not isolated until 1906 by Bordet 
and Gengou. The organism was originally classified as Haemophilus pertussis due to its 
growth requirement for blood but was found not to need the giowth factors X (liaemin) and 
V (nicotinamide adenine dinucleotide). Moreno-Lopez (1952; cited by Paiton, 2004) later 
reclassified the organism in its own genus, Bordetella.
B. parapertussis was isolated originally from a mild case of human pertussis (Bradford and 
Slavin, 1937, cited by R. Parton) and later fiom lambs showing signs of pneumonia 
(Cullinane et al, 1987). B. bronchiseptica was first isolated from the respiratory tracts of 
dogs by Ferry (1910, cited by Parton, 2004) and is also now known to infect many 
mammals, including humans, although infection in humans is relatively uncommon and 
usually occurs in irnmunocompromised hosts (Woolfrey and Moody, 1991). Some cases of 
humans infected with B. bronchiseptica have been related to contact with infected animals 
(Gueirard et a l, 1995). When B. bronchiseptica causes bacteraemia in humans there is 
evidence of a primary respfratory tract infection, which probably provides access to 
secondaiy haematogenous growth (Cookson et al, 1994).
B. avium is usually isolated from turkey poults and other birds with respiratory disease 
(Kersters et al, 1984). Bordetella hinzii, a species similar to B. avium, can cause secondary 
or opportunistic infections in poultry (Vandamme et al, 1995). Bacteremia caused by B. 
hinzii has been described in an immunocompromised patient without evidence of respir atory 
infection (Cookson ef n/., 1994).
B. holmesii isolates were originally classified as GDC non-oxidiser group 2 but were re­
named when they were found to conform to the description of the family Alcaligenaceae 
and the genus Bordetella (Weyant et al, 1995). The first isolates were from the blood of 
patients that had underlying clinical conditions but, more recently, this species has been 
isolated from the sputum of immunocompromised patients and from nasopharyngeal 
specimens of patients suspected to have pertussis (Tang et al, 1998; Yih et al, 1999). The 
prevalence of B. holmesii carriage in asymptomatic individuals is unknown, therefore it 
cannot be presumed that B. holmesii is the causative agent of respiratory infection in man 
(Yih et al, 1999). The species B. trematum has been isolated from human wound and ear 
infections and these isolates were originally described as atypical Bordetella or as 
unidentified organism (Vandamme et al., 1996).
The recently described B. petrii is distinct from the other seven known members of the 
genus. To date B. petrii is the first member of the genus to be isolated fiom the environment 
and capable of anaerobic growth. It was originally isolated from a mixed dechlorinating 
culture and the organism is able to reduce selenate to its elemental form, selenium (von 
Wintzingerode et al, 2001). B. petrii is suggested to be closely related to an environmental 
progenitor of bordeteHae and fiirther characterisation of this species may provide interesting 
information on the early evolution of members of this genus (Gerlach et al, 2001).
1.2 B. pertussis the organism
B. pertussis is a small (0.2-0.5 qm x 0.5-2 |rm) Gram-negative, aerobic, non-motile, 
bacterium. Growth of B. pertussis was originally achieved in 1906 by Bordet and Gengou 
using a glycerol-potato extract medium without peptone and containing blood. The Bordet- 
Gengou (BG) medium, with minor modifications, is still used today for cultivation of the 
organism. B. pertussis forms tiny (0.5 mm in diameter) convex pearl-like glistening colonies
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when grown on BG medium and each colony is surrounded by a narrow zone of haemolysis. 
After 5-6 days of incubation the diameter of the colonies increase to 2-3 mm (Roberts and 
Parton, 2001). The organism is a strict aerobe with an optimum growth temperature of 35- 
37*^0 , it does not ferment carbohydrates and its energy is primaiily obtained from oxidation 
of amino acids (Roberts and Parton, 2001). B. pertussis has simple nutritional requirements 
and can be cultured in a simple buffered salts medium containing several amino acids, an 
organic sulphur source and several growth factors. The amino acids required for its growth 
are glutamic acid or proline and growth factors are nicotininc acid (an essential vitamin for 
B. pertussis), glutathione and ascorbic acid. Of the Bordetella species, B. pertussis is the 
most fastidious. It is sensitive to unsaturated fatty acids or residual detergents that may be 
found on laboratory glassware. B. pertussis is also known to release these fatty acids into 
the growth medium (Frohlich et al, 1996). Media used for the growth of B. pertussis are 
usually supplemented with substances, such as blood and starch, which can absorb these 
growth inhibitors.
Traditionally, B. pertussis virulence factors have been divided into two groups: adhesins and 
toxins. In addition, the organism produces other factors to cause disease. Figure 1.2.1 
depicts the organism and its virulence factors, which are described in detail in the following 
sections.
1.3 ADHESINS AND AUTOTRANSPORTERS
1.3.1 Filamentous haemagglutinin
Filamentous haemagglutinin (FHA) is expressed by B. pertussis and similar proteins are also 
expressed by B. parapertussis, B. bronchiseptica and B. avium. Filamentous haemagglutinin 
is the major adhesin of B. pertussis, and is synthesised as a 367 kDa protein (Domenighini et 
a l, 1990). The structural gene is fhaB, and the accessory gene fhaC  is required for its 
secretion and activation (Locht et al, 1993).
Makhov et a l (1994) investigated the structure of the B. pertussis FHA molecule by 
combining electron microscopy and circular dichioism spectroscopy with computational 
analyses of its amino acid sequence. The FHA molecule was found to be 50 nm in length 
with a globular head consisting of 2 domains, a 35 nm long shaft, and a small flexible tail.
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Figure 1.2.1. B. pertussis virulence factors. B. pertussis a Gram-negative organism with 
inner and outer membranes (IM and OM). The adhesins are shown in blue and the 
toxins are shown in red. Adapted from Locht et al (2001). The key lists the abbreviated 
virulence factors that will be described in this section.
Key:
Fha -  Filamentous haemagglutinin
Fim -  Fimbriae
TCT -  Tracheal cytotoxin
DNT -  Dermonecrotic toxin
PTX -  Pertussis toxin
CyaA -  Adenylate cyclase toxin
Tcf -  Tracheal colonisation factor
BrkA -  Bordetella resistance to killing protein A
Vag8 -  Virulence-activated gene 8 protein
bvg -  bordetella virulence gene
vrgs - virulence-repressed genes
vags -  virulence-activated genes
Bats -  Bordetella autotransporters
Typel/III/IV- secretion systems
Exb/TonB/FauA/Bfe - Iron uptake systems
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Biosynthesis of FHA is dependent on the outer-membrane associated accessory protein, 
FhaC. Interactions between the FHA precursor and FhaC are highly specific and involve an 
amino-proximal secretion domain on FHA. FhaC is able to form channels thiough which 
FHA is believed to cross the outer membrane in an extended conformation (Locht et al, 
2001). A newly identified autotransporter, SphBl (see section 1.7), was found to 
proteolyticaUy process the FHA precursor to release the N-terminal 220kDa ‘mature’ 
protein as it reaches the cell surface (Coutte et al, 2001). Haemagglutinating and adherence 
activities have been associated almost exclusively with this 220kDa species (Domenighim et 
al, 1990).
FHA has multiple binding activities; there are at least two separate sites involved in separate 
adhesion reactions, the Ai’ginine-Glycine-Aspai’tic acid (RGD) motif and the 
haemagglutination site, which are located at opposite ends of the molecule. FHA binds 
specifically to sulphated glycolipids but not to gangliosides or other neutral glycolipids, 
suggesting that epithelial cell surface sulphated glycolipids fiinction as receptors for FHA. 
The molecule may utilise sulphated glycohpids and proteoglycans commonly found on the 
surface of human cells and tissues to initiate infection. The specificity that FHA has for 
binding to these molecules is responsible for its haemagglutinating activity (Hannah et al, 
1994). Interaction of its RGD sequence with CR3 integrins triggers invasion of cells without 
generating an oxidative buist, allowing survival of B. pertussis vyithin the macrophage 
(Locht et al, 1993). Both FHA and fimbriae are involved in the adhesion of B. pertussis to 
laryngeal epithelial cells but only FHA is involved in the adherence to bronchial epithelial 
cells (van den Berg, 1999). FHA has the ability to mediate the attachment o f B. pertussis to 
neutrophils but does not block phagocytosis (Weingart and Weiss, 2000).
FHA is probably involved in the first steps of B. pertussis pathogenesis as the fha  genes are 
activated together with bvg genes (see section 1.6). Within a few minutes following 
environmental changes that allow vii’ulence expression, BvgA activates its own expression 
and the expression of the fha  genes. The fhaC  gene is co-transcribed with the fimbriae 
accessory genes in a common polycistronic operon (Locht et al, 1993). This suggests that 
the B. pertussis fimbriae, along with FHA, may act during the initial steps of infection. It 
was demonstrated using a B. bronchiseptica fhaB  deletion strain in a rat respiratory model
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that FHA is absolutely required for the colonisation of the trachea (Cotter et al, 1998). In 
order for bacteria to resist the clearing action of the mucociliary escalator, efficient 
adherence to ciliated tracheal epithelial cells is required, and FHA may provide this. Tins 
molecule was not required for establishment of tracheal colonisation in anaesthetised animals 
in which the mucociliary clearance and lower airway protection were compromised. FHA 
has been demonstrated to provide protection against B. pertussis infection. Mice that were 
immunised with FHA by intraperitoneal or intramuscular inoculation, then challenged with 
an aerosol of B, pertussis, had significantly reduced bacterial colonisation in the lungs and 
trachea (Kimura et al, 1990). FHA is currently included in multicomponent acellular 
pertussis vaccines.
1.3.2 Fimbriae
Bordetella species express fimbriae of at least four serotypes, Fim2, Fim3, FimX and FimA. 
In B. pertussis and B. bronchiseptica the locus that is required for secretion and assembly of 
fimbriae {fimB,fimC and fimD) is located between fhaB  and fhaC  (Mattoo et al, 2000). B. 
pertussis fimbriae are composed of a major subunit, either Fim2 or Fim3, and a minor 
subunit FimD (Geuijen et al, 1997). Expression of fim2 and fim3 genes are positively 
regulated by the bvg locus and by phase variation (this operates at the level of individual fim  
genes). Phase variation is characterised by switching between a high and a low level of 
expression of a particular fim  gene. A region located 100 bp upstream of the fim3 gene is 
involved in this regulation (Willems et al, 1990) where a stretch of Cytosines (Cs) upstream 
of the putative -10 box on the fim  promoter would be subject to slip-strand mispairing 
during chromosome replication. Analysis of the fim3 genes in the + or - phases have 
revealed that insertions and deletions of 1-5 bp in this stretch of Cs are responsible for 
fimbrial phase variation (Willems et al, 1990) but this differs for fiimX due to the stretch of 
Cs being shorter suggesting that a deletion had occurred. The fim3 promoter region was 
found to be conserved in the other B. pertussis fimbrial genes fim2 and the silent gene fimX. 
The B. pertussis fimbrial operon also contains a pseudogene, at its 5' end (Boschwitz 
et al, 1997). This gene is expressed by B. bronchiseptica in a ^vg^-regulated manner. It was 
suggested that fim3, fim2 and fim X  were derived fiom an ancestor of fimA that was 
duplicated to positions outside the fim  operon. The differences in host range between B, 
pertussis and B. bronchiseptica may be due to differences in fimA expression.
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The major fimbrial subunit of B. pertussis is able to bind to the sulphated 
glycosaminoglycans: heparan sulphate, chondroitin sulphate and dextran sulphate. Mutations 
in fim ov fha  genes decreased binding of B. pertussis to heparan sulphate (Geuijen et al,
1996). Proteins that are able to bind to heparin (this molecule is a polysaccharide structurally 
similar to heparan sulphate) contain local accumulations of positively-charged amino acid 
residues bounded by negatively-charged amino acid residues. Two such regions, HI and H2, 
important for bmding to heparin, have been found in Fim2 and there were regions outside of 
HI and H2 that may also be important for binding to sulphated sugars (Geuijen et al, 1998). 
Major heparin-binding sites identified in Fim2 are part of the epitopes recognised by human 
antibodies, suggesting that the heparin-binding regions are exposed at the fimbrial surface 
and are immunodominant (Geuijen et al, 1998). Comparison of the heparin-binding regions 
of Fim2 with Fim3 sequence showed that homologous regions were present. Since B. 
pertussis fimbriae show weak serological cross-reactivity, the differences in primary 
structure in the heparin-binding regions of Fim2 and Fim3 may affect antibody binding but 
not heparin binding, allowing the bacteria to evade antibody mediated host defences by 
switching fimbrial gene expression.
Immunoelectron microscopy has located the minor subunit, FimD, at the fimbrial tip 
(Geuijen et al, 1997). B. pertussis FimD interacts with the integrin very late antigen-5 
(VLA-5) on monocytes, which activates CR3 resulting in enhanced binding of B. pertussis 
to the CR3 receptor via FHA (Hazenbos et al, 1995). Similar to the major fimbrial subunits, 
FimD also binds to the sulphated sugar heparin.
The role of fimbriae in the pathogenesis of Bordetella spp. has been investigated using 
mutant strains. A B. bronchiseptica mutant that was unable to express fimbriae was 
defective in its ability for efficient establishment and persistent colonisation of the rat trachea 
(Mattoo et al, 2000). The role of FimD in the colonisation of the mouse respiratory tract 
was studied using fimbrial and FHA mutants of B, pertussis (Geuijen et al, 1997). Mice 
were infected intranasally with the wild type strain or one of the mutant strains. Compared 
to the FHA and FimD"^  mutants (the major subunits were not expressed, only the minor 
subunit was expressed), the FimD" mutant (which did not express major or minor subunits) 
showed the lowest level of colonisation with the most pronounced defect in the mouse
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trachea. However, the FimD" mutant was found to produce 75% less FHA than the wild- 
type and this may have been partly responsible for the difference in colonisation behavioui'. 
The FFIA mutant was far less affected in its colonisation ability than FimD mutant so it was 
assumed that colonisation defects were due to the lack of the minor subunit (Geuijen et al,
1997). B. pertussis fimbriae were found to confer a high level of protection against challenge 
with B. pertussis, demonstrated by a reduction in colonisation by the bacteria in the mouse 
nasopharynx, trachea and lungs following vaccination with a preparation containing both 
fimbriae (Willems et al, 1998).
1.3.3 Autotransporters
A number of B. pertussis vkulence factors are classified as autotransporter proteins and use 
the type V secretion system (Henderson and Nataro, 2001). This secretion system depends 
on the protein moiety that mediates export through the outer membrane being contained 
within the precursor of the secreted protein itself. There are three distinct domains for the 
majority of autotransporters, an amino-terrninal leader peptide, the surface-localised mature 
protein (passenger domain) and a carboxy-terminal domain (P domain) that mediates 
secretion through the outer membrane (Henderson et al, 1998). It is believed that these 
three domains confer all the requirements for transport tluough the inner and outer 
membranes. From the whole-genome sequences of B. pertussis, B. parapertussis and B. 
bronchiseptica, many other putative autotransporters have now been identified amongst 
these Bordetella. To date, genes with potential to encode 21 of these proteins (Pai'kliill et 
al, 2003) are known. B. bronchiseptica encodes the greatest number of autotrasnsporters. 
The other two species, B. pertussis and B. parapertussis, have fewer autotransporter genes 
and more autotransporter pseudogenes (non-functional) than B. bronchiseptica. The 
autotransporters that have been best clmacterised (pertactin, tracheal colonisation factor, 
virulence-activated gene 8, bordetella resistance to killing protein A) and one that is of 
particular interest to this study (bordetella autotransporter protein C) are described below 
and shpwn Fig. 1.3.3.1.
Figure 1.3.3.1: Schematic diagram showing similarities between the autotransporter 
proteins, pertactin (Pm), tracheal colonisation factor (Tcf), bordetella resistance to killing 
protein A (BrkA), virulence-activated gene 8 (Vag8) and bordetella autotransporter protein 
C (BapC). Numbering relates to the amino acid position and Arginine-Glycine-Aspartatic 
Acid (RGD) sites are indicated. Pertactin is also shown with its immunodominant region 1 
(GGXXP)x and immunodominant region 2 (PQP)%.
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1.3.3.1 Pertactin
Pertactin (Prn) was demonstrated to be capable of functioning as an adhesin for mammalian 
cells such as Chinese hamster ovary (CHO) cells and this attachment involved the 
participation of an RGD-containing sequence within this molecule (Leininger et al., 1991). 
The name pertactin was proposed for this protein due to its function, [per (pertussis) and 
taetin (‘tactus’ to touch)] (Leininger et al, 1991). A Prn mutant of B. pertussis adhered 30- 
40% less well than the wild-type strain to CHO and HeLa cells. This decrease in adherence 
rather than complete inhibition supports the role of other factors such as FHA and fimbriae 
involved in B. pertussis adherence to these cells. The gene, prnA, which encodes Prn is 
controlled by the bvg locus (Charles et al, 1989). The 93 kDa protein precursor of B. 
pertussis is cleaved at the carboxy terminus to generate a mature protein of 69 kDa, known 
as the passenger domain (Charles et al, 1994). The site where cleavage is proposed to occui* 
is at Aspartatic acid (D) 631 (Passerini de Rossi et al, 1999). The processed mature 
passenger domain remains noncovalently associated with the 30 kDa carboxy-terminal 
domain (P domain) (Henderson and Nataro, 2001). Pertactin is also expressed by B. 
parapertussis and B. bronchiseptica and a similai* cleavage event also occurs to generate 
mature passenger proteins of 68 kDa and 70 kDa, respectively (Charles et al, 1994).
Pertactin contains two repeat regions, region 1 Glycine-Glycine-X-X-Proline (GGXXP)x at 
positions 939-1014 and region 2 P-Glutamine-P (PQP)x at positions 1878-1943 (Fig. 
1.3.3.1; Charles et a l, 1989). These repeat regions of Prn have been shown to be 
immunodominant as demonstrated by monoclonal antibody mapping. Charles et al, (1991) 
identified that region 2 was more immunogenic than region 1 and a B cell epitope, 
recognised by mice and humans, was identified within region 1. Investigation of prnA 
sequence variation between B. pertussis, B. parapertussis and B. bronchiseptica determined 
that sequence variation was mainly found in region 2 (Boursaux-Eude and Guiso, 2000). 
This is consistent with the fact that there is a lack of cross-protection between the Prn 
molecules of these thi ee species.
Pertactin is the only Bordetella autotransporter for which the crystal structure has been 
determined (Emsley et al, 1996). The mature protein comprises a 16-stranded parallel P 
helix with a V-shaped cross-section. Several loops Jfrom the helix protrude, each containing
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sequence motifs associated with the biological activity of the protein. One of the loops is 
formed from the GGXXP repeats (immunodominant region 1). Pertactin was shown to be 
protective when adult female BALB/c mice were immunised intranasally with B. pertussis 
Prn and then challenged by aerosol exposure to B. pertussis. The mice that had been 
immunised with this antigen were greatly enhanced in then ability to clear B. pertussis from 
their lungs (Roberts et al, 1993). Pertactin is included in some of the multicomponent 
acellular vaccines that are currently in use (van Loo et al, 2002). Several authors have 
described sequence variation between the immunodominant region 1 of Prn molecules 
expressed by circulating B. pertussis isolates and this is reported in section 1.13.2. In an 
intranasal challenge of mice with B. pertussis, a Dutch whole-cell vaccine preparation of a 
strain expressing prnA{V) afforded less protection against B. pertussis strains expressing 
prnA(2) o rprnA{3) than against a strain expressingprnA(l) (King et al, 2001).
1.3.3.2 Tracheal colonisation factor
Transposon phoA insertions were used to identify virulence-activated genes (yags) of B. 
pertussis strains. One such strain, SK34, contained a gene interrupted by the transposon that 
was designated vag-34. This gene was characterised and renamed tracheal colonisation 
factor (tcfA) (Finn and Stevens, 1995). In mouse studies, a tcfA mutant strain SK34 was 
significantly less able to colonise and persist in the tracheas when compared to B. pertussis 
strain 18323\ However, the number of bacteria isolated from the lungs of mice infected 
with SK34 and 18323^ did not differ significantly (Finn and Stevens, 1995). The mutant 
strain SK34, was defective in producing four outer-membrane proteins. Three of these (92 
kDa, 90 kDa and 60 kDa) were only visible on immunoblots and the fourth (30 kDa) was 
visible on SDS-PAGE. In vitro translation and transcription data revealed that TcfA 
migrates as two bands of approximately 90 kDa. However, from its derived amino acid 
sequence a mass of 68 kDa is predicted. The 68 kDa form of TcfA contains 10% proline 
residues and it is known from previous Prn studies that the presence of proline residues 
affect migration of the protein in SDS-PAGE. Therefore, the four proteins found correspond 
to the precursor forms (92 and 90 kDa), mature protein (60 kDa) and the C-terminal |3 
domain (30 kDa). After cleavage of its signal sequence, the resulting 64kDa mature protein 
is translocated across through the outer membrane via its C-terminal tail. Proteolytic 
cleavage occurs at D393 releasing the 34 kDa passenger domain from the 30 kDa p domain,
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which would then remain embedded in the outer membrane (Fig. 1.3.3,1; Finn and Stevens, 
1995; Passerini de Rossi et al, 1999). The 34 kDa passenger domain contains an RGD motif 
implicated in integrin binding (Fig. 1.3.3.1; Henderson and Nataro, 2001). Unlike Prn the 
majority of the N-terminal domain is released from the B. pertussis surface although culture 
supernates of B. pertussis were found to contain only the 60 kDa mature form, indicating 
that outer-membrane associated and secreted versions of passenger domain exist (Finn and 
Stevens, 1995). Western blotting showed that Tcf was not present in B. parapertussis or B. 
bronchiseptica and these results agree with the sequencing of the Bordetella genomes, 
which revealed that tcfA is not present in B. parapertussis and is present only as a 
pseudogene in B. bronchiseptica (Parkhill et al, 2003). Tracheal colonisation factor has 
been shown to exhibit protective activity. Mice that were immunised with attenuated Vibrio 
cholerae, used as a live oral vaccine, expressing B. pertussis Tcf showed protection against 
B, pertussis infection of the trachea, with approximately 10-fold reduction in colonisation by 
the bacteria but not of the lungs (Chen et al, 1998).
1.3.3.3 Bordetella resistance to killing protein A
B. pertussis mutants were generated using insertion Tii5 lac to interrupt genes and those 
that were not deficient in expressing any of the previously characterised vags were further 
investigated. One such B. pertussis mutant strain, BPM2041, possessed all the known vags 
but was 10 times less virulent in mice, suggesting that a previously unidentified virulence 
factor gene had been interrupted (Fernandez and Weiss, 1994). BPM2041 was more 
suseeptible to killing than BP338, the parent strain, by normal human serum via the classical 
complement pathway, and this Tn5-interrupted locus was called brk (bordetella resistance to 
killing). The brk locus was found to contain two divergently transcribed open reading 
frames, labelled brkA and brkB (Fernandez and Weiss, 1994). It was demonstrated that it is 
BrkA that primarily mediates serum resistance. A B. pertussis BrkA deletion mutant strain 
behaved identically to BPM2041 as did another strain that had most of brkA and brkB 
deleted. The BrkB mutant strain was not statistically significantly reduced in its capacity to 
survive in human serum (Fernandez and Weiss, 1998). B. pertussis mutant strains that were 
deficient in expressing other virulence factors such as FHA, dermonecrotic toxin (DNT), 
pertussis toxin (PT), adenylate cyclase toxin (CyaA), Tcf and virulence-activated gene 8
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(Vag8), were unaffected, indicating that they played a negligible role, in serum resistance 
(Fernandez and Weiss, 1998).
Bordetella resistance to killing protein A has a predicted molecular mass of 103 kDa and 
BrkB has a molecular mass of 32 kDa, (Fernandez and Weiss, 1994). There is a 42 amino 
acid signal sequence that is required for BrkA to traverse the inner membrane (Fig. 1.3.3.1; 
Oliver et al, 2003a). Bordetella resistance to killing protein A is cleaved at D731 during 
secretion to yield a 73 kDa N-terminal passenger domain and a 30 kDa C-terminal P domain 
(Passerini de Rossi et al, 1999). The BrkA junction, situated between residues Glycine (G) 
601 to Alanine (A) 692, confers stability to the BrkA passenger domain. Deletion of this 
junction renders BrkA susceptible to degradation by outer membrane proteases and the 
junction also appeared to be important for folding of the passenger domain (Oliver et al, 
2003b). Sequence conservation of this junction is found in many autotransporters, although 
the conserved domain is not found in Tcf. The minimum translocation unit necessary to 
mediate the secretion of the BrkA passenger domain to the bacterial surface is the 42 amino 
acid signal peptide, and a 30-39 amino acid region preceding the p domain, together with the 
p domain (Oliver et al, 2003a). It was previously suggested that BrkB may aid in the 
secretion of BrkA, but BrkA appears to be present in its processed form in BrkB mutant 
strains (Fernandez and Weiss, 1994). The other suggestion for the function of BrkB is that it 
serves to counteract the damage caused by complement attack.
Database seaiching for homologues of BrkA and BrkB revealed that the best match for 
BrkA was Prn and the best match for BrkB was a protein encoded by an E. coli open 
reading frame of unknown function (Fernandez and Weiss, 1994). Most striking similarity 
between BrkA and Prn was found at their C-terminal ends where they are 54.5% identical 
over the last 300 amino acids and share a C-terminal outer membrane localisation motif The 
proteolytic processing sites are conserved and BrkA also has two RQD-motifs although the 
spacing of the two RGD sequences is not shared between the two proteins (Fig. 1.3.3.1). 
Positioning and alignment of the first RGD is similar between the two proteins whereas the 
positioning and alignment of the second RGD sequence is not (Fernandez and Weiss, 1994). 
The brk locus is present in B. parapertussis and B. bronchiseptica, although brkA is 
considered to be a pseudogene in both species (Parkhill et al, 2003). The B. pertussis type
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strain, 18323^, was found to be more serum sensitive than BP338 and, when an extra copy 
of the brk locus was added to a B. pertussis isolate, there was an increase of 2-5 fold in 
serum resistance. A B. holmesii strain, which was isolated from a septicaemic patient, was 
reported to exhibit serum resistance equivalent to that of B. pertussis BP338 (Fernandez and 
Weiss, 1998). To date, it is not known whether or not B. holmesii possesses BrkA (Gerlach 
et a l, 2001). The advantage given to B. pertussis expressing BrkA may be that resistance to 
killing by the antibody-dependent pathway of complement enables the organism to colonise 
previously infected or vaccinated individuals (Fernandez and Weiss, 1998).
1.3.3.4 Virulence-activated gene 8
Like T c f\ and BrkA, virulence-activated gene 8 (Vag8) is the product of a gene positively- 
controlled by the bvg locus, and was initially discovered by transposon TxyphoA mutagenesis. 
A 95kDa protein, Vag8, was identified to be the fourth member of the autotransporter 
family (Finn and Amsbaugh, 1998). A B. pertussis mutant strain, SK8, defective for Vag8, 
was significantly less able to colonise and persist in the lungs and tracheas of mice when 
compared to B. pertussis strain 18323^ (Finn and Amsbaugh, 1998). This protein showed 
greatest homology with the C-terminal ends of Pm, BrkA, and Tcf, with amino acid identity 
of their transport domains ranging from 33-44%. Virulence-activated gene 8 also contains 
an RGD motif (Fig. 1.3.3.1). The N-terminus of this polypeptide possesses a predicted 37 
amino acid signal sequence and the cleavage of this would generate a mature protein of 91 
kDa (Finn and Amsbaugh, 1998). However, with Vag8, this cleavage event may not occur 
as the predicted size corresponds to that of the size of the band visualised on SDS-PAGE 
(Finn and Amsbaugh 1998). Virulence-activated gene 8 had been detected in whole-cell 
lysates of B. bronchiseptica but not those of B. parapertussis, although the complete gene is 
present in the B. parapertussis genome (Parkhill et a l, 2003). Higher expression of Vag8 
was detected in B. pertussis compared to B. bronchiseptica.
Virulence-activated gene 8 appears to be involved in the type III secretion system in B. 
bronchiseptica. Genes encoding components of the type III secretion system and its 
potential translocated proteins have been identified in B. bronchiseptica, ovine B. 
parapertussis, human B. parapertussis and B. pertussis. Previously this secretion system 
appeared to only be expressed in B. bronchiseptica and ovine B. parapertussis strains (Yuk
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et al, 1998; 2000), but it is now thought to be also expressed by B. pertussis and human B. 
parapertussis isolates (Hennuy et al, 2002). B. bronchiseptica contains a ôvg-regulated 
extracytoplasmic sigma factor (ECF), TrS, which controls the expression of virulence 
factors including the type III secretion system. Virulence-activated gene 8 was identified to 
be also regulated by TrS and analysis of the vag8 promoter region revealed the presence of 
three putative sites where ECFs might bind. Western blot analysis of culture supernate from 
a B. bronchiseptica Vag8-deficient strain showed that type III effector proteins were not 
secreted, indicating that vag8 was required for type III secretion (Foreman-Wykert et al, 
2002).
1.3.3.5 Bordetella autotransporter protein C
Bordetella autotransporter protein C (BapC) is a newly identified member of the 
autotransporter family. The B. pertussis bapC gene sequence was originally submitted to 
GenBank as a putative autotransporter protein gene (accession number AF081494) named 
bap5 (Blackburn, 2000) and later submitted independently as bapC (AJ277634). The 
potential role of bapC was identified using a B. pertussis bapC mutant in in vitro and in vivo 
studies. The mutant strain was less able to colonise the respiratory tract in a mouse model 
when compared to the parent strain and was more susceptible to complement-mediated 
killing in vitro than the parent strain (Bokhari, 2002). Bordetella autotransporter protein C 
has properties in common with the other members of the autotransporter family, particularly 
BrkA (Blackburn, 2000; Bokhari, 2002). Bordetella autotransporter protein C is predicted 
to be 79.5 kDa. No N-terminal signal sequence was detected but the C-terminal domain is 
characteristic of the autotransporter protein family (Fig. 1.3.3.1; Blackburn, 2000). Removal 
of this domain would yield a matme passenger protein of 49 kDa and the predicted protein 
sequence also has an RGD motif (Fig. 1.3.3.1). Bordetella autotransporter protein C was 
found to be regulated by the bvg locus (Bokhari, 2002) and is predicted to be also encoded 
by B. parapertussis and B. bronchiseptica (Fai'khill et al, 2003). To date there is no 
information on the protective abilities of BapC.
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1.4 TOXINS
1.4.1 Adenylate cyclase toxin
The gene cyaA, controlled by the regulatory locus bvg, encodes adenylate cyclase toxin 
(CyaA) comprised of 1706 amino acids. The cya operon is composed of cyaA and three 
accessory genes cyaB, D and E, that are located downstream and are necessary for the 
secretion of CygiA (Goyard and Ullmann, 1991), The product of the cyaC gene is required to 
activate the CyaA protoxin to enable it to cariy out its biological activities. Adenylate 
cyclase toxin, originally described by Hewlett et al. (1976), is one of the major viiulence 
factors secreted by B. pertussis and is also expressed by B. parapertussis and B. 
bronchiseptica. It is a bitunctional protein with cytotoxic and haemolytic activities (Ladant 
and UUmann, 1999). Adenylate cyclase toxin is constructed in a modular fashion with its 
enzymic (AC) domain located witliin the first 400 residues with the haemolytic domain 
taking up the 1306 residues at the C-terminal end (Fig. 1.4.1.1).
The enzymic and haemolytic fimctions are able to act independently of one another. Khelef 
et al, (1992) showed that B. pertussis mutants without the AC enzymic activity retained full 
haemolytic activity. Adenylate cyclase toxin exhibits three important characteristics. Firstly, 
it is an important virulence factor. A B. pertussis CyaA mutant, ËP348, was unable to cause 
lethal infection in an infant mouse model at a dose that was 10,000 times greater than the 
wild type LD50 (Weiss et al, 1984). Secondly, AC enzymic activity of CyaA is activated up 
to 1000 fold by the eukaryotic protein calmodulin (CaM), in a dose dependent manner 
(Wolff et al, 1980). Lastly, CyaA delivers its AC domain to the eukaryotic cell cytosol 
where high levels of cAMP, a known inhibitor of phagocyte function, are produced firom the 
substrate ATP which paralyses the target cell and may defend B. pertussis against 
phagocytic attack (Confer and Eaton, 1982).
Within the AC domain there aie two subdomains designated T25 and T18 (Fig. 1.4.1.1). 
The T25 domain, residues 1-224, contains the catalytic site where ATP is bound and boxes 1 
and 11 are the regions that have been shown by mutation studies to be involved in catalysis. 
T18 lies between residues 225-299 and this subdomain contains the calmodulin binding site 
and box III, a site that is also involved in catalysis (Mock and UUmann, 1993). The regions 
involved in catalysis were located initiaUy by comparing the catalytic domain of B. pertussis
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Figure 1.4.1.1: Schematic diagram o f Bordetella pertussis adenylate cyclase toxin (CyaA). 
Numbering represents the amino acid residues. The enzymic (AC) domain, residues 1-400, 
is depicted with two subdomains (T25 and T18). Boxes I-III are regions that are involved in 
catalysis and CBS denotes the calmodulin-binding site. The C-terminus (400-1706) is 
depicted here with hydrophobic segments, modification site (palmitoylation of lysine 983) 
and calcium binding sites in the repeated region. Adapted from Ladant and UUmann 
(1999).
o
CyaA and the central part of the Bacillus anthracis adenylate cyclase, which revealed a high 
degree of homology (Glaser et al., 1991).
Lysine (L) 58 and L65 are critical residues for the expression of enzymic activity. Other 
critical residues are Aspartatic acid (D) 188, D190, Histidine (H) 298 and Glycine (G) 301. 
When these residues were altered, the ability of CyaA to bind to ATP analogues was 
diminished (Glaser et aL, 1991). Situated between T25 and T18 is an epitope insertion site 
where it is possible to insert exogenous peptides without compromising the function of 
CyaA (Ladant et aL, 1992).
The C-terminal domain, residues 400-1706 (Fig. 1.4.1.1), has several features that aid in its 
ability to mediate the binding and internalisation of the toxin into eukaryotic tar get cells. 
There is a pore-forming region with four hydrophobic segments situated between residues 
500-700 (Fig. 1.4.1.1) (Ladant and UUmann, 1999). An amphipathic and potentiaUy a- 
heUcal segment of CyaA that includes glutamate residues 509 and 516 is important for AC 
translocation across the target ceU membrane and this segment modulates the formation of 
CyaA channel membranes and their cation selectivity (Osickova et al, 1999). The 
haemolytic domain also displays structural chai’acteristics that link CyaA to the bacterial 
Repeats in ToXin (RTX) famUy (Coote, 1996). These toxins are characterised by a series of 
tandem repeats that are rich in G and D residues. This repeated motif domain is made up of 
42 copies of the sequence GGXGXGXDXLX. As with many other RTX toxins, the 
haemolytic activity of CyaA, although weak, is attributed to its abUity to form cation- 
selective channels in ceU membranes. This repeat region is also the main calcium-binding site 
of the protein. RTX toxins are post-translationally activated by a modification that is 
mediated by an accessory protein (Ludwig and Goebel, 1999). Palmitoylation of CyaA 
occurs at L983 (Fig. 1.4.1.1) mediated by the accessory protein CyaC. Tins modification is 
required for the toxic and haemolytic properties of CyaA (Hackett et al, 1994) as weU its 
protective properties (Betsou et al, 1993). C-terminal modification and the repeat portion 
(last 800 amino acid residues) of CyaA are crucial for the immunoprotective activity of the 
entire molecule (Betsou et al, 1995a).
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Entry of the AC domain into the target cell is rapid and proceeds without a lag phase. This 
suggested that it occurs by direct penetration of the plasma membrane (Ladant and UUmann, 
1999). CycUc AMP generation paraUels intraceUular AC accumulation, therefore the 
activation of the bacterial enzyme must be rapid, occurring coincidently with the entry of the 
AC domain (Friedman et al, 1987). Protein-protein interactions between CyaA molecules, 
which have been indicated to be involved in haemolysis, appear to be also involved in the 
intemaUsation of the AC domain (Iwaki et al, 2000). High-afBnity calmoduUn binding is not 
required for the efficient delivery of the AC domain of CyaA into target cells (Heveker and 
Ladant 1997). Intoxication is thought to be a two-step process. Firstly CyaA binds to the 
ceU surface, which requires the integrity of the carboxy-terminal moiety of the protein and 
palmitoylation of L983. The second step is the actual translocation of the AC domain of the 
bound CyaA through the plasma membrane of the ceU and this step is temperature- 
dependent (Ladant and UUmann, 1999). A stretch of 15 amino acids located at the C- 
terminus of CyaA appears to be necessary for toxin insertion into target ceU membranes. 
This stretch of amino acids is distinct from the C-terminal signal sequence required for the 
secretion of CyaA toxins via the ABC secretion system (Bejerano et al, 1999). The 
cytotoxic activity of CyaA is calcium-dependent and the translocation process occurs only at 
concentrations greater than 0.1 mM (Rose et al, 1995). Calcium-binding properties of 
CyaA have been analysed and it has been shown that there are probably two classes of 
binding sites that have different affinities. The first class may consist of 3-5 high-affinity 
calcium-binding sites, and the second class consists of about 45 low-afiBnity calcium-binding 
sites (Rose et al, 1995). Calcium-binding to the high affinity sites appeared to be critical for 
membrane-binding capabiUty and haemolytic activity of the toxin. Binding to the low-afSnity 
sites may be involved in the cytotoxic activity of CyaA (Rose et al, 1995) and has been 
demonstrated to induce a steep increase in the channel-forming activity of CyaA (Knapp et 
al, 2003).
Comparisons between CyaA and EF (oedema factor from Bacillus anthracis) have been 
made regarding their activation by CaM. CyaA has 100-fold higher affinity for CaM than EF 
(Shen et al, 2002). Oedema factor and CyaA have about 3 orders of magnitude higher AC 
activity than the AC activity of host cells, therefore entry of EF and CyaA should raise 
cAMP concentrations of host cells to levels that disrupt ceUular function. The affinity of EF
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for CaM is low at resting calcium concentrations in target cells so that EF may be minimally 
activated. Oedema factor becomes tightly associated with CaM and is hilly active only when 
intracellular calcium is elevated from 20-50 nM to 1 pM (Shen et al, 2002). Adenylate 
cyclase toxin has a 100-fold higher affinity for CaM than EF and CyaA is optimally activated 
at resting calcium concentrations. Oedema factor activity may be regulated by the 
intracellular calcium concentration while CyaA is fuUy active regardless of the intracellular 
calcium concentration of its host cell (Shen et al, 2002).
The role that CyaA may have in the pathogenicity of B. pertussis has been investigated. 
Adenylate cyclase toxin may be involved in B. pertussis-mdvLccd lung inflammation and in 
apoptotic death of alveolar* macrophages. The resulting apoptosis may play a role in the 
initiation of infection (Gueirard et al, 1998). Further studies have been carried out 
investigating B. pertussis induced apoptosis of macrophages mediated by the organism. It 
was determined that both domains of CyaA, AC and haemolysin, were necessary to induce 
macrophage apoptosis as a mutated protein containing only the haemolysin domain was 
unable to induce apoptosis (Bachelet et aL, 2002). Monocytes infected with wild-type B. 
pertussis in vitro have higher levels of cAMP and release lower amounts of TNF (enhance 
anti-microbial immune defences, mediate apoptosis and modulate Hsp70 expression), O2' 
(acts as defence mechanism against pathogens) and FIsp70 (induction of Hsp70 during 
phagocytosis may trigger protective fimctions) compared to monocytes infected with a B. 
pertussis CyaA mutant (Njamkepo et aL, 2000). This relationsliip that occurs between CyaA 
expression and various host cell activation/adaptive pathways during B. pertussis monocyte 
interaction demonstrates how B. pertussis may subdue host cells during infection (Njamkepo 
et aL, 2000). Through the action of CyaA, a decrease in intracellular ATP secondary to a 
rise in cAMP contributed to the mitochondrial dysfunction that determines that apoptotic 
fate of macrophages (Bachelet et aL, 2002). There is a correlation between the ability of 
CyaA to induce macrophage death and the internalisation of the protein thiough a vesicular 
pathway that requires actin polymerisation. Once successfully transported, CyaA 
accumulates in intracellular vesicles in macrophages leading to apoptosis (Khelef et aL, 
2001). Harvill et al (1999) compared wild-type and cyaA deletion strains of B. 
bronchiseptica in immunocompetent and immunocompromised mice. It was found that 
CyaA targets one or more aspects of the innate immune response, one of which is probably
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neutrophils. This was further investigated and it was demonstrated that CyaA inhibits both 
Fc receptor-mediated attachment and phagocytosis of B. pertussis by neutrophils (Weingart 
et al, 2000). Adenylate cyclase toxin binds specifically to eukaryotic target cells via awPz 
integrin (CDllb/CD18) and this interaction is required for several activities including the 
intracellular delivery of the AC domain into leukocytes, cAMP production and CyaA- 
induced cell death (Guermonprez et al, 2001). Zaretzky et al. (2002) state that there are 
studies being carried out investigating CyaA delivery fi*om B. pertussis to target cells. It has 
been noted that FFIA B. pertussis mutants secrete much more CyaA into the culture 
supernate than wild-type B. pertussis strains and the presence or absence of FHA was the 
only known viiulence determinant (compared to Prn, endotoxin and pertussis toxin) that was 
associated with the release of CyaA (Zaretzky et al, 2002). From purification studies it was 
also demonstrated that there is a direct physical interaction between CyaA and FHA. This 
interaction of CyaA and FHA may help to increase the local concentration of ÇyaA on the 
outer membrane of B. pertussis and adherence to host cells mediated by FHA may be 
coupled to dehvery of CyaA to target host cell (Zaretzky et al, 2002).
Purified active CyaA exhibited protective activity in mice against intranasal challenge with B. 
pertussis 18323^ and the protective efficacy was similar to the protective efficacy of whole­
cell pertussis vaccine (Guiso et al, 1991; Hormozi et al, 1999). The CyaA molecule has 
been investigated for its potential inclusion in future generations of acellular pertussis 
vaccines (MacDonald-Fyall, 2002). It was reported that when mice were immunised with 
CyaA alone a strong IgG response was produced and this was boosted by a second vaccine. 
Also, when CyaA was combined with a protective antigen mixture (pertussis toxin (PTX), 
FHA and Prn) containing those commonly used in aceUulai* vaccine preparations, anti-PTX, 
-FHA, and -Prn IgG levels were also raised compared to mice with just the antigen mixture 
alone (MacDonald-Fyall, 2002). Recently, it was demonstrated that CyaA has adjuvant 
activity promoting Th2 (T helper type 2) and Trl (T regulatory type 1) responses and the 
enhancement of antigen-specific IL-lO-producing cells also occurs (Ross et al., 2004). Due 
to the ability of CyaA to deliver its AC domain to the eukaryotic cell cytosol, it has also 
been investigated for its use as a multi-purpose vaccine. B. pertussis CyaA was expressed in 
recombinant form in E. coli with a lymphocytic choriomeningitis virus (LCMV) 
nucleoprotein CDS*^  T cell epitope inserted between residues 224 and 225 (Saron et al.,
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1997), Cytotoxic T cells stimulated by the recombinant CyaA were able to recognise virus- 
infected target cells and protected mice against challenge with the virus. These data 
encourage the use of CyaA for the development of safe non-repHcative anti-viral vaccines 
(Saron et aL, 1997). Guermonprez et al, (1999) demonstrated that recombinant CyaA is 
processed intracellularly for presentation of epitopes to CD8  ^T cells, which is important for 
the design of recombinant CD8  ^T cell-specific vaccines. The binding interaction of CyaA to 
eukaryotic target cells via umPz integrin (CDl lb/CD 18) could be specifically exploited so 
that detoxified mutants of CyaA might be able to deliver pharmacologically active molecules 
to CDl if f  cells, without effecting other cell types (Guermonprez et al, 2001).
1.4.2 Pertussis Toxin
Pertussis toxin (PTX), an AB toxin, is structured as a hexamer composed of five dissimilar 
subunits, designated S1-S5 relative to their electrophoretic mobilities in denaturing gels 
(Locht and Keith, 1986). The subunit SI (A moiety) contains an enzymic adenosine 
diphosphate (ADP) ribosylation activity and subunits S2-S5 (B moiety) contain target cell 
receptor binding activity (Locht et al, 2001). Matuie proteins contain 234 amino acids for 
SI, 199 amino acids for S2 and S3, 110 amino acids for S4 and 100 amino acids for S5. The 
total molecular weight for the holotoxin was calculated to be 104,950 (Locht and Keith, 
1986). All the genes for the PTX subunits are closely linked in an operon and are probably 
expressed in a precise ratio, which is similar to that of other ABs toxins such as, cholera and 
E. coli heat-labile toxins (Locht and Keith, 1986). Directly downstream of the PTX 
structural genes there is a region that encodes proteins necessary for the transport of PTX 
designated the pertussis toxin liberation, ptl, locus (Weiss et aL, 1993). The secretion of 
PTX with the Ptl system uses the Type IV secretion pathway (Burns, 2003).
Pertussis toxin structural and export opérons are also present in B. parapertussis and B. 
bronchiseptica (Parkhill et al, 2003). The S2 subunit is present as a pseudogene in B. 
parapertussis but there are no identifiable pseudogenes of the toxin in B. bronchiseptica 
(Parkhill et al, 2003). Lack of PTX expression in B. bronchiseptica, and also in B. 
parapertussis, is due to differences in the promoter regions of the opérons. Parkhill et al 
(2003) compared the sequence preceding the PTX SI subunit gene, ptxA, of these species 
and found that 62% of the base changes were due to changes in B. pertussis, while the
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sequence was conserved in the other two species. Several of these changes occur within the 
RNA polymerase or BvgA binding sites (see section 1.6) and the effect of these was to 
increase the similarity to the or putative BvgA binding consensus sequence. It is 
suggested that recent mutations in B. pertussis have acted to increase the regulated 
expression of PTX in this organism.
Pertussis toxin is important in the pathogenesis of B. pertussis as it has been described as 
both a toxin and an adhesin. Using a PTX B. pertussis mutant strain, BP357, in infant mouse 
model studies it was determined that PTX is an important virulence factor due to the fact 
that the LD50 for the mutant strain was more than 1,000 times higher than that of the wild- 
type B. pertussis strain (Weiss et al., 1984). The toxin is involved in a number of in vivo 
activities, such as histamine sensitisation, insulin secretion, lymphocytosis promotion and 
immunopotentiating effects (Locht and Keith, 1986). The molecular action of PTX involves 
three steps: binding of the toxin to its receptors via the B oligomer, retrograde transport to 
the endoplasmic reticulum, membrane translocation of the SI-subunit and intracellular 
expression of the ADP-ribosyl-transferase activity catalysed by the SI subunit. (Locht and 
Antoine, 1999). Pertussis toxin was investigated for its potential as a colonisation factor and 
it was found that its enzymic activity rather than its cell binding activity was necessary for 
fuU colonisation in the mouse model (Carbonetti et al, 2003). Several of the toxin’s 
biological effects can be reproduced in the mouse model by injection of PTX and some of 
these effects are long lasting (Munoz et al., 1981). For these reasons PTX has been 
suggested to have a central role in pertussis pathogenesis and in some way being responsible 
for the prolonged course of the disease and for the symptoms that persist after infection has 
cleared (Pittman, 1984). However, the precise role of PTX and its main site of action in the 
host stiU remain obscure (Hewlett, 1997a). Chemically-detoxified PTX (PTXd) has been 
demonstrated to be protective in the mouse model against intracerebral and aerosol 
challenges of B. pertussis (Sato and Sato, 1984) and this molecule has been included in all 
acellular pertussis vaccine preparations (Hewlett, 1997a). More recently, plasmid DNA 
expressing PTX SI subunit was evaluated for immunogenicity and for the ability to induce 
protection against PTX challenge or B. pertussis infection in mice. This DNA vaccination 
induced anti-PTX IgG antibody production, inhibited leukocytosis-promoting activity and 
induced protection against intracerabral challenge ofB. pertussis (Kamachi et al, 2003).
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1.4.3 Dermonecrotic Toxin
Dermonecrotic toxin (DNT) was originally referred to as heat-labile toxin as its activity was 
destroyed by heating at 60°C for 10 min. This toxin is lethal when injected intravenously or 
intraperitoneally into animals and the most chaiacterised action of this toxin is its ability to 
induce skin lesions m animals when injected intradermally (Endoh et al, 1990). 
Dermonecrotic toxin is a member of a family of bacterial cytotoxins that are all large 
polypeptides and affect regulation of cell growth or division (PuUinger et al, 1996).
DNT is expressed by B. pertussis, B. parapertussis, B. bronchiseptica and B. avium and the 
DNTs ifom each species were compared on a genetic level. Similarity was found between 
DNTs of B. pertussis, B. parapertussis and B. bronchiseptica, but there were genetic and 
biological differences between these DNTs and the B. avium DNT (Walker and Weiss, 
1994). The toxin is another virulence factor that is controlled by the regulatory locus bvg 
(section 1.6). Avhulent phase B. bronchiseptica strains express some DNT but in much 
reduced amounts compared to expression by wild-type strains (PuUinger et al, 1996). 
Dermonecrotic toxin is known to induce nuclear* division without subsequent cell division, 
resulting in bi- or multi-nucleation and stimulation of stress fibre formation. This toxin binds 
to cells through its N-terminal region consisting of 54 amino acids (Matsuzawa et al, 2002) 
which recognises an unknown ceU surface receptor which may be uncommon because only a 
few ceU lines are sensitive to DNT. The production of B. bronchiseptica DNT is necessary 
for the production of lesions in swine, turbinate atrophy and pneumonia developed by pigs 
infected with wild-type DNT^ B. bronchiseptica strains (Brockmeier et al, 2002). B. 
bronchiseptica dnt mutants were reduced in their ability to cause turbinate atrophy and 
pneumonia, but were not completely avirulent (PuUinger et al, 1996). Pigs infected with the 
mutants did experience clmical signs of sneezing, coughing and inflammation m the nasal 
cavity. The role of DNT in the pathogenesis of B. pertussis is stiU unclear. However, the 
dermonecrotising activity appears to be due to a specific constrictive effect on vascular 
smooth tissue muscle. This effect on simUar tissues in the respiratory tract could induce a 
local inflammatory reaction and could account for some of the pathology of pertussis 
(Parton, 2004).
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1.4.4 Trachea! Cytotoxin
Tracheal cytotoxin (TCT) was discovered to cause cUiostasis and ciliated cell extrusion in 
hamster tracheal organ cultures and inhibition of DNA synthesis in hamster trachea epithelial 
cell cultures (Goldman et al, 1982). The toxin is known to be expressed by B. pertussis, B. 
parapertussis, B. bronchiseptica and B. avium. Purified and biologically-active TCT 
contains amino acids and amino sugar residues consistent with a peptidoglycan structure and 
was found to be a fragment of peptidoglycan released from the B. pertussis cell (Cookson et 
al, 1989). The structural features of TCT were defined using fast atom bombardment mass 
spectrometry and its primary stmcture was determined to be N-acetylglucosaminyl-1,6- 
anhydro-N-acetylmuramylalanyl-y-glutamyldiamino-pimelylalanine (Cookson et al, 1989).
B. pertussis endotoxin (section 1.4.5) plays an important role in combination with TCT to 
damage the aiiway epithelium. Tracheal cytotoxin and endotoxin were synergistic in the 
induction of IL-la mRNA and protein (this is an essential intermediate in the toxicity 
pathway), and production of nitric oxide (Flak and Goldman, 1999; Flak et al, 2000). Tins 
production of nitric oxide results in the depletion of intracellulai* iion, which inhibits a 
number of kon-containing enzymes that are important for DNA synthesis (Heiss et aL, 
1994). Flak et al, (2000) have suggested that these factors act together to activate a 
localised antibacterial nitric oxide response from epithelial cells, B. pertussis may have 
evolved to take advantage of this system by releasing a large amount of peptidoglycan pieces 
which would lead to over-stimulating the defence system to autotoxic levels, resulting in 
cüiated cell damage compromising the natural airway mechanism and the corresponding 
coughing reaction becomes an efficient means for disease transmission.
1.4.5 Endotoxin
Bordetella spp. endotoxins differ from one another in thek structure. The endotoxin of B. 
pertussis is referred to as lipo-oligosaccharide (LOS) (Brodeur et al, 1993). The structure 
of LOS is comprised of a lipid A domain with a branched chain core oligosaccharide and this 
is referred to as LPS-B. The addition of a trisaccharide to this produces LPS-A (Chaby and 
Caroff, 1988; Caroff et al, 2000). The two LPS phenotypes can be distinguished 
electrophoretically, either wild-type (Lps AB) or phase variant (Lps B) (Peppier, 1984). The 
wild-type pattern consists mainly of an electrophoretically slower migrating LPS-A band
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with lesser amounts of the faster migrating, LPS-B band. The phase variant LPS consists of 
a single faster migrating band, indistinguishable from the wild-type band LPS-B. B. 
parapertussis and B. bronchiseptica endotoxins consist of smooth type lipopolysaccharide 
(LPS) with higher molecular weight 0-polysaccharide components (Parton, 2004).
The LPS expression of the Bordetella species and its dependency on growth temperature 
was analysed by oxidative silver staining of proteinase-K treated bacteria separated by 
Tricine-SDS-PAGE (van den Akker, 1998). Three B. pertussis strains were compared for 
their LPS expression as shown by theii' profiles on Tricine-SDS-PAGE. B. pertussis grown 
at 37°C contained the wüd-type pattern and the organism grown at 25°C contained only the 
expected phase variant LPS-B band. There were no differences between profiles and it was 
also found that BvgAS was not involved in the biosynthesis of its LPS (van den Akker,
1998). There were differences in the profiles visualised using Tricine-SDS-PAGE for ovine 
and human B, parapertussis strains. These differences were host-specific and profile 
differences were apparent for those grown at 2>TC compared to B. parapertussis grown at 
25°C. For some B. bronchiseptica strains, LPS expression was subject to phase variation 
controlled by BvgAS, unlike B. pertussis, and this was not host restricted (these strains were 
isolated fiom pig and dog hosts). B. avium strains had similar LPS expression profiles when 
grown at their host natural body temperature (41 °C), however these profiles differed from 
each other when the organism was grown at other culture temperatures of 25°C and 37°C. 
Modulation by temperature shift did not affect the LPS expression profiles of B. holmseii, B. 
hinzii (except for one human isolate in which an additional LPS was expressed at 41°C) and 
B. trematum (van den Akker, 1998). B. petrii had not been described at the time of 
publication of the above study and there is no information on its LPS structure or its 
expression.
The B. pertussis genetic locus, wlb, consisting of 12 genes (wlbA~L), was found to be 
required for LPS-A biosynthesis. This locus was also found in B. parapertussis and B. 
bronchiseptica (Allen et al, 1998). Deletion of the wlb locus fi’om B. pertussis and B. 
bronchiseptica followed by complementation studies had revealed that this locus was solely 
required for LPS-A synthesis and the biosynthesis of LPS-B was unaffected (Allen et al,
1998). B. parapertussis does not express LPS-A and this may be possibly due to the
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presence of a mutation in the gene wlhH (Allen et al, 1998). Allen et a l  (1998) also 
demonstrated that deletion of the wlb locus in B. parapertussis and B. bronchiseptica 
prevented 0-antigen biosynthesis and it was proposed that there is a gene or genes present 
within wlb locus that is involved in its biosynthesis. The effect of wild-type and wlb deletion 
strains of B. pertussis, B, parapertussis and B. bronchiseptica in mouse respiratory tract 
infection models were compared (Harvill et al, 2000). All three mutants were defective in 
the colonisation of the respiratoiy tract of mice. B. pertussis LOS molecules were required 
for efficient nasal colonisation. In B, parapertussis they were required for initial colonisation 
of the lungs and in B. bronchiseptica they were required for extended survival in the lower 
respiratory tract of normal mice but not in mice lacking adaptive immunity (Harvill et al, 
2000).
Adjacent to the wlb locus is the wbm locus that is responsible for the biosynthesis of the 0-* 
antigen. The wbm deletion B. parapertussis and B. bronchiseptica mutants differed in their 
ability to colonise the respiratory tract of mice. The B. parapertussis mutant was severely 
defective in its ability to colonise the trachea and lungs, whereas the B. bronchiseptica 
mutant showed almost no defect (Bums et al., 2003). When the ability of serum complement 
to khl Bordetella was also investigated, wild-type B. parapertussis and B. bronchiseptica 
were unaffected by high concentrations of naïve-rabbit, -rat, or -mouse serum while the 
wbm deletion mutants were sensitive to very low concentrations of serum. It was suggested 
that the O-antigen provides protection from the bactericidal activities of serum complement 
in B. parapertussis and B. bronchiseptica (Bums et ah, 2003).
B. pertussis LOS has the properties of toxicity, pyrogenicity and adjuvanticity characteristic 
of endotoxin (Parton, 2004). It also has the ability to induce antiviral activity, B-cell 
mitogenicity and polyclonal B-cell activation (Chaby and Caroff, 1988). B. pertussis LOS in 
the whole-cell pertussis vaccine is considered to contribute to the vaccine’s toxicity and 
reactogenicity, therefore it was suggested that LOS should be excluded from acellular 
pertussis vaccines (Robinson era/., 1985).
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1.5 OTHER POTENTIAL VIRULENCE FACTORS
1.5.1 Outer-membrane protein P
B. pertussis produces a 40 kDa porin protein which complexes in the outer membrane to 
form a channel for anionic molecules and this porin resembles the derepressible porin protein 
P o f Pseudomonas aeruginosa (Armstrong et al, 1986). The structural gene for the major 
Bordetella pertussis porin, OmpP was identified and sequenced by Li et al (1991). Outer- 
membrane protein P is expressed by Bvg^ and Bvg' B. pertussis strains and Southern blot 
analysis had also revealed the presence of the gene in B. parapertussis and B. 
bronchiseptica.
1.5.2 Outer-membrane protein Q
The gene ompQ encodes a porin-like outer-membrane protein Q (OmpQ), which has a 
molecular mass of 39.1 kDa (Finn et al, 1995). From mouse model studies it has been 
demonstrated that a mutant B. pertussis 18323^ strain lacking OmpQ was not adversely 
affected in its ability to survive after aerosol challenge in the mouse model of infection and 
was not affected in its ability to survive in vitro (Finn et al, 1995). The lack of effect was 
unexpected as Finn et a l (1995) had suggested that OmpQ may have an important role in 
allowing the bacterium to have access to essential nutrients. In the mouse model system, it 
may be that other outer membrane proteins are able to substitute for OmpQ or the protein 
may not be involved in the infectious process. Outer-membrane protein Q is expressed along 
with other Bvg^ proteins and it was suggested that the protein may play a role in the 
establishment of a carrier state. The gene ompQ was present in B. parapertussis and B. 
bronchiseptica but was not found to be present in B. avium (Finn et al, 1995).
1.5.3 Bordetella intermediate phase protein
Bordetella intermediate phase protein (BipA), a surface-expressed protein, is encoded by the 
gene bipA. The protein is expressed by B. pertussis, ovine B. parapertussis and B. 
bronchiseptica strains but not by human B. parapertussis strains (Fuchslocher et al, 2003). 
This can be attributed to bipA being a pseudogene in human B. parapertussis strains. 
Reverse transcriptase PCR analysis indicated that bipA was expressed maximally under 
semi-modulating (Bvg  ^phase) conditions and that expression was controlled at the level of 
transcription (Stockbauer et al, 2001). However, levels of BipA expression differ in ovine
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B. parapertussis strains compared to B. pertussis and B, bronchiseptica strains due to 
sequence differences present at positions predicted to be involved in BvgA-mediated 
transcriptional activation (Fuchslocher et al, 2003). The C-terminus of BipA is exposed on 
the surface of B. bronchiseptica and, consistent with this topology, the predicted amino acid 
sequence of N-terminal 500 amino acids shares significant similarity with the membrane 
localisation domains of EFIEC (enterohaemorrhagic Escherichia coU) and EPEC 
(enteropathogenic E. coli) intimin and Yersinia invasin. The fact that bipA is absent from 
some B. bronchiseptica strains and is not expressed or expressed at veiy low levels, for 
example in ovine B. parapertussis strains, suggests that the potential role that BipA plays in 
the infectious cycle is either not essential or can be compensated for by other genes 
(Fuchslocher et al, 2003). However, BipA could play some important role that is unique to 
the strains that express it.
1.5.4 Vir90
A potential virulence factor of B. pertussis, Vir90, has been described recently (Passerini de 
Rossi et al, 2003). The protein sequence displayed closest homology with a number of 
ferrisiderophore receptors fr om Gram-negative bacteria. Open reading fr ames of vir90 were 
also found in B. parapertussis and B. bronchiseptica genomes. This protein is encoded by a 
gene of 2322 bp, which is liighly conserved between B. pertussis and B, bronchiseptica 
(99% homology) and between B. pertussis and B. parapertussis (98% homology). The vir90 
promoter was scamied for regulatory regions; putative -10 and -35 sites, Bvg A bindmg sites 
and a putative Fur box overlapping the -10 site were found (Passerini de Rossi et a l, 2003). 
The expression of vir90 was demonstrated to increase when B. pertussis was grown in low 
iron growth conditions and its expression was iron regulated. Therefore, it was suggested 
that Vir90 may play a role in the uptake of iron.
1.6 REGULATION OF pertussis VIRULENCE FACTORS
B. pertussis can alternate between virulent and avirulent states either by phase variation or 
by phenotypic modulation. Inactivation of the bordetella virulence genes locus, bvgAS, by 
mutation (phase variation), or repression of its products (BvgAS) by the presence of 
modulating signals (phenotypic modulation), results m the loss of virulence gene expression 
(Cotter and DiRita, 2000). Phase variation was first described by Leslie and Gardner (1931,
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cited by Roberts and Parton, 2001) as a stepwise degradative process from phase I, fresh 
virulent isolates, to phase IV, avirulent isolates. Isolates that are phase IV no longer express 
the virulence factors described previously, except for TCT and LOS. These mutants occur at 
the frequency of 1 per 10^  to 10® organisms due to spontaneous mutation in bvgAS (Weiss et 
al, 1983). Goldman et al (1984) described phase variation as an ordered gradual process 
composed of several non-random and inter-dependent events. Phenotypic modulation, 
originally described by Lacey (1960, cited by Parton, 2004), is completely reversible and it 
has been suggested that it could be used as a mechanism to escape host defences (Weiss and 
Walker, 1984). The C (cyanic) avirulent, Bvg“, mode occurs when grown in modulating 
conditions in vitro such as high concentrations of magnesium sulphate or nicotinic acid and 
the X (xanthic) virulent, Bvg^, mode occurs when there are no such modulating signals 
(Roberts and Parton, 2001).
The bvg locus sequence was described by Arico et a l (1989). The predicted products of this 
locus are homologous to a family of regulatory proteins that transmit sensory signals using a 
conserved two-component motif. Originally bvgA, B and C were described. bvgA encodes a 
transcriptional activator and, in the absence of modulating conditions, it was proposed that 
BvgC activated BvgA by phosphorylation (Arico et al, 1989). It was later discovered that 
BvgB and BvgC were part of one larger protein and this was termed BvgS (for sensor) 
(Stibitz and Yang, 1991). BvgA, a 23 kDa protein, is located within the cytoplasm and 
BvgS, a 135 kDa protein, has transmembrane topology (Fig. 1.2.1), BvgS acts as a sensor of 
conditions in the external envfronment and transduces those signals to the inside of the cell 
where communication with BvgA by phosphorylation results in the expression of bvg- 
assoeiated factors (Fig. 1.2,1) (Stibitz and Yang, 1991). BvgAS uses a four-step Histidine 
(H)-Aspartic acid (D)-Histidine-Aspartic acid phosphotransfer signalling mechanism (Cotter 
and DiRita, 2000). The first three phosphotransfer domains are contained on BvgS and the 
last is contained on BvgA, When BvgS is activated, it autophosphorylates at H729 in the 
transmitter domain. This phosphoryl group is transferred to D1023 in the receiver domain 
and then to HI 172 in the histidine phosphotransfer domain or the phosphoryl group can be 
transferred from the BvgS receiver to water to form inorganic phosphate. The 
phosphorylated histidine phosphotransfer domain is the substrate for the phosphorylation of 
D54 in the BvgA receiver. Phosphorylated BvgA can bind DNA via its helix-turn-helix
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domain, and it functions as a transcriptional activator and repressor, resulting in the 
expression of distinct phenotypic phases (Cotter and DiRita, 2000). The amount o f BvgA 
protein detected m the lysates of B. pertussis decreases significantly in cells grown under 
modulating conditions or in cells that have bvg locus mutations (Stibitz and Yang, 1991). 
Similar regulation of virulence factors is also known to occur in B. parapertussis, B. 
bronchiseptica and B. avium (Parton, 2004).
Transposon TophoA mutagenesis was used to facilitate isolation of gene fusions between 
phoA and B. pertussis genes encoding secreted proteins. By isolating these Tn phoA fusions 
controlled by modulating signals, genes that were activated or repressed by BvgAS were 
identified (Knapp and Mekalanos, 1988). This work led to the discovery of virulence- 
repressed genes (vrgs) and virulence-activated genes (vags), (Fig. 1.2,1). The products of 
vrgs are considered to be related to C-mode products. The virulent and avirulent phases or 
modes are now referred to as Bvg^ and Bvg', respectively.
A temperature switch (firom 25 to 37°C) induces the expression of a number of bvg- 
regulated genes in two temporal steps (Scarlato et al, 1991). The first step of activation 
involves the PI and P4 promoters at the bvg locus and the fhaB  gene promoter. The second 
step of activation includes the bvg P3 promoter and the promoters of the ptx and cyaA 
genes. The fact that FHA Is synthesised before PTX and CyaA suggests that the differential 
activation of adhesins and then toxins is part of the infection process and results firom a 
selective advantage (Scarlato et al, 1991). That is, the adhesins such as FHA are necessary 
for adherence to eukaryotic cells in the first stage of infection and the expression of the 
toxins may not be required until B. pertussis is at the correct anatomic site of the upper 
respiratory tract. Early and late promoters are recognised with high and low affinity by 
phosphorylated BvgA, respectively (Zu et al, 1996). Recognition of the late-activated 
promoters requires a larger amount of phosphorylated BvgA compared to the early 
promoters.
The bvg locus was thought to only consist of bvgS and bvgA until Merkel and Stibitz (1995) 
reported the discovery of a third component of the locus, bvgR, in B. pertussis, which is 
responsible for repression of genes. The bvgR locus lies immediately downstream of bvgAS
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and is convergently transcribed relative to bvgAS. The bvgR promoter was found to be 
significantly stronger than the fha  promoter and such a high level of expression was 
considered unusual for a transcriptional regulator (Merkel et al, 2003). Results of the study 
suggested that the bvgR transcript is very unstable and is rapidly degraded in the cell after 
synthesis. BvgR (as well as FHA) is expressed early and this may be required to repress the 
expression o f a gene product(s) that may interfere with colonisation of the host by factors 
such as FHA (Merkel et al, 2003).
There are three known phase phenotypes: Bvg\ Bvg and Bvg'. The Bvg^ phase is 
characterised by the expression of Bvg-activated virulence factors and the lack of expression 
of the Bvg" phenotype. In the Bvg" phase, Bvg-activated virulence factors are not expressed 
and a specific set of proteins that are unique to B. pertussis, B. parapertussis and B, 
bronchiseptica are expressed. B. pertussis grown in submodulating conditions of nicotinic 
acid or magnesium sulphate express the Bvg' phenotype (Cotter and DiRita, 2000). This 
phase is characterised by the absence of expressed Bvg" proteins, the presence of some of 
the Bvg-activated proteins and the presence of proteins that are unique to this phase, such as 
BipA (Cotter and DiRita, 2000). These distinct phases may be expressed at different stages 
of infection by the organism, or outside the host during transmission or for survival in the 
environment (Cotter and DiRita, 2000; Coote, 2001).
1.7 COMPARISON OF B, pertussis, B, parapertussis AND E. bronchiseptica 
GENOMES
During the course of this PhD study the complete genome sequences of B. pertussis 
(Tohama-I), B. parapertussis (12822, human strain) and B. bronchiseptica (RB50, rabbit 
strain) were published (Parkhill et al, 2003). The B. bronchiseptica genome is the largest of 
the three genomes, ca. 5.3 Megabases (Mb) with 5007 predicted genes. The B. 
parapertussis genome is ca. 4.8 Mb with 4404 genes and the B. pertussis genome is ca. 4.1 
Mb with 3816 genes. Parkhill et a l (2003) estimated the time of divergence of the three 
species based on the pairwise synonymous substitution rates for approximately 3000 genes 
that are common to the three species. Estimated times to the last common ancestors were 
0.27-1.4 million years, for B. bronchiseptica and B. parapertussis, 0.7-3.5 million years B. 
bronchiseptica and B. pertussis and 0.8-4.0 million years for B. parapertussis and B.
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pertussis. B. pertussis is known to be a clonal species and this and other evidence has 
suggested a much more recent origin (Musser et al, 1986; Gerlach et al, 2001). The 
suggestion of recent origin can also be related to the fact that the fii’st recorded clinical 
description of the highly characteristic disease, pertussis, was in 1578. The genome data 
suggest that the genetic uniformity in B. pertussis reflects a recent bottleneck (due to the 
human population not increasing at a rate to support a larger B. pertussis population, the 
aUehc diversity is reduced) rather than recent descent from B. bronchiseptica. Another 
possible explanation is that B. bronchiseptica might be sufficiently genetically diverse that 
isolates exist which are much more similar to the last common ancestor of B. pertussis than 
B. bronchiseptica RB50 strain.
Analysis of the genomes revealed that 114 genes were unique to B. pertussis, 50 genes were 
unique to B. parapertussis whereas B. bronchiseptica had over 600 genes that were not 
found in either B. pertussis or B. parapertussis. Twenty-three genes that were found in B. 
pertussis and B. parapertussis were not found to be present in B. bronchiseptica. From the 
predicted frmctions of the products of the genes not present in the B. bronchiseptica genome 
it appeared that very few would be involved in pathogenicity or in specifying host range. The 
type of genes lost by B. pertussis or B. parapertussis with respect to B. bronchiseptica 
indicated that many of them were involved in membrane transport, small molecule 
metabolism, regulation of gene expression and synthesis of surface structures. B. 
bronchiseptica has over 1000 genes in common with B. parapertussis and 100 genes m 
common with B. pertussis. Three hundred and fifty-eight genes in B. pertussis and 200 
genes in B. parapertussis appeared to have been inactivated by insertion of IS elements, hi- 
frame stop codons or frameshifts. This has occurred to a lesser extent in B. bronchiseptica 
as it only has 19 pseudogenes.
The distinct traits of each species have been suggested to be due to independent mechanisms 
of large-scale gene inactivation and loss in B. pertussis and B. parapertussis. Their limited 
host range, compaied to B. bronchiseptica, could be due to the loss of host-interaction 
mechanisms. Increased virulence for humans of B. pertussis could be due to an over­
expression or constitutive expression of virulence factors that are subject to tighter temporal 
or environmental control in B. parapertussis and B. bronchiseptica. B. pertussis may have
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followed this evolutionary path due to opportunities for increased transmission rate provided 
by the increase in size and density of human populations (Parkhill et al, 2003).
Antoine et al (2000) searched the B. pertussis genome that was available at the time to 
identify new potential virulence factors. A suicide vector was developed for rapid gene 
inactivation by homologous recombination and generation of transcriptional fusions between 
the interrupted genes and a promoterless lacZ. The genes identified included putative 
virulence factors. Two genes that code for putative proteins homologous to FHA were 
found. These authours described a gene, adhS, encoding a putative signal peptide bearing 
protein, which was homologous to a salivary streptococcal adhesin. Five other 
autotransporters {phg, aidB, sphBl, sphB2 and sphB3) were also identified. Expression 
levels of sphB2 and sphBS were very low or undetectable, however phg, aidB, and sphBl 
were better expressed. A serine protease homologue, sphBl, was also identified to be 
another vag. The completion of the B. pertussis genome has thus led to the discovery of 
other novel molecules and will help to identify other putative virulence factors and 
protective proteins.
1.8 CLINICAL ASPECTS OF PERTUSSIS
1.8.1 Pertussis symptoms
B. pertussis infection is transmitted via respiratory secretions fi*om an infected individual to a 
new host under conditions of close contact and is highly contagious during the first week of 
illness. During this stage up to 90% of susceptible family contacts of an index household 
case develop pertussis (Hodder and Mortimer, 1992). The clinical symptoms of pertussis 
can be split into three phases, catarrhal, paroxysmal and convalescent. Following exposure 
there is an incubation period that varies between 7 and 13 days. Non-specific symptoms then 
develop, which last approximately 7 days, and this is knovm as the catairhal phase. These 
symptoms consist of nasal congestion, low-grade fever and mild cough (Hodder and 
Mortimer, 1992). The catarrhal phase gradually becomes the paroxysmal phase as the non­
productive cough becomes a paroxysmal cough with mucus secretion and vomiting. The 
paroxysmal phase may last for 1-6 weeks. The action of coughing attempts to clear the 
viscous respiratoiy secretions and is often followed by inspiration against a narrowed glottis, 
which produces the characteristic whoop. Physical damage can result fi'om the paroxysmal
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coughing, such as rupturing the frenulum of the tongue, or cause spontaneous 
pneumothorax, inguinal hernia and rectal prolapse (Kerr and Matthews, 2000). The other 
characteristic signs of the paroxysmal phase include leukocytosis, lymphocytosis, weight 
loss, occasional hypoglycaemia and, rarely, encephalopathy (Kerr and Matthews, 2000). 
Central nervous complications are relatively frequent and convulsions can also occur'. During 
the convalescent phase the cough gradually starts to subside but it can be reactivated by 
subsequent, unrelated infection.
Age is an important determinant of disease severity and prognosis. Infants under the age of 
one year have the highest mortality rate (Hodder and Mortimer, 1992). Seventy-nine percent 
of reported deaths from pertussis in the United States (US) occurred in infants under one 
year of age. This age group is also more likely to be hospitalised than older individuals and 
to suffer complications such as pneumonia, and central nervous system manifestations. 
During 1980-1989, of the pertussis patients under 1 yr in the US, 69% were hospitalised, 
3% had convulsions, 0.9% had encephalopathy and 0,6% died (Kerr and Matthews, 2000). 
During 1995-1997 in the United Kingdom (UK), 65% of pertussis hospital admissions were 
infants less than 1 year of age (van Buynder et al, 1999). The clinical symptoms of pertussis 
in adults and adolescents aie generally considered to be milder.
A recent study has confrimed that vaccination status significantly changes the clinical 
presentation of pertussis and that this disease is more severe in unvaccinated individuals 
(Tozzi et al, 2003). Clinical presentation was found not to vary with the background 
incidence of pertussis i.e., during epidemic periods, pertussis symptoms were not more 
severe. The recommended World Health Organisation (WHO) case definition of pertussis 
for surveillance purposes includes spasmodic coughing for 2 weeks. As a result of this strict 
definition the impact of pertussis may be underestimated in vaccinated children and in older 
age groups. Tozzi et a l (2003) recomnlended that children with prolonged cough should 
always be considered for diagnosis of pertussis, even those that have been vaccinated.
1.8.2 Treatment of pertussis
Antibiotic treatment in the catarrhal or early paroxysmal stages can ameliorate the symptoms 
of pertussis and eliminate the infection. Treatment of patients in later stages of infection may
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have no clinical benefit but it could potentially limit the spread of the organism to susceptible 
contacts (Parton, 2004). There are several antimicrobial agents that have been reported to be 
effective in vitro against B. pertussis, such as ampiciUin, chloramphenicol, tetracycline and 
erythromycin (Hodder and Mortimer, 1992). However, these antibiotics have not been 
equally effective against pertussis infection in vivo. AmpiciUin was ineffective in eradicating 
B. pertussis fi*om the nasopharynx and patients that were treated with tetracycUne or 
chloramphenicol had slower eradication of B. pertussis than those treated with 
erythromycin. Erythromycin is stUl the antibiotic of choice for treating pertussis infection 
(Hodder and Mortimer, 1992). Patients receiving treatment become culture-negative within 
a few days but, if therapy is not continued for the recommended two weeks, culture results 
may become positive again. Recent reports have described US B. pertussis isolates that were 
resistant to erythromycin (HUl et al., 2000; Wilson et al, 2002; Bartkus et al, 2003). In a 
study of 1,030 US B. pertussis isolates that were screened for erythromycin resistance using 
the disk dififtision assay, it was determined that five (0.5%) of these isolates displayed a 
heterogeneous phenotype after 5-7 days of incubation (Wilson et al, 2002). B. pertussis 
isolates are normally grown for 3-5 days using this assay, therefore potentially missing 
detection of resistant isolates. As a result of the study it was recommended to grow isolates 
for an extended period of 5-7 days. Even though the number of erytliromycin-resistant B. 
pertussis isolates known are small it is important to screen future isolates to determine if this 
number will increase.
1.9 PERTUSSIS VACCINATION
Pertussis vaccination is considered to be more effective at preventing disease rather than 
infection due to the fact that the interepidemic period has not increased since the 
introduction of vaccination (Crowcroft and Britto, 2002). Pertussis vaccines used world­
wide are generaUy whole-ceU vaccines (WCVs). Vaccine potency, reactogenicity and the 
immune response that they produce, as well as the vaccination schedules, vary fiom country 
to country. Currently, worldwide pertussis vaccination of children is about 80% 
(http ://www. who. int/vaccines/en/pertussis. shtml).
The composition of many vaccines is unknown. However, the World Health Organisation 
recommendation is that WCVs must contain Fim2 and Fkn3, by selection of the appropriate
36
B. pertussis strains (WHO, 1990). A US vaccine was found to contain 0-0.66 pg FHA/dose 
and 0.02-0.68 pg total PTX/dose (0-0.28 pg PTX/dose is biologically active). The 
Wellcome vaccine was found to contain 1.6 pg FHA/dose, 4.7 pg Fim2/dose and 0.3 pg 
PTX/dose (biologically active). The amount of Fim3 in this vaccine was estimated to be 
similar to that of Fim2 (Robinson et a l, 1985). Whole-ceU vaecines were also found to 
contain the virulence factor CyaA. The AC enzymic activity of CyaA was measured in 
several commercial vaccines and it was found that all of the vaccines tested from one 
particulai' manufacturer had significant AC activity (Hewlett et a l, 1977). The original 
observation of AC activity in a WCV was thought to be due to the association of CyaA with 
the whole organism and the possible secretion of the enzyme into the medium of the vaccine 
during storage and handling. The authors analysed the same vaccine again which was stored 
at 4°C and found that it contained enzymic activity equivalent to 10% of the value measured 
5 years previously (Hewlett et a l, 1977). The current UK whole-ceU vaccines contain less 
than 2x10^ ® kiUed B. pertussis ceUs in a 0.5 ml dose, with a potency of more than 4 
international units by comparison with the International Standard for Pertussis Vaccine in 
the intracerebral mouse protection test (Roberts and Parton, 2001), The pertussis 
component is usuaUy combined vrith diphtheria and tetanus toxoids (DTP) and absorbed to 
aluminium hydroxide and with thiomersal as a preservative (Roberts and Parton, 2001). 
Local and systemic reactions have been associated with the administration of WCV. Local 
reactions include redness, swelling, pain and fever and these are reported to increase in 
frequency and severity with increasing number of doses. Systemic reactions that have been 
described were drowsiness, fretfulness, vomiting, anorexia, persistent or unusual crying but 
these were significantly less frequent with increasing dose number (Cody et al,, 1981).
Before the introduction of pertussis immunisation in the UK in the 1950s, the number of 
notifications per year for England and Wales exceeded 100,000 
(http://www.hpa.org.uk/topics_az/whoopingcougiT/gen_info.htm) (Fig. 1.9.1). Between 
1948 and 1960 there were case reports describing vaccine complications ranging from 
encephalopathy and coma to permanent neurological injury and death. Flowever clinical 
trials of immunisation prior to 1960, carried out by the Medical Research Council, involved 
over 36,000 children of which there were no reported cases of encephalopathy (Baker,
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Figure 1.9.1: Pertussis notifications and vaccine coverage for England and Wales from 
1940-2000 (source: Immunisation Department, Health Protection Agency Communicable 
Disease Surveillance Centre, London)
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2003). Vaccine acceptance was over 80% in 1972 and the number of pertussis notifications 
was 2069.
In January 1974 there was a published report Ifom the Hospital for Sick Children, Great 
Ormond Street describing a potential link between pertussis vaccination and permanent brain 
damage. This and other adverse publicity given to the vaccine resulted in a drop in vaccine 
uptake, which led to two epidemics, 1977-1979 and 1981-1983 (Baker, 2003). There were
200,000 extra pertussis notifications and 100 deaths in the 1970s and the 1980s. No 
significant link was ever established between the pertussis WCV and brain damage (Cody et 
al, 1981). By the late 1980s immunisation rates were at pre-1974 levels (Baker, 2003). 
Currently, vaccine coverage is ca. 95% with pertussis at historically low levels (Fig. 1.9.1). 
In 1991 an accelerated vaccination schedule was introduced and babies were vaccinated at 2, 
3 and 4 months rather than 3, 5 and 10 months of age.
One positive result fiom the above health scare has been investigations worldwide into the 
development and use of the less reactogenic acellular pertussis vaccines (ACVs). Field trials 
of various AC Vs have been carried out in Sweden, Italy, Germany and Senegal. To date 
PTX, in the toxoided form, is the one component present in every ACV tested (Hewlett, 
1997a). The monocomponent ACV consisted of PTX alone, which was toxoided by 
hydrogen peroxide treatment. Pertussis toxoid and FHA were used for the two component 
ACV and the addition of Prn was used for the three component AC Vs. The five component 
vaccines contained the same antigens that were used for the three component ACV with the 
addition of Fim2 and Fim3. Most of the vaccines contained chemicaUy-toxoided PTX (using 
formaldehyde, glutaraldehyde, or hydrogen peroxide) and one was genetically toxoided 
(Hewlett, 1997b). A genetically toxoided PTX molecule has been prepared by substituting 
two amino acids in the SI subunit (Roberts and Parton, 2001). The latter was considered to 
be an improvement over the chemically toxoided PTX as this treatment can alter the 
structure and epitopes of molecules and reduce immunogenicity, thus requiring larger 
amounts of the antigen (Roberts and Parton, 2001).
Many of these trials differed in their design and m the composition of the vaccines used but 
several general conclusions have been drawn from the vaccine trials overall (Hewlett,
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1997b), Use of ACVs results in fewer local adverse reactions than those associated with 
WCVs. However, as with WCVs, the frequency of local adverse reactions increases with the 
number of doses. Acellular vaccines also result in significantly lower rates of infrequent, but 
more severe, systemic reactions such as hypotonic-hyporesponsive episodes and febrile 
convulsions (Grant and Cherry, 2002). Acellular vaccines provide some level of protection 
against pertussis and there was a general trend that the more components an ACV contained 
the greater the protection (Hewlett, 1997b). Most current WCVs have greater efficacy than 
all ACVs except the five-component ACV (Grant and Cherry, 2002). The five-component 
ACV and WCV used in an Italian study were equally efficacious against typical pertussis 
(Olin et a l, 1997). The first ACV was developed in Japan, and tliese vaccines were licensed 
for immunisation of children aged two year s or more in 1981 and in 1989 they were licensed 
for use in infants aged more than 3 months. The first US acellular pertussis vaccine was 
licensed for use in 1991 (http://www.who.int/vaccines/en/pertussis.shtml). Due to the results 
of a recently published UK study, an ACV was introduced in the UK as a pre-school booster 
in November 2001 (Crowcroft et al, 2003). Using ACVs also offers the opportunity to 
extend pertussis prevention thr oughout the community to include vaccination of adolescents 
and adults, as WCVs have unacceptable side-effects when given past early childhood 
(Campins-Marti et al, 2001). For implementation of booster vaccines across the population, 
it has been recommended that pertussis booster should be incorporated with tetanus and 
diphtheria toxoids and administered every 10 years (Heininger, 2001).
1.10 DIAGNOSTIC TESTS AVAILABLE FOR DETECTING Æ pertussis
1.10.1 Culture
Culture is considered the ‘gold standard’ for diagnosing pertussis infection due to its 
specificity. However, it is slow and has low sensitivity compared to other diagnostic 
techniques, in particular polymerase chain reaction, where comparative studies have been 
undertaken (van der Zee et al, 1993; Muller et al, 1997; Lind-Brandberg et al, 1998; 
Kosters et al, 2001). Success of isolating B. pertussis from clinical specimens is dependent 
on several aspects. The sensitivity is dependent on collection methods, devices used, 
transport and enrichment media, conditions and duration of transport, choice of media, and 
incubation conditions and duration, B. pertussis should preferably be isolated from 
nasopharyngeal aspirates (NBAs) rather than nasopharyngeal swabs (NPSs). It has been
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reported that there is a 15% gain in isolation rate when using NBAs (Guiso, 1997). The use 
of transport and enrichment media can increase the isolation of B. pertussis from clinical 
samples (Guiso, 1997). For transportation of NBSs, Regan and Lowe medium containing 
half-strength charcoal agar, horse blood and the antibiotic cephalexin (which supresses 
growth of normal nasopharyngeal flora) is the recommended transport medium (Regan and 
Lowe, 1977), The medium that is suitable for transportation of NBAs samples is Casamino 
acids solution held at 4°C (Cassiday et al, 1994).
Isolation of B. pertussis is optimal at the end of the incubation period, during the catarrhal 
stage and at the beginning of the paroxysmal phase (Muller et al, 1997). Dirring this stage, 
isolation o î B. pertussis may be as high as 90% (Kerr and Matthews, 2000). For primary 
isolation of B. pertussis, the Regan and Lowe medium is recommended, but for laboratory 
cultivation cyclodextrin sohd medium is considered to be a better growth medium for B. 
pertussis than Bordet-Gengou medium. This medium contains heptakis (2,6-O-dimethyl) 
beta-cyciodextrin (MeCD), which is known to be a significant growth stimulant for B. 
pertussis (Aoyama et al, 1986). Isolation rate was determined to be better with this medium 
and it has a longer shelf-life than BG medium. Positive cultures obtained later in infection 
may be a marker of delay in the clearance of B. pertussis from the respiratory epithelium 
with greater tissue damage and a more severe presentation of pertussis (Tozzi et al, 2003).
1.10.2 Direct fluorescent antibody
Direct fluorescent antibody (DFA) test allows the direct detection of B. pertussis or B. 
parapertussis or their components in clinical samples. The DFA test uses fluorescein- 
labelled antibodies to B. pertussis and B. parapertussis to detect the bacteria in clinical 
specimens by fluorescence microscopy. Background staining has been reported to be 
problematic for tins technique when using monoclonal and polyclonal reagents (Tilley et al,
2000). The morphology of the organism can be difficult to verily as B. pertussis is small and 
the presence of cell artefacts also hinders the process (Tilley et al, 2000). Low sensitivity 
for the DFA reagents has been reported, ranging from 28-50% (Tilley et al, 2000). This test 
is also prone to false-positives (Ewanowich et al, 1993; leven and Gossens 1997), which 
can be attributed to the presence of other bacterial species (unencapsulated Haemophilus 
influenzae, Proteus mirabilis and Staphylococcus epidermidis) being significantly cross-
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reactive with commercial DFA reagent (Ewanowich et al, 1993), Ewanowich et a l (1993) 
also reported a high proportion of samples, 88.4%, DFA positive, but culture negative.
1.10.3 Serology
There are a variety of serological assays that have been used to confirm diagnosis of 
pertussis, such as agglutination, complement fixation and enzyme-linked immunosorbent 
assays (ELISA) (Roberts and Parton, 2001). Of these assays, ELISA has been used as a base 
method for serology (Hallander, 1999). It is used to determine serological response to 
vaccination or infection by measuring changes in antibody levels induced by exposure to 
relevant antigens and also to compare antibody levels after immunisation with different 
vaccines or in a single serum test for diagnostic purposes (Hallander, 1999), Diagnostic 
sensitivity is dependent on the timing of sample collection, on the choice of antigen and the 
class of immunoglobulin (Hallander, 1999).
Serology has been used to measure anti-pertactin (anti-Prn), anti-filamentous haemagglutinin 
(anti-FHA) and anti-pertussis toxin (anti-PTX) antibodies in populations (Garcia-Corbeira et 
al, 2000; Van der Wielen et al, 2003). Of these, the most widely used antigens aie PTX 
and FHA (Hallander, 1999). There are tlnee different classes of antibodies (IgG, IgA and 
IgM) to specific B. pertussis antigens that can be used (Hodder and Mortimer, 1992). High 
IgA titres are considered to be indicative of infection and high IgM titres are not found in 
infected, previously immunised patients. Tests for IgG antibodies to PTX and to FHA are 
both very sensitive in typical cases of pertussis (Hallander, 1999). After infection with R. 
pertussis, antibodies can only be detected relatively late in the process of the disease, that is 
1-2 weeks after the beginning of the symptoms in the non-vaccinated infected individuals 
(Muller et al, 1997). Pertussis toxin antibody response can be considered as a specific 
marker for pertussis as an antibody response to FHA also occurs after infection with B. 
parapertussis and potentially after exposure with nonencapsulated H. influenzae. IgG 
antibody responses to Pm have also been investigated for use m diagnostic serology 
(Hallander, 1999) where antibody responses have been demonstrated both in individuals 
with pertussis and individuals with parapertussis. Prn IgG antibody determinations were 
recommended to be used alongside PTX and FHA assays in vaccinated individuals rather 
than alone (TroUfors et al, 2003).
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Differences in the distribution of antibodies to PTX, FHA and Prn were found amongst 
various age groups. An increase of anti-FHA and anti-PTX levels occurs with increasing age 
and levels of antibodies to the latter antigen peak in the adolescent/young adult (15-24 
years) age group (Garcia-Corbeira et al., 2000; Van der Weilen et al, 2003). It has been 
observed that there is a decrease m anti-Prn levels with older age groups (Van der Weilen et 
al, 2003). Pertussis immunity is known to wane after vaccination or infection, therefore the 
increase of anti-PTX in the adolescent and young adult age groups may be due to repeated 
exposure to B. pertussis, which would suggest a widespread circulation of the organism in 
the population (Garcia-Corbeira et al, 2000). This would also suggest that this age group 
could be the main reservoir of infection and for these reasons vaccine boosters should be 
administered to individuals of this age (Van der Wielen et al, 2003). A recent study has 
investigated the seroepidemiology of pertussis by examining the distribution of high titre 
anti-PTX IgG antibodies amongst the UK population (Nardone et a l, 2004). It was 
determined that there was an important circulation of serologically-deftned pertussis 
infection in the UK population that often remains unreported or undiagnosed. In 1996 the 
incidence of pertussis was higher than that reported, 2232 per 100,000 versus 6 per 100,00 
(Nardone et a l, 2004).
1.10.4 Polymerase chain reaction
Due to problems associated with other previously-described diagnostic tests such as lack of 
sensitivity, specificity and time delay, there is a need for a rapid, specific and sensitive 
method for detecting B. pertussis from clinical specimens. Polymerase chain reaction (PCR) 
in particular is a specific and sensitive method. Comparison of PCR with culture and DFA 
revealed that the three techniques had similar specificities (99.3%, 100% and 94.6% 
respectively) but differed in their sensitivity. PCR was the most sensitive (95%), culture was 
36% and DFA had the lowest sensitivity ranging from 5.2-11.4% (Tilley et a l, 2000). 
Several diagnostic PCR assays have been developed to target the following genes, ptx, cyaA, 
outer membrane porin and insertion sequences (Douglas et a l, 1993; Mastrantonio et al, 
1996; van der Zee et al, 1996a; Muller et al, 1997; Farrell et al, 1999, 2000; Fiy et a l,
2004). Thorough investigation and optimisation of PCRs that amplify a portion of the genes 
that encode insertion sequences, 1^481 and IS7007, has been carried out by several groups 
(Glare et al, 1990; van der Zee et al, 1993; Backman et al, 1994; Farrell et al, 1999;
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Reischl et al, 2001; Kosters et al, 2001; Sloan et al, 2002; Podder, 2003). The target 
sequences IS457 and IS7 007 can be used to determine if B. pertussis or B. parapertussis are 
present, respectively.
There are disadvantages with utilising IS481 as a diagnostic target as it has been reported 
that an IS4S7-like sequence is present in B. holmesii (Loeffelholz et al, 2000; Kosters et al,
2001). Loeffelholz et al (2000) tested B. holmesii isolates along with B. pertussis isolates 
using IS4<^ 7 PCR, and they both gave positive results and the level of sensitivity for B. 
holmesii was smnlar to that of B. pertussis. Direct sequencing of the 1^481 amplified 
product revealed that, in all six B. holmseii strains, there was the presence of two 1^481 
alleles that differed by two nucleotides (Reischl et al, 2001). Restriction fragment length 
polymorpliism analysis has revealed that there are more than 50 copies of 1S481 in B. 
pertussis and only 8-10 copies in B. holmesii suggesting that IS481 sequences in B. 
pertussis have been present longer. IS481 may have been inherited from an ancestor 
common to both species and the fact that they can colonise the same anatomic site, the 
upper respiratory tract, suggests the opportunity for horizontal transfer of this element. 
Podder (2003) has utilised the reported sequence differences between IS481 of B. pertussis 
and B. holmesii and developed a PCR assay that discriminated between each species. Recent 
work has also demonstrated the isolation of \S48l from human R. bronchiseptica isolates 
(Gladbach et al, 2002). Sequence analysis of the 200 bp fragment from the human R. 
bronchiseptica isolate revealed 97% homology with the consensus sequence which was 
derived from the two IS481 GenBank sequences that are available. This information 
questions whether 1^481 should still be considered as an optimal PCR target for diagnosis of 
R. pertussis infection.
The promoter region of ptx can be used to detect and discriminate R. pertussis, B. 
parapertussis and R. bronchiseptica due to this region being significantly different between 
the three species (Nygren et al, 2000). Pertussis toxin promoter has been used as taiget to 
detect R. pertussis from clinical samples in several studies (Houard et al, 1989; 
Mastrantonio et al, 1996). Insertion sequence 481 and ptx promoter have been used 
together as PCR tests for detection of R. pertussis (Houard et al, 1989; Farrell et al, 2000; 
Qin et al, 2002). Some clinical samples can be 1^481 negative and positive for the presence
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oîptx  promoter. This may be related to the other Bordetella species having the ptx promoter 
and not the insertion element 1^48L  A third target has been used, the pertussis specific porin 
gene (PO), if there was no consensus between the results of the other two PCR tests (Qin et 
al, 2002).
There is the possible danger regarding an over reliance on PCR, which may lead to the over­
diagnosis of pertussis (Lievano et al, 2002). During a pertussis epidemic in New York, 
unvaccinated children that were exposed to PCR-confirmed cases of pertussis did not 
become ill, and vaccinated children did become ül. B. pertussis may not have been the 
primary or only cause of the outbreaks that were investigated. A positive PCR result due to 
transient colonisation with B. pertussis or a false-positive (contamination of PCRs were 
found) would lead to misdiagnosis of pertussis in persons with cough illness due to other 
agents.
1.10.5 Radioactive and conductimetric assays
The presence of AC enzymic activity in clinical specimens from pertussis-infected individuals 
has been suggested for use in diagnosis of pertussis (von Koenig et al, 1989; Confer et al, 
1990; Scheftel et al, 1992). Confer et a l (1990) developed a novel method to assay 
adenylate cyclase activity of nasopharyngeal swabs by determining the conversion of 
radioactive ATP to cAMP using a commercial kit. This assay took 24 h from initiation of 
assay to completion of the assay. The swabs were incubated overnight in 1 ml of modified 
Stainer-Scholte broth before the assay was carried out. In a separate study, trials with 
clinical material showed that 90% of modified Stainer-Scholte broths inoculated with nasal 
swabs required incubation for 72 h for measurable AC activity (von Koenig et al, 1989), 
and thus differed from the AC assay used by Confer et al (1990) that only required 24 h. 
The detection limit for this radioactive assay was measured by viable counting and was 
determined to be 3-6 x 10'^  cfu ml"' for nasal swabs that had been incubated in SS liquid 
medium (von Koenig et al, 1989). A similai' method involved the collection of NPSs, which 
were immediately used for inoculation of Stainer-Scholte media and for bedside inoculation 
on to BG agar (Scheftel et al, 1992). Inoculated Stainer-Scholte medium was incubated for 
18 h at 37°C and the culture supernate was assayed for AC activity using a radio­
competition kit. All AC-positive samples were isolated from infants under 3 months. There
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was 100% correlation between AC positive and culture positive samples (Scheftel et ah, 
1992). Scheftel et a l (1992) reported that B. pertussis was not isolated from any of the 36 
AC negative samples. These assays that detected the presence of AC used radioisotopes and 
were time-consuming as well as expensive. A novel conductimetric assay that is rapid and 
inexpensive has been used to detect AC enzymic activity (Lawrence et al, 2002). This assay 
involves a continuous recording of adenylate cyclase activity by the conductimetric 
determination of enzyme-coupled pyrophosphate cleavage. Features of this conductimetric 
assay wiU be reported and discussed later.
1.11 TYPING METHODS FOR DISCRIMINATION OF R. pertussis ISOLATES.
Various techniques have been used to study B, pertussis populations but some of these 
techniques are not easily compared between laboratories. Standardisation of techniques 
would allow isolates from different geographic regions to be compared and spread of 
individual isolates to be traced. Analysis and comparison of B. pertussis populations from 
different countries is especially important for deterniiming effectiveness of different 
vaccination schedules and vaccines used. Mooi et a l (2000) have proposed that there should 
be a standardisation of techniques to study B. pertussis, including serotyping, DNA 
fingerprinting (PFGE) and typing of the pertussis toxin SI subunit, pertactin genes and other 
genes that encode virulence factors. These typing techniques and others will be described.
1.11.1 Serotyping
Three different serotypes are used to differentiate B. pertussis isolates, serotype 1, 2 and 3 
and isolates may be serotype 1; 1,2; 1,3 or 1,2,3 (Roberts and Parton, 2001). Comparison of 
serotyping results between laboratories is difficult due to the different sera and assays used. 
Assays include slide agglutination tests, traditionally with antisera raised in rabbits and made 
monospecific by absorption with heterologous strains (Parton, 2004). Mooi et a l (2000) 
recommended that serotyping should be carried out using monoclonal antibodies with a 
standard protocol, due to the lack of uniformity of different polyclonal sera preparations. 
Serotype antigens 2 and 3 are fimbrial antigens located on the major fimbrial subunits 
(section 1.4.2; Mooi et a l, 2000). Serotype antigen 1 (agglutinogen 1) is common to all 
fresh isolates and is located on LPS. Serotyping is not very discriminatory and does not 
provide much useful information for epidemiological studies of B. pertussis populations.
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However, it is still useful as fimbrial antigens are potentially important in protection (Roberts 
and Parton, 2001).
1.11.2 Pulsed-field gel electrophoresis
Pulsed-field gel electrophoresis (PFGE) has been considered to be the gold-standard for 
typing B. pertussis strains due to its discriminatory power. Fragments of genomic DNA are 
generated using rarely-cutting restriction enzymes and are analysed using PFGE to produce 
a fingerprint for that organism. This technique has been used in epidemiological 
investigations to identify outbreak-associated isolates, determine genetic variation between 
vaccine isolates and recent clinical isolates, and transmission of B. pertussis isolates 
(Brennan et al, 2000; Weber et al, 2001; Hardwick et al, 2002; De Schutter et al, 2003; 
Kourova et al, 2003; Peppier et al, 2003). A study of French and Russian B. pertussis 
isolates revealed that there had been a shift in PFGE type with time as the PFGE profiles of 
vaccme strains and pre-vaccination era isolates differed fiom those of isolates that were 
circulating at the time (Weber et al, 2001; Kourova et al, 2003). A Canadian study 
demonstrated that there was a uniformity of PFGE types within epidemiologicaUy-linked 
clusters of pertussis cases (Brennan et al, 2000). Beall et al (1995) described the PFGE 
technique for typing B. pertussis isolates using two possible combinations of restriction 
enzymes, Xbal with Spel or Drel (Beall et al, 1995). The restriction endonucleases Spel 
and Drel were usefiil for further discrimination when Xbal profiles showed minor 
differences. Results also demonstrated detectable differences in profiles after repeated 
subculture of R. pertussis isolates. This was reported for all three enzymes.
Mooi et al (2000) have recommended that DNA fragments to be analysed by PFGE should 
be cut with two enzymes: Xbal and Spel. There has been no standardisation of this method 
and there are problems relating to reproducibility. Hardwick et al (2002) reported a PFGE 
technique using only XbcH and compared results between five laboratories. A major source 
of variability within a laboratory was derived from the preparation of DNA from different 
cultures rather than from use of different gel preparations or use of different equipment. 
Comparison of PFGE profiles between laboratories is hindered by the unknown 
reproducibility of DNA fragment sizes (paitial digestion) and of the profiles. Their 
standardised procedure produced PFGE profiles that were sufficiently reproducible to allow
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each laboratory to define each of the test profiles by molecular sizes of its composite 
fragments. The profiling results from each laboratory were readily compared. The PFGE 
technique has also been applied to a small set of B. holmesii strains and the restriction 
enzymes employed were Xbal and Spel. The limited number of band patterns that were 
observed suggested that the B. holmesii genome may be highly conserved or that further 
investigation would be required as the restriction enzymes that were used may not be those 
that would optimally discriminate the B. holmesii strains (Mazengia et al, 2000).
1.11.3 1S1002 restriction fragment length polymorphism
Another approach to study population structure of closely-related bacteria is based on the 
insertion sequence (IS)-associated DNA polymorphism. There are two main insertion 
elements found scattered along the B. pertussis genome, 1^481 and IS1002. For this 
method, chromosomal B. pertussis DNA is digested with a restriction endonuclease, and the 
resulting fragments are separated by gel electrophoresis. A DNA probe comprised of an 
internal fragment of IS1002 is obtained by PCR, labelled and then hybridised to the 
separated DNA fragments under high stringency conditions. Applying this method using the 
high copy number 1S^ <^ 7 (>80 copies) resulted in a complex fingerprint pattern that was not 
easily analysed (van der Zee et al, 1996b). Insertion sequence 1002 (4-8 copies) restriction 
fragment length polymorphism (RFLP) fingerprinting produces patterns that can be easily 
analysed and has been used to study population structure and epidemiology of B. pertussis 
isolates. For Dutch strains there was a shift in population structure over time. Van der Zee et 
al (1996b) speculated that this shift in population structure may have been due to vaccine- 
driven evolution. There was a large overlap of RFLP types between Dutch and German B. 
pertussis populations, which may have been due to the close proximity of the countries. B. 
pertussis isolates from more distant countries such as Canada and Japan, showed less 
overlap of RFLP types amongst their B. pertussis populations. This study was further 
expanded to type a large number of Dutch B. pertussis isolates from 1949-1996 (van Loo et 
al, 1999). Significant differences in DNA types between populations from five time periods 
were observed. The most pronounced difference was between the pre-vaccination group of 
isolates and the ensuing time group. Van Loo et al (1999) suggested that these differences 
were driven by whole-ceU pertussis vaccination in The Netherlands. However, random drift 
and changes in the human population unrelated to vaccination camiot be disregarded. A
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comparison of the Dutch B. pertussis isolates from 1996 (Dutch epidemic year) did not 
reveal major shifts in DNA type or genetic diversity and there was no evidence for 
introduction or expansion of a particular- strain (van Loo et al, 1999).
1.11.4 Multilocus enzyme electrophoresis
Multilocus enzyme electrophoresis (MLEE) has been used to determine genetic diversity and 
structures in natural populations of a variety of bacterial species (Selander et al, 1986). The 
genetic diversity and relationships within and amongst B. pertussis, B. parapertussis and B. 
bronchiseptica was determined by investigating the electrophoretic variation in 15 metabolic 
enzymes (Musser et al, 1986). Each isolate was characterised by its combination of alleles 
at the 15 enzyme loci, and distinctive profiles corresponding to unique multilocus genotypes 
were designated as electrophoretic types (ETs). Fourteen ETs were found amongst the 60 
isolates investigated. The MLEE results have demonstrated that the Bordetella spp. 
populations are clonal. Musser et a l (1986) have shown that B. pertussis strain 18323 is 
atypical and that it is probably more closely related to R. bronchiseptica isolates than R. 
pertussis isolates. Only three ETs were found amongst 23 R. pertussis isolates investigated. 
However, this was increased to four ETs in a later study with 18 R. pertussis isolates (van 
der Zee et a l, 1997). In contrast, IS1002 RFLP typing had revealed 45 DNA types amongst 
213 R. pertussis isolates investigated. The latter method has revealed a faster molecular 
clock probably due to the transposition of and recombination between IS elements (van Loo 
et al, 1999).
Van der Zee et a l (1997) determined the distribution of thiee different IS elements 
1^1002 and ISlOOl) within different multilocus genotypes of R. pertussis, B. parapertussis 
and R. bronchiseptica. B. bronchiseptica showed the highest degree of genetic diversity and 
isolates were subdivided in three distinct clusters of ETs. Both MLEE and distribution of 
ISlOOl showed that R. parapertussis was more closely related to particular R. 
bronchiseptica strains that were grouped in cluster C (strains predominantly isolated from 
pigs) than other ETs of R. bronchiseptica. This is suggested to reinforce the notion that R. 
parapertussis is another lineage of R. bronchiseptica. Ovine and human R. parapertussis 
isolates were closely related but were distinct and showed differences in genetic diversity. 
Based on MLEE and IS typing, ovine R. parapertussis show a greater degree of divergence
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than human B. parapertussis isolates. B. pertussis and B. parapertussis may have derived 
from distinct clones of B. bronchiseptica because the ETs of B. pertussis and B. 
parapertussis m*e distantly related and both species contain different IS elements. Genetic 
diversity of B. pertussis is relatively large compared to that of B. parapertussis.
1.11.5 Repetitive element PCR fingerprinting
There are three known repetitive elements that may be present on bacterial genomes, 
repetitive extragenic palindromic (REP), enterobacterial repetitive intergenic consensus 
(ERIC) and BOX (conserved DNA element found within the intergenic regions of Gram- 
positive bacterial chromosomes) (Stem et al, 1984; Hulton et al, 1991; Martin et al, 
1992). REP and ERIC were originally described in Escherichia coli and Salmonella 
typhimurium (Stem et al, 1984; Hulton et al, 1991), and BOX was originally described in 
Streptococcus pneumoniae (Martin et al, 1992). REP, ERIC and BOX sequences have been 
utilised as PCR targets for DNA fingerprinting of several bacterial pathogens (Versaiovic et 
al, 1991; van Belknm et al, 1996; Sechi et al, 1998; Jersek et al, 1999; Zavagha et al, 
2000). Consensus outward facing primers have been designed to target these repetitive 
elements and are used in PCR to amplify the region between neighbouring elements. This 
process generates DNA fingerprints that enable the differentiation of eubacterial species and 
strains. Gillings and Holley (1997) have shown that ERIC-PCR patterns can also be readily 
generated from eukaryotes and bacteriophage even when using the recommended standard 
PCR annealing temperature of 52^C.
The discriminatory powers of three DNA commonly used fingerprinting techniques to type 
B. pertussis were compared; PFGE, randomly amplified polymorphic DNA (RAPD)-PCR 
and ERIC-PCR (Moissenet et al, 1996). The technique RAPD-PCR involves the 
amplification of arbitary DNA targeted by short random primers producing a DNA 
fingerprint. Of the three techniques, PFGE was considered to be the optimal method to 
discriminate B. pertussis isolates. ERIC- and RAPD-PCR fingerprinting methods were 
found to be poor in discriminating the isolates. A search of the B. pertussis Tohama-1 
genome using Basic Local Alignment Sequence Tool (BLAST) (Altschul et a l, 1990) 
during this PhD study revealed that ERIC sequences were not present. The ERIC-PCR 
annealing temperature used in the above study was lower than the standard 52®C annealing
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temperature. Moissenet et al (1996) used an initial annealing temperature of 26°C followed 
by 40°C.
1.11.6 Multilocus sequence typing
Maiden et al (1998) described a molecular technique that could be used to type bacterial 
pathogens causing disease locally or globally. Multilocus enzyme electrophoresis was 
adapted to produce the method, multilocus sequencing typing (MLST), that assigned alleles 
directly from nucleotide sequences of internal fragments of housekeeping genes rather than 
comparing electrophoretic mobilties of the enzymes they encode. This allelic profile is 
assigned a sequence type (ST). Multilocus sequence typing has several advantages over 
MLEE, firstly more variation would be detected resulting in greater discrimination between 
strains. Multilocus sequence typing data can be compared easily between laboratories 
compared to MLEE data, which is difficult to compare between different laboratories. The 
sequence typing data is submitted and stored in an expanding database 
(http://www.mlst.net), which has produced a powerful tool for global epidemiology (Maiden 
et al, 1998). Multilocus sequence typing was originally described for Neisseria meningiditis 
and Streptococcus pneumoniae (Maiden eta l, 1998; Enright and Spratt 1998). Tins method 
is used for several apphcations, including tracking the emergence of antibiotic-resistant 
pathogens, association of particular genotypes with vintlence and antigenic characteristics, 
and global spread of disease caused by novel variants (Urwin and Maiden 2003). The data 
have also been used in evolutionary and population analyses that estimate recombination and 
mutation rates and investigate evolutionary relationships among bacteria that are classified as 
belonging to the same genus.
1.12 SEQUENCE TYPING OF B, pertussis VIRULENCE GENES
Sequencing of vir ulence-associated B. pertussis genes has similar advantages to the MLST 
technique described in section 1.11 with regard to the fact that results from different 
laboratories could be easily compared and such a method can be informative for clonal 
organisms such as B. pertussis. Several sequence typing studies of B. pertussis isolates have 
been reported. The genes that encode the virulence factors pertussis toxin SI subunit (ptxA) 
and pertactin (prnA) have been demonstrated to contain polymorphic regions that can be 
used to type B. pertussis isolates (Mooi et a l, 1998). B. pertussis is known to be clonal
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from MLEE studies, see section LI 1.4, and sequencing of its housekeeping genes (van Loo 
et al, 2002). Therefore using virulence-related genes that are under adaptive pressure will 
potentially show greater variation than that exlnbited by its housekeeping genes. Targets 
chosen for study of the epidemiology of circulating strains by van Loo et al (2002) included 
genes coding for surface proteins and pertussis ACV components. The following genes were 
sequenced: pertactin (prnA), subunits of pertussis toxin, (ptxA, B, C, D and E), fimbriae 
{ftm2 and fim3), filamentous haemagglutinin (fhaB), tracheal colonisation factor (tc/A), 
outer membrane proteins {ompP and ompQ), bordeteUa intermediate phase protein {bipA), 
bordetella resistance to killing protein A {brkA) and virulence-activated gene 8 (vagS). Only 
the genes ptxA, ptxC, tcfA, fim2 and prnA showed variation in B. pertussis isolates. Van Loo 
et a l (2002) characterised strains from The Netherlands, Finland, Italy, United States and 
Japan using a MLST scheme based on three of these genes: ptxA, ptxC  and tcfA, Further 
information relating to this scheme will be reported and discussed later.
Sequence analyses from different countries can be directly compared to determine if B. 
pertussis populations world-wide are the same or if they differ in some or aU gene tar gets. 
However, agreement is required with regard to the gene target and its regions that are 
analysed for an individual typing scheme. The results of sequence typing studies relating to 
shift in B, pertussis populations and how this may relate to the resurgence in pertussis are 
described in sections 1.13.2 and 1.13.3.
1.13 EPIDEMIOLOGY OF PERTUSSIS
1,13.1 World-wide epidemiology of pertussis
B. pertussis causes 20-40 million cases of pertussis worldwide each year. Ninety percent of 
these cases are from developing countries and there are an estimated 200,000-400,000 
fatalities, mainly in infants (http://www.who.int/vaccines/en/peitussis.slitml). The majority of 
the most severe cases of pertussis and fatalities occur in young infants but pertussis can 
cause disease at any age. In Western countries, about 10-12% of all pertussis cases have 
been reported from individuals more than 15 years old. Incidence of pertussis is cyclic with a 
peak approximately every 4 years as seen in the data from the UK (Fig. 1.9.1). Cycles are 
caused by the changing number of susceptible individuals and the rate of transmission by B. 
pertussis. After a peak, the number of susceptible people is low and there is tittle
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transmission. As immunity wanes and newborn infants enter the community, there is an 
increase in the number of susceptible individuals, resulting in greater transmission and a new 
peak (Robbins, 1999).
1.13.2 Genetic and antigenic shifts in B. pertussis population
Comparisons of currently circulating isolates with pre-vaccination era isolates and vaccine 
strains used in various countries have revealed that a shift in the B. pertussis population has 
occurred over time. Sequence typing of several virulence factors along with PFGE and 
1^1002 RFLP have revealed this trend (see sections 1.11.2, 1.11.3 and 1.12). A shift in 
pertactin (prnA) and pertussis toxin SI subunit (ptxA) gene types in B. pertussis strains 
circulating in the pre-vaccination era compared to recent isolates has occurred and it was 
suggested, after a study in The Netherlands, that these shifts were driven by vaccination with 
Dutch WCV (Mooi et al, 1998). The emergence and subsequent dominance in circulating 
strains ofprnA and ptxA types not found in the WCV were subsequently described in several 
other countries, including US, Finland, Poland, and Italy (Mastrantonio et al, 1999; Mooi et 
al, 1999; Cassiday et al, 2000; Gzyl et al, 2002). The situation for B. pertussis isolates 
from the UK differs regarding ptxA variation m that the same ptxA allele was found in two of 
three WCV strains and in recently circulating isolates (Fry et ah, 2001).
There was no apparent shift in prnA type until the early 1980s; that is, the vaccine strains, 
pre-vaccination isolates and strains isolated after implementation of vaccination all contained 
prnA{\) in The Netherlands, Finland, US, UK and Poland (Mooi et al, 1998; 1999; 
Cassiday et al, 2000; Fry et al, 2001; Gzyl et al, 2002). No Polish isolates were available 
from the 1980s so it is not possible to determine when T\on~prnA(\) alleles appeared in this 
country. There were differences between the B. pertussis populations from these countries 
with regard to the ptxA alleles that were present during the pre-vaccination era to the 1980s. 
Dutch isolates during this period contained ptxA(ll) or ptxA(3) and the country's vaccines 
contain both ptxA alleles (Mooi et al, 1998). The US isolates from a similar time period 
were ptxA{\), ptxA{2) and ptxA(3) and the US vaccines (that are known) contain ptxA(2) 
(Cassiday et al, 2000). The Finnish B. pertussis population contained only ptxA(2) and its 
vaccines contain the same ptxA alleles as the Dutch vaccines (Mooi et al, 1999). B. 
pertussis isolates from UK and Poland containedptxA{\) andptxA{2) (Fry et al, 2001; Gzyl
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et al, 2002). The Polish vaccine strains aie ptxA{2) whereas the UK vaccine strains are 
ptxA(l) andptxA{2).
The presence of prnA{2) and prnA(3) was found in 16-24 (20-30%) Dutch isolates from 
1981-1988 (Mooi et al, 1998). From 1989 onwaids, the frequency oîprnA{2) màprnAQ) 
increased, 204 of 227 (90%) Dutch isolates were either of these alleles. During 1993- 
1996, the predominance ofprnA(2) and prnA(3) alternated in successive years (Mooi et al, 
1998). It should be noted that, when The Netherlands had the unexpected epidemic in 1996, 
prnA(3) was predominant. The frequency of vaccine alleles ptxA{2) and ptxA(3) decreased 
after the introduction of vaccination, ptxA(l) was not present until 1975-1985 and this allele 
was in 150 of 170 (88%) Dutch isolates during 1990-1996 (Mooi et al, 1998). The 
presence of the non-vaccine prnA, prnA(2), isolates became apparent in the US B. pertussis 
population dui’ing 1975-1987. This shifted until 64 of 92 (70%) US isolates were prnA{2) 
during the 1990s. A shift in ptxA types was also apparent with a decrease mptxA(f) and an 
increase oîptxA{\) until 1989-1999 when 72 of 92 (78%) were ptxA{\) (Cassiday et al, 
2000). During 1990-1996 four prnA alleles {prnA(\yprnA{A)) were present in the Finnish B. 
pertussis isolates with the non-vaccine type, prnA{2), as the predominant type found in 31 of 
43 (72%) isolates (Mooi et al, 1999). From 1982 onwards, all Finnish isolates contained the 
non-vaccine typo,ptxA(l) (Mooi et al, 1999). During the 1990s, Polish isolates were 
predominantly, 11 of 19 (58%), the vaccine prnA type, prnA(l), and the predominance of 
ptxA(l) shifted until all Polish isolates from the 1990s (including 2000) w ere;?W (l) (Gzyl 
et a l, 2002). A shift in prnA type amongst UK isolates was apparent after 1982. During 
1982-1985 and 1998-1999, 21 of 86 (24%) isolates and 56 of 105 (53%) of isolates were 
non-prnA{\), respectively. The frequency of ptxA{\) amongst the UK B. pertussis 
population increased until 1990-1999 when all isolates were ptxA{\) (Fry et a l, 2001). A 
similar study was also carried out on recent Italian B. pertussis isolates. Italy differs from the 
other countries in that it has a history of low vaccination. Even with this history of low 
vaccination, similar ptxA and prnA types were found amongst the recent Italian isolates and 
these differed from the alleles found in the Italian vaccine strains. The vaccine strains were 
prnAiX) and ptxA(2) or prnA{5) and ptxA{3), All Italian strains from 1993-1995 were 
ptxA{\). Of these isolates, 65 of 129 (51%) were prnA(3\ 53 (41%) w ere/)W (2), 8 (6%) 
wereprnA{V) and 3 (2%) wereprnA(5) (Mastrantonio et a l, 1999).
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The prnA and ptxA trends in the different B. pertussis populations studied are veiy similar in 
that these populations had similar prnA and ptxA types during the pre-vaccination era and 
the alleles that are now found are also similar. The polymorphic regions of prnA and ptxA 
regions interact directly with the immune system. Mooi et al (1998) suggested that the 
expansion of particular prnA and ptxA types is not a consequence of variation in these 
particular molecules only but is due also to changes in other bacterial antigens which affect 
strain fitness and which may be linked to particular ptxA and prnA types. An MLST scheme 
adapted for typing B. pertussis isolates had demonstrated that predominant MLST types that 
were present in the pre-vaccination era were found only at very low firequencies or not at all 
amongst recent isolates. A predominant type, MLST-5, was present in the Netherlands, US 
and Japan and this MLST type was not apparent in B. pertussis isolates until 1990s (van 
Loo et al, 2002). Determining whether a sliift in MLST type has occurred in the UK B. 
pertussis population has been investigated during this PhD and the results will be reported 
and discussed later.
1.13.3 Resurgence in pertussis
Pertussis has been increasing recently in several countries that have had vaccination 
programmes implemented since the 1950s. Several explanations have been put forward for 
the resurgence of pertussis in a vaccinated population. These include improved surveillance, 
changes in case definitions and diagnostic techniques. It has also been suggested that it is 
possibly due to demographic changes, waning vaccine-induced immunity, changes in vaccine 
effectiveness, changes in vaccine coverage and adaptation of B. pertussis population to 
vaccine-induced immunity. Countries that have reported an increase in pertussis cases 
include The Netherlands, Canada, Australia, Poland, US and Taiwan. In 1996, The 
Netherlands had an unexpected pertussis epidemic that showed an incidence that was five­
fold higher than previous epidemics (Mooi et al, 1998). In 1996, there were 2,771 reported 
cases of pertussis compared with 319 cases reported during the previous year (de Melker et 
al, 1997). The study of age distribution of pertussis in The Netherlands had shown that 
there was a significant decrease in the proportion of patients aged less than 1 year (21% in 
1989 to 7% in 1996) and a significant increase in the proportion of patients aged 1-4 years 
(21% in 1989 to 30% in 1996). There was also a decrease from 1989 to 1995 in those 
infected with pertussis aged 5-9 years but, by 1996, this incidence had increased to 39%. A
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sequencing study of prnA and ptxA allelic variation in the Dutch B. pertussis population 
revealed that, during 1996, isolates were predominantly non-prnA and non-ptxA vaccine 
typQS, prnA{3) andptxA{\). From a previous study it was known that the Dutch whole-cell 
vaccine strain expressing prnA{\) was not as protective against B. pertussis strains 
expressing prnA{2) or prnA(3) (King et a l, 2001). It has been suggested tliat this shift may 
have played a part in the resurgence of pertussis (Mooi et al., 1998). However, a shift has 
also been demonstrated in the UK and Finnish B. pertussis populations but this has not been 
accompanied by resurgence in pertussis levels (Mooi et al., 1999; Fry et al., 2001).
In Canada, the incidence of pertussis has increased four-fold, from 5 per 100,000 in the late 
1980s to about 20 per 100,000 in recent years (Hoey, 2003). In Australia, since the 1990s, 
pertussis notification rates have increased noticeably from record low levels that were seen 
during the 1970s and 1980s (Menzies et al, 2003). A Polish study had noted that, during 
the 1990s, there was an increase in morbidity and an unexpectedly large number of pertussis 
notifications were observed in 1997 and 1998 (Gzyl et al, 2002). This Polish study had 
noted that there was increase in pertussis. However, vaccine prnA types were still 
predominant amongst recent B. pertussis isolates. The US had reported an increase in 
pertussis incidence since the 1980s, from 0.75 per 100,000 in 1980 to 2.74 per 100,000 in 
1998 (Yih et al, 2000) and the highest number of pertussis cases in the US since 1967 
occurred in 1996 (Cassiday et al, 2000). It was suggested that, unlike The Netherlands, 
much of this increase in the US occuned amongst patients aged 10-19 years. Similar to The 
Netherlands, this increase was suggested to be related to the shift in its B. pertussis 
population from the predominance of vaccine prnA and ptxA alleles to those that are non­
vaccine types. In Taiwan, pertussis vaccination lias been carried out since 1955 and, during 
1971-1991, the annual numbers of reported pertussis cases were aU in single digits (Lee et 
al, 2003). Since a pertussis outbreak in 1992 there has been an upward trend in the number 
of cases.
Several studies relating to waning vaccine-induced immunity have reported an increase in the 
pertussis incidence amongst adults and adolescents (Yih et al, 2000; Guris et al, 1999; 
Gilberg et al, 2002; Hoey 2003). B, pertussis infection in adults produces a wide spectrum 
of symptoms thus making the correct diagnosis of a suspected pertussis case difficult,
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leading to potential under-reporting of the disease and providing a reservoir of infection to 
the unvaccinated population. It is mainly accepted that atypical or asymptomatic symptoms 
of pertussis infection occur" within these individuals but in one study with reported cases in 
adolescents and adults, 83% and 87% respectively, had paroxysmal coughing and many had 
whooping, apnoea and vomiting at the time of diagnosis (Yih et al, 2000). An investigation 
of the predominance of Chlamydia pneumoniae amongst adults that had a cough for more 
tlran two weeks revealed that pertussis infection was more predominant, 18.5% versus 6.5% 
in controls, and dual infections were also found (Miyashita et al, 2003). There is evidence 
of transmission of B. pertussis from symptom-free adults and adolescents to susceptible 
children. Asymptomatic B. pertussis infection was detected amongst household members of 
infants and children with pertussis (De Schutter et al, 2003). There was homogeneity of 
isolates recovered fr om contacts and the primary case of infection within a frmily. It was 
suggested that well-vaccinated adolescents and adults play an important role in the 
epidemiology of pertussis by acting as reservoirs of spread to incompletely vaccinated and 
non-vaccinated children but the mechanism for tins transmission is unclear.
1.13.4 Pertussis epidemiology in the UK
The UK B. pertussis population has demonstrated a shift fr om vaccine prnA types to non­
vaccine prnA types, as seen in several other countries. The UK B. pertussis population 
differs from others with regard to its ptxA trend. It is unique in the fact that the recent toxin 
type is the same as that found in its whole-cell pertussis vaccine strains as well as in pre­
vaccination isolates (Fry et al, 2001). Resurgence of pertussis m various countries has been 
described above but this situation has not been seen in the UK. In fact, pertussis incidence is 
at historically low levels. A pertussis epidemic took place in the UK during the late 1970s 
and the early 1980s but this was due to a decrease in the vaccine uptake rate (Fig. 1.9.1; see 
section 1.9), An enlianced surveillance programme in the UK during 1995-1997 was 
undertaken to monitor the pertussis situation in England and Wales. From this study it was 
found that pertussis is increasingly affecting younger, unvaccinated children and to a lesser 
extent adolescent and young adults (van Buynder et al, 1999). The proportion of 
notifications occurring in patients 15 years of age and older since 1991 has increased fr om 
4.4% to 9.3% and for those 6 months and younger notifications increased from 6.3% in 
1991 to 19.1% in 1997 (van Buynder et al, 1999). It was also found that there was a
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continuing significant and under-reported mortality associated with pertussis in the very 
young age group.
A recent UK study aimed to determine whether parents or siblings were the source of 
pertussis infection for infants too young to be protected by vaccination (Crowcroft et al, 
2003). It was found that pertussis was a more fi-equent cause of admission to the paediatric 
intensive care unit (PICU) than previously thought. For most of the infants in this study, the 
symptom presentation was atypical therefore pertussis was not suspected and the case would 
have not been otherwise investigated or notified as pertussis. Under-notification and under 
ascertainment of severely-affected infants requiring admission to the PICU was also 
described (Crowcroft et al, 2003). This study highlighted the potential carriage of B. 
pertussis by individuals. There were household contacts that had no symptoms but these 
individuals had either PCR-positive results or anti-PTX IgG levels indicating recent 
infection. There could be several explanations for these indications of pertussis infection 
such as false PCR positives, carriage of B. pertussis, modification of disease through 
vaccination and subcHnical infection with immunological boosting. Highly sensitive 
diagnostic methods such as PCR may be detecting carriage in individuals, if it does occur, 
which might explain the persistence of the infection in the community despite high 
vaccination coverage. Even though overall levels of pertussis have declined in recent times, 
and are greatly reduced compared to those of the pre-vaccination era, it still remains a 
significant cause of mortality and severe morbidity in the very young.
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1.14 AIMS AND OBJECTIVES
The main aim of this study was to investigate whether the adenylate cyclase toxin gene and 
other virulence-related genes of Bordetella pertussis could be used as potential 
epidemiological markers. A sequencing study has been previously carried out on B. 
pertussis isolates from the United Kingdom (UK) dating from the pre-vaccination era to 
present day using pertactin and pertussis toxin SI genes as markers and similar studies 
have been carried out in several other coimtries. Several vfrulence-related genes are to be 
investigated for the presence of polymorphic regions and, once identified, the allele 
frequencies of individual genes should be determined for the UK B. pertussis population 
from the pre-vaccination era to present day (1920-2002). Gene marker sequence typing 
studies are to be applied to UK B. pertussis isolates to determine whether a genetic shift 
has occurred in the B. pertussis population from the pre-vaccination era to present day and 
if circulating isolates are of the same gene types as the B. pertussis whole-cell and acellular 
vaccine strains.
The virulence factor, adenylate cyclase toxin has been described previously as target for 
diagnostic tests using conventional radioisotopic assays or for polymerase chain reactions. 
A novel conductimetric assay that has been developed within the Division of Infection and 
Immunity detects the presence of adenylate cyclase by its enzymic activity. It is important 
to determine whether this assay could be used in a diagnostic setting. This involves 
developing and optimising a quick and easy protocol for detecting enzymic (AC) activity 
from B. pertussis cells and determining the sensitivity of the assay. To aid with the 
optimisation of the conductimetry assay as a diagnostic test, constructs containing the 
adenylate cyclase toxin promoter inserted upstream of promoterless reporter genes, lux 
(this operon codes for the enzyme luciferase and the substrate luciferin that are required for 
the light emitting reactions) and green fluorescent protein {gfp), will be developed to 
determine when the optimal expression of adenylate cyclase toxin gene occui’s during the 
growth of the organism.
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2.0 Materials and Methods
2.1 BACTERIAL STRAINS AND CULTURE CONDITIONS
2.1.1 Bordetella strains
Bacterial strains used in the conductinietiy and sequencing analysis studies are described in 
Table 2.1.1.2.1.1.1. Other studies were performed using a panel of 152 United Kingdom 
(UK) clinical isolates oîB. pertussis, from 1920 to 2002 (Table 2.1.1.2), and all isolates in 
this study were assumed to be epidemiologically unrelated. The three strains used in the 
preparation of one of the UK whole-cell pertussis vaccines (Medeva Pharma), were 
CN2992, CN5476 and CN3099. In addition, the .isolate Tohama-I (components of which 
are used in acellular pertussis vaccines in the UK and other countries) and the type strain of 
B. pertussis (18323^, NCTC10739^) were also characterised. Appendices 6-8 list further 
information on the UK isolates. The years of isolation and numbers of clinical isolates in 
the panel are listed in Table 2.1.1.2. Not all isolates were examined for all targets and data 
from a previous study (Fry et ah, 2001) were used to aid the selection of subsets of isolates 
containing representatives of all known Bordetella isolates. These isolates were obtained 
from the Division of Infection and Immunity (DII), University of Glasgow; Glasgow 
Veterinary School, University of Glasgow; the Respiratory and Systemic Infection 
Laboratory (RSIL), Health Protection Agency, Colindale, London; the National Collection 
of Type Cultures (NCTC), Colindale, London; and the Wellcome Bacterial Collection held 
byNCTC.
2.1.2 Growth of Bordetella
Isolates of Bordetella pertussis, B. parapertussis, B. bronchiseptica, B. avium, B. 
trematum, B. hinzii and B. holmesii were grown either on (i) Bordet-Gengou (BG) agar 
(Appendix 1.1) in a humidified environment at 37°C for up to 3 days or (ii) on blood 
charcoal agar (Media Services, CPHL, HPA) at 37°C with 5% CO2 for up to 5 days. To 
obtain visible colonies, B. avium, B. bronchiseptica, B. trematum and B. hinzii required 
incubation for only one day, B. parapertussis required two days and B. holmesii required 
three days. Some B. pertussis isolates required incubation for up to five days. Bacterial 
growth on solid media was used for inoculation into liquid medium, preparation of cell 
lysates for conducthnetiy analysis or for preparation of DNA. To check for haemolysis 
Bordetella spp. were grown on BG sandwich plates. This medium was prepared by pouring 
a layer of BG agar without blood and, once set, a thin layer of BG agar with blood was
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poured on top. For liquid culture, B. pertussis was inoculated from BG plates into Stainer- 
Scholte (SS) liquid medium or Cyclodextrin Liquid (CL) medium (Appendices 1.2 and 1.3) 
and grown for three days (unless stated otherwise) at 37°C with shaking at 150-200 rpm. 
The volume of liquid medium inoculated varied, either a loopful of bacteria in 5 ml liquid 
medium in a universal or approximately 1.5 ml of bacterial culture to 250 ml of hquid 
medium in a 500 ml flask. Bacterial growth in liquid culture was used for growth curve 
analysis, preparation of urea extracts and for use in conductimetry analysis.
2.1.3 Storage of Bordetella
Long-term storage of Bordetella spp. was achieved by either (i) suspension of bacteria in 
1% (v/v) Casamino acids (CAA) solution (Appendix 1.4) containing 20% (v/v) glycerol 
and storage at -70°C or (ii) suspension in nutrient broth with 15% (v/v) glycerol and 
storage on pre-autoclaved Embroidery beads (2mm, Ellis and Farrier Ltd) at -80°C. From 
some of the suspensions, bacterial pellets were obtained by centrifugation and stored at - 
80°C for subsequent DNA extraction. All media were sterilised by autoclaving at 15 p.s.i 
(12UC)for 15 mm.
2.1.4 Escherichia coli strains
Escherichia coli strains (Table 2.1.4.1) used for maintenance and cloning of Im  (operon 
encodes for luciferase and luciferin) and gfp (green fluorescent protein) reporter plasmids 
(section 2.15) are listed in Table 2.2.2.1. E. coli isolates were obtained from Stratagene and 
the Division of Infection and Immunity (DII), University of Glasgow.
2.1.5 Growth of EL coli
E. coli strains were grown on Luria Bertram (LB) agar (Appendix 1.5) or on SGAL™/LB 
Agar Blend (Sigma), prepared according to manufacturer’s instructions, if blue and white 
colony selection was required for identification of successfully transformed cells, with the 
appropriate antibiotics. The resulting white colonies potentially contained the plasmid with 
insert due to disruption o f the plasmid-encoded p-galactosidase. Inoculated plates were 
incubated overnight at 37°C and inoculated LB broth (Appendix 1.5) was incubated 
overnight at 3TC  with shaking at 150-200 rpm. All media were sterilised by autoclaving at 
15 p.s.i (12UC) for 15 min.
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Table 2.1.4.1, E. coli strains used
Strain Genotype Source
XL-1 Blue MRF'
Supercompetent
cells
iS{mrcA)183 A(mcrCB-hsdSMR-mrr) 
173, endAl, supE44, thi-1, recAl, 
gyr96, relAl, lac proAB 
lacPZAM15, Til5 (Kan’’)]
Stratagene
XL-2 Blue recÂl, endAl, gyrA96, thi-1, hsdRl?, 
supE44, relAl, lac proAB 
lacfZAM lS Tn/0(Tet^ Amy Cam'l
Stratagene
SMIO Ipir thi-1, thr, leu, tonA, lac Y, supE, 
recrt ::RP4-2-Tet::Mu, Kafr , Àpir
Division of Infection and 
Immunity
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2.1.6 Storage of E. coli
Stocks of E. coli were prepared by adding 300 pi of 70% (v/v) glycerol (sterile-filtered) to 
700 pi of an E. coli overnight culture in LB broth and stored at -80°C.
2.2 DNA EXTRACTION
2.2.1 Genomic DNA extraction
Genomic DNA for use as template in the polymerase chain reaction (PCR) was extracted 
from Bordetella spp. and E. coli using (i) an in-house (DII) boiling protocol or (ii) a 
commercial kit (Nucleon BACC2 genomic DNA extraction kit, Amersham Biosciences).
(i) A loopful of bacterial cells from a BG plate was suspended in 100 pi of Double 
Processed Tissue Culture Water (Sigma) in a 1.5 ml microfuge tube to produce a turbid 
suspension. The suspension was placed in a heating block set to 100°C and incubated for 
10 min to allow lysis. Suspensions were placed at -20°C for 5 min to snap-freeze then 
allowed to thaw and these suspensions were centrifiiged at 6,700 x g for 10 min (Biofrige 
pico, Heraeus). The resulting supernate (containing DNA template) was transferred to a 
fresh tube and stored at -20°C. A volume of 1 pi of this DNA solution was used as template 
in subsequent PCR reactions.
(ii) Genomic DNA was extracted with the Nucleon genomic DNA extraction kit BACC2 
according to the manufacturer’s instructions (Amersham Bio sciences). A previously- 
prepared B. pertussis cell pellet was suspended in lysis solution, Reagent B. A volume of
2.5 pi of 50 pg ml"^  of RNase A was added to the suspension and this was incubated for 30 
min at 37°C. The lysed suspension was de-proteinised using sodium perchlorate followed 
by the extraction of DNA using chloroform and Nucleon® resin. DNA was precipitated 
with ice-cold 95% ethanol and the resulting pellet was washed twice with ice-cold 70% 
ethanol. The pellet was resuspended in 50 pi of nuclease-free water (Promega) and the 
DNA concentration determined using a GeneQuant II spectrophotometer (Amersham 
Biosciences) at A260 and stored at -20°C. The amoimt of genomic DNA used as template in 
subsequent PCR reactions was 100 ng.
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2.2.2 Plasmid purification
Plasmid DNA (pGEM®-T Easy (Promega), pSB395 and pPROBE-AT', Table 2.2.2T) was 
extracted from B. pertussis and E. coli using the QIAprep® Spin Miniprep kit (Qiagen) 
according to the manufacturer’s protocol. E. coli was grown at 37°C overnight in 5 ml of 
LB with 12.5 pg ml"^  of tetracycline or 150 pg ml'  ^of ampicillin. B. pertussis was grown at 
37°C for 3 days in 10 ml of SS and 12.5 pg ml'* of tetracycline. Purity of B. pertussis 
cultures was ensured by using the Gram stain method. Bacterial cells were pelleted by 
centrifugation for 10 min at 4,000 x g  (Megafuge. 1.0, Heraeus). Pellets were resuspended 
in 250 pi of buffer PI. A volume of 250 pi of lysis solution, buffer P2, was added and the 
solution was mixed gently for a few sec. Buffer N3 (350 pi) was added to neutralise the 
reaction and the tube was inverted several times. Tubes were centrifuged for 10 min at 
11,200 X  g  (Biofuge pico, Heraeus) and the resulting supernate was decanted into QIAprep 
columns which were then centrifuged to allow binding of DNA to the column. A volume of 
500 pi of buffer PB was added to the column to remove any endonucleases. The second 
wash step, addition of 0.75 ml of buffer PE, was to remove any traces of salts and the 
column was centrifuged for one minute at 11,200 x g. The column was centrifuged for a 
further minute at the same speed to remove any further traces of buffer PE. The plasmid 
DNA was eluted by the addition of 50 pi of buffer EB and the DNA was stored at -20°C. 
Purified plasmid was not quantified throughout this study. Instead the intensity of the 
purified plasmid band on 1% (w/v) agarose gel gave an indication of how much plasmid 
was present and this determined the volume added in fiirther assays.
2.3 Restriction Digests
Suitable restriction enzymes were selected to digest the plasmids pGEM®-T Easy 
(Promega), pSB395 and pPROBE-AT' (Table 2.2.2.1) as well as the insert cyaA promoter 
region, amplified with prhners CyaAl/CyaA6 or CyaAl/CyaA8 (section 2.4). The program 
Webcutter 2.0 (www.firstmarket.com/cutter/cut2.html) was used to analyse the amplified 
B. pertussis cyaA promoter region for the presence of restriction sites, thus determining 
which enzymes would be suitable for the digestion of this region. Any restriction enzyme 
that digested this region was disregarded. Purified plasmid preparations isolated from B. 
pertussis and E. coli were digested using appropriate enzymes for use in hgation reactions 
or to isolate an insert that the plasmid already contained. The restriction enzymes used
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Table 2.2.2.I. Plasmids used.
Plasmid Comment Source/Reference
pGEM®-T Easy High copy number plasmid. Contains T7 and SP6 promoters flanking a multiple 
cloning region within the a-peptide 
coding region of P-galactosidase. An 
insertion within this region allows 
recombinant clones to be identified by 
blue/white screening. Amp^
Promega
pSB395 broad host range mobilisable (oriV, oriT) medium copy number plasmid. Contains 
the promoterless luxCDABE operon. Tet*^
Provided by Dr M. 
Lynch, Winson et a l, 
1998
pPROBE-AT' broad host-raiige plasmid derived from the B. bronchiseptica plasmid pBBRl. 
Contains the promoterless gfp gene. Amp^
Provided by Dr M. 
Lynch, Miller el a l, 
2000
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during this study were Kpnl, Sad, Pstl and EcoPl (Promega). The volume of purified 
plasmid added was 10 pi, with 3 pi of buffer H (90 mM Tris-HCl, 10 mM magnesium 
chloride, 50 mM sodium chloride, used with Pst\ and EcuRI) or buffer J (10 mM Tris-HCl, 
7 mM magnesium chloride, 50 mM potassium chloride and 1 mM dithiothreitol, used with 
Kpnl and Sad) and 1 pi (10 Units (U)) of appropriate restriction enzyme to a total reaction 
volume of 30 pL The digest reaction was incubated at 37°C overnight. To ensure that 
digestion had been successful the reactions were analysed by electrophoresis on a 1% (w/v) 
agarose gel with a 1 kb ladder (Invitrogen Ltd) (section 2.6).
2.4 Primer design
Ohgonucleotide primers were designed to target eight genes; pixC, tcfA,fim2, vagS, ompQ, 
cyaA, bapC and brkA. GenBank sequences were analysed for suitable sequences to be 
selected for use as primers for PCR amplification and sequencing of (i) a small region of 
polymorphism {ptxC, tcfA, fim2, vag8 and ompQ), (ii) a large section of a gene for 
investigation of polymorphism (cyaA) or (in) a complete open reading frame (bapC and 
brkA). Once primers were selected they were analysed using the internet program 
NetPrimer (http://www.premierbiosoft.com), thus ensuring that the selected primer 
sequence did not contain any potential secondary structures such as hairpins, cross-dimers 
and self-dimers. NetPrimer also calculated the melting temperature of each designed 
primer. Primers (50 nmol and desalted) were obtained from Invitrogen Ltd. The primers 
were resuspended in 10 mM Tris-HCl, 1 mM EDTA (TE) pH 8.0 buffer (Sigma) to give a 
stock concentration of 1 pg pf*. Table 2.4.1 shows the primers used in this study. Basic 
Local Alignment Search Tool (BLAST) (Altschul et al., 1990; 
http://www.ncbi.nlm.nih.gov) was used to check that the primer sequences would target the 
desired B. pertussis gene sequence. Using the BLAST option available through the Sanger 
website (http://www.sanger.ac.uk), it was possible to check that primer sequences were 
unique for the appropriate target and would not amplify any other B. pertussis sequences. 
BLAST was also used to check for potential nucleotide variation of the adenylate cyclase 
toxin gene (cyaA) between B. pertussis strains, as the available genome sequence is of 
Tohama-I and the GenBank sequence is of the atypical B. pertussis strain 18323^ 
(NCTC10739'*’).
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Table 2.4.1. Oligonucleotides designed for this study for amplification and sequencing of 
the target genes of B. pertussis. Sequences that are highlighted in red indicate restriction 
sites that have been engineered into the primer sequences; Kpnl (GGTACC); HindlW 
(AAGCTT) and BgBl (AOATCT). The position of the primer is according to the numbering of 
the sequences of the following GenBank accession numbers: cyaA, Y00545; tcfA, U16754; 
vag8, U90124; ptxC, M13223; brkA, U 12276; bapC, AF081494; ompQ, 1316266, fim2, 
Y00527 and luxC AF403784.
Primer
name
Sequence (5'-3') Gene Position Source of 
information
CyaA IF TCGTGGGCAAGCAGGACCGC cyaA 3586-3605 E. Packard
CyaAlR GCCGCCAACCAGGGTGTCGT cyaA 4136-4117 E. Packard
CyaA2F ACGACACCCTGGTTGGCGGC cyaA 4117-4136 E. Packard
CyaA2R CCTGGATGGATCATGGCGGA cyaA 4636-4617 E. Packard
CyaA3F TCCGCCATGATCCATCCAGG cyaA 4617-4636 E. Packard
CyaA3R CACCACGTTCTCGATACCGG cyaA 5186-5167 E. Packard
CyaA4F CCGGTATCGAGAACGTGGTG cyaA 5167-5186 E. Packard
CyaA4R TGCCCAAGCTCAGGAATACG cyaA 5496-5477 E. Packard
CyaASF CGTATTCCTGAGCTTGGGCA cyaA 5477-5496 E. Packard
CyaASR GCGCCAGTTGACAGCCAGGG cyaA 6098-6079 E. Packard
CyaAl GGTACCGGCGAAGCTTAGGGCC
CAGCTGCA
cyaA 287-303 M. Lynch
CyaA8 CTCGAGATCTACGCCATCGGCC cyaA 1396-1376 M. Lynch
CyaA6 ACGCCCAAGATCTTTGGTGGC cyaA 1165-1146 M. Lynch
LUXCr GGATTGCACTAAATCATCACTTT
CG
luxC 1007-983 E. Packard
CyaApF CATCATGGTTGCGCCGGAAT cyaA 570-589 E. Packard
CyaApR GATTGAACGGATTCGCACCG cyaA 958-939 E. Packard
CyaPins-
S
CGATCGCGATCGCGTTCG(FLUO) cyaA 685-696 E. Packard
CyaP-A (RED640)GCTTGCTCGCTTATTTA
TCTCCCTTGAAG(PHOSPHATE)
cyaA 698-726 E. Packard
PtxS3F CAGCCCGTATGAAGGCAGGT ptxC 3433-3452 E. Packard
PtxAJKS
S3R
TCTTTCAAGGGATTCATTCGCG ptxC 3700-3679 F. Mooi
PtxS3-
3270F
TTTATCGCGAAACTTTCT ptxC 3270-3287 N. Fry
PtxS3-
3658R
biotin-TGGACAGGCGAACAG ptxC 3658-3644 N, Fry
PtxS3-
3610FS
GGCAGCGTCGATATG ptxC 3610-3624 N. Fry
Fim2-
632F
biotin-TGGGTGCGAACGAGGCGA fim2 632-649 N. Fry
Fim2>
900R
CCGGCCGGGCTCCTTGAG fim2 900-885 N. Fry
Fim2-
720RS
GTAGCGCATCGTGAC fim2 720-706 N. Fry
OmpQ-
1377F
GCCTATGTCGTGACGCTG ompQ 1377-1394 N. Fry.
OmpQ-
1533R
biotin-AGAAGCGCTGGGTCA ompQ 1533-1519 N. Fry
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OmpQ-
1444FS
GGTATATGAAAGGCTACGA ompQ 1444-1462 N. Fry
TcfAFl ACGCCAGCCTGCCAAGACG tcfA 4-22 E. Packard
TcfARl GGCTGCGCTTGAAATCCTCC tcfA 529-510 E.Packard
TcfAF TTCTTGCGCGTCGTGTCTTC tcfA 270-289 F. Mooi
TcfAR4 TTCGGAGTTTTCGTCATTGCG tcfA 813-792 F. Mooi
TcfAF4 CTCCGGTTGCGAAGCCAGGT tcfA 577-597 E. Packard
TcfAR5 GATTCAAGCCTCCAGCCGAC tcfA 1032-1014 E. Packard
TcfAF2 TCGTCTGGCGGACATACCCC tcfA 688-707 F. Mooi
TcfAR3 GCGGTTGCGGACCTTCAT tcfA 1339-1322 F. Mooi
TcfAF3 AAACGGTGGCAACGGTGG tcfA LI 233-1250 F. Mooi
TcfAR2 CCTTGGCGTCGTCCACCT tcfA 1867-1850 F. Mooi
TcfAM GCGGTGGCTGGCTACACC tcfA 1693-1710 F. Mooi
TcfAR6 TACCAGGCGTAGCGATAGC tcfA 2345-2327 E. Packard
BapC IF GATTCGGTCCTGCGTGGTTC bapC 219-238 E. Packard
BapC IR ACGGCCCCATCCTCTACGCT bapC 748-729 E. Packard
BapC2F TCAATGGCGAGGCGAACATC bapC 694-713 E. Packard
BapC2R TCATCTCGAACAGGCCGCTT bapC 1371-1352 E. Packard
BapC3F TGCCGAAAGCGACGGAGAAT bapC 1301-1320 E. Packard
BapC3R GTCGAGCTGCTGCTTCTGGG bapC 1790-1771 E. Packard
BapC4F TGGTATGCGGAAGGCAATGC bapC 1683-1702 E. Packard
BapC4R AGGTGCCGCCTTCGTCCTTG bapC 2244-2225 E. Packard
BapCSF ACGTTGCACGACGGCTGGT bapC 2130-2149 E. Packard
BapCSR ATGCGCCGCTACCAGGTG bapC 2548-2531 E. Packard
92KF GATTGATATCGAGGCGGCCAAG vag8 3-24 F. Mooi
92KR4 AACCACCAGCCCCTGTGC vag8 684-667 F. Mooi
92KF7 AGGAGGAGGCACGCGTTTG vag8 495-513 F. Mooi
92KR2 TACTCTCGCCGTCGACCTCC vag8 1249-1230 F, Mooi
92KF5 ATCGATATCGATGGCGGCTG vag8 2425-2444 F. Mooi
92KR TTCACCAGCTGTAGCGATACCC vag8 2838-2817 F. Mooi
BrkAF GTCGTTTCCTTCGCGTCACC brkA 1139-1158 F. Mooi
BrkARS ATCGGCTCCATCCCTTCCCC brkA 1709-1690 E. Packard
BrkAF2 CCATCGATGCCACCGAGG brkA 1607-1624 F. Mooi
BrkAR4 TCGACACCGTGGTTCCGTCC brkA 2221-2202 E. Packard
BrkAF7 ACAGTCAGCGTGCAGGGCGA brkA 2113-2132 E.Packard
BrkAM2 AATGGTGGAATGCTGCGGAG brkA 2766-2746 F. Mooi
BrkAM 1 GACACGCCGCTGAAGCTGAT brkA 2647-2666 F. Mooi
BrkAR3 ATCCTCCGCCAGGCTGTAGC brkA 3291-3272 E. Packard
BrkAF3 CATACCCAGGGGCAGGGC brkA 3199-3216 F. Mooi
BrkARl GTGTCGAGATAGTAGCCGCCAT brkA 3710-3689 E. Packard
BrkAF6 CCTGCTCGGCTACACCTATGC brkA 3591-3611 E. Packard
BrkAR6 CCTGGCGGGGTTTTTCATTG brkA 4270-4251 E. Packard
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Oligonucleotide primers to target a 2512 bp C-terminal region of the cyaA gene encoding 
the immunodominant moiety (Betsou et al, 1995a) were designed from the available 
sequence (Y00545) described by Glaser et a l  1988. Five primer pairs targeting bases 3586- 
6098 (Table 2.4.1) were used to amplify this region (regions I-IV, Fig. 2.4.1).
A section of the cyaA gene including the promoter region used to study gene expression 
with a lux reporter for bio luminescence studies was amplified with primers CyaAl and 
CyaA6/CyaA8 targeting bases 287-1165/1396 (Y00545) (Table 2.4.1). Primers, CyaApF 
and CyaApR, were later designed to tai’get polymorphisms found within the region 570- 
958 previously determined from sequencing data of the cyaA promoter.
The complete open reading frame was sequenced for hapC (2280 bp in total) with primers 
BapC IF and BapC5R targeting bases 219 -  2548 (AF081494). The primers (BrkAF and 
BrkAR6) tai-geted nucleotides 1139-4270 (U12276) (van Loo et al, 2002; this study) 
amplifying 3033 bp of the brkA gene in total (Table 2.4.1). Three described polymorphic 
sites of vag8 were targeted by the following primers 92KF and 92KR4, 92KF7 and 92KR2, 
92KF5 and 92KR, and the primers used are those previously described (van Loo et al, 
2002), The ptxC primers (PtxSBF and PtxAJK8S3R) targeted bases 3433-3700 (van Loo et 
al, 2002; this study).
Primers TcfAFl and TcfAR6 targeted bases 3-2345 of tcfA (U16754). The primers TcfAR3 
and TcfAF2 were used to amplify a region, which was previously determined to be 
polymorphic (van Loo et al, 2002). Primers TcfAF4 and Tc£AR5 were designed to clarify 
some tcfA sequences queried as tcfA(2) or tcfA(5) alleles, and bases 578-1032 were 
amplified. The open readmg frame of tcfA, bases 3-2345, was amplified for two B. 
pertussis isolates that were designated tcfA{6), to check for further polymorphisms and for 
submission of the sequence to GenBank.
Primers for amplification and sequencing of ptxC ,fm 2  and ompQ for Pyrosequencing (see 
section 2.10 for further details) were designed by N. Fry using the program OLIGO plus 
Pyrosequencing software (Table 2.4.1). Primers were ordered from MWG-Biotech AG and 
resuspended in TE buffer pH 8.0 (Sigma) to give a stock concentration of 100 pmoles pf* 
and then stored at -20°C. One of each set of the primers was biotinylated at the 5'-end.
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Figure 2.4.1: Schematic of the B. pertussis adenylate cyclase toxin (CyaA), showing the 
enzymic (AC) domain (amino acids 1-400), the hydrophobic membrane spanning domain, 
the site of post-translational modification and the 42 calcium-binding nonapeptide repeats. 
Numbering represents amino acid residues. Arrows indicate the regions (I-V) of CyaA 
corresponding to the regions of the cyaA gene amplified by the five primer pairs (CyaAl F- 
CyaASR, Table 2.4.1) (adapted fi"om Ladant & UUmann, 1999).
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Primers ptxS3-3270F and biotin-ptxS3-3658R targeting bases 3270-3658 (M l3223) were 
used to amplify ptxC for analysis by Pyrosequencing. The sequencing primer of the 
amplified ptxC product was ptxS3-3610FS. Th&fim2 primers (biotin-fim2-632F and fim2- 
900R) targeted bases 632-900 (Y00527) and the sequencing primer, fim2-720RS, was 
used. Outer-membrane protein Q primers (ompQ-1377F and biotin-ompQ-1533R) were 
used for amplification, targeting bases 1377-1533 (U16266) and ompQ'-UddFS was used 
as the sequencing primer.
2.5 POLYMERASE CHAIN REACTION (PCR)
All PCR reaction mixtures contained 1.5 mM MgCb and 200 pM of each deoxynucleotide 
in a fmal volume of 50 pi. In addition, mixtures designed to amplify cyaA and tcfA 
contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.0 pM of each primer, (except for cya- 
2F and -2R, 0.1 pM), 5% (v/v) dimethyl sulphoxide (Sigma) and 1 U of Taq DNA 
polymerase (Invitrogen). Other target reaction mixtures contained HotStarTaq™ DNA 
polymerase with Q-solution (Qiagen), and 1.0 pM of each primer (Invitrogen), except for 
hapC-5V and -5R (0.1 pM). Template DNA (ca. 100 ng or 1 pi of boiled extract) was 
added and reaction mixtures containing no added DNA served as negative controls. 
Triplicate reactions were prepared for products that were to be sequenced by the dideoxy 
method. Amplification was performed using a DNA Engine (MJ Research) with the 
following conditions: predenaturation for 10 min at 94°C, then 30 cycles of dénaturation 
for 2 min at 94°C, annealing for 2 min at 60°C, extension for 1 min at 72°C and a final 
extension step of 10 min at 72°C.
2.6 AGAROSE GEL ELECTROPHORESIS
Agarose gels (2%, w/v) were used for electrophoretic analysis of PCR product sizes 
predicted to be between 156 and 762 bp, 1% (w/v) agarose gels were used for analysis of 
digested products. PCR product (5 pi) was mixed with 5 x Tris-borate-EDTA (TBE, 1 x 
TBE contains 89 mM Tris, 89 mM Boric acid and 0.2 mM EDTA) DNA loading buffer 
(Appendix 2.1) in a v:v ratio of 1:1 prior to loading into the wells of agarose gels made up 
m TBE buffer. Volumes ranging ffom 10 pi -  15 pi of digested vector was applied to the 
gel. A volume of 30 pi of digested vector containing insert was applied and aliquoted 
between two wells due to the volume being too large for one well. Molecular weight
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markers (100 bp and 1 kb ladders, Invitrogen) were used according to the manufacturer’s 
instructions, 0.1 pi of desired marker per mm of lane width (0.5 pg) was added to loading 
buffer. Agai'ose (type II-A medium EEO, Sigma or Gibco Low-Grade) was dissolved in 1 x 
TBE buffer (Appendix 2.2). Gel preparation and electrophoresis was done in one of two 
ways (i) the solution was allowed to cool (approx 50°C) and ethidium bromide (Sigma) 
was added to a-final concentration of 1 pg m l'\ Once the gel had set, it was immersed in a 
tank containing 1 x TBE buffer. Samples were applied and electrophorised at a voltage of 
lOOV until the marker dye had migrated an appropriate distance to enable visualisation of 
the DNA. (ii) The gel was prepared without the addition of ethidium bromide. Once the 
products had migrated a reasonable distance on the gel, it was stained in 1 x TBE 
containing 1 pg ml'* ethidium bromide for approx 20 min. After electrophoresis DNA was 
visualised either by (i) being placed on a Dual Intensity Transilluminator and viewed using 
a UVP Gel Documentation System ImageStore 5000 Version 7.12 (Ultra Violet Products 
Ltd, Cambridge) or (ii) viewed usmg a transilluminator with the Polaroid MP-4 system and 
black and white 667 film (Polaroid).
2.7 EXTRACTION OF DNA FROM AGAROSE GEL
Once amplified plasmid DNA containing the CyaA 1-6/1-8 insert (amplified with primers 
CyaAl and CyaA6/8) had been purified and digested with appropriate restriction enzymes, 
the restriction fiagments were visualised using gel electrophoresis. The digested insert was 
isolated and purified using the QIAquick® gel extraction kit (Qiagen) following the 
protocol described for gel extraction using a microcentrifuge. Plasmid DNA that had been 
digested was run in triplicate on a 1% agarose gel. The digested inserts were excised from 
the gel and pooled together in sterile 1.5 ml microfuge tubes. Gel slices in the microfuge 
tubes were weighed and three volumes of Buffer QG to 1 volume of gel (assuming 100 
mg=100 pi) were added. Tubes were incubated at 50°C for 10 min in a heating block. 
Every 2 min, the tubes were vortexed to aid gel fragments to dissolve. One gel volume of 
isopropanol was added to the sample and this mixture was added to a QIAquick spin 
column. Columns were centrifuged for 1 min at 11,200 x g  (13,000 rpm) (Biofuge pico, 
Heraeus). To remove any remaining traces of agarose 0.5 ml of buffer QG was added and 
the column was centrifriged for 1 min. A volume of 750 pi of Buffer PE was added and the 
column was centrifuged as before, the flow-through was discarded and the column was
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spun for a further minute to remove traces of Buffer PE, DNA was eluted with 50 pi of 
Buffer EB and stored at -20°C.
2.8 DIGESTED PLASMID AND PCR PRODUCT PURIFICATION
Digested plasmid for use in ligation reactions was purified using the QIAquick® gel 
extraction kit (Qiagen) and amplified PCR products were purified using (i) QIAquick® gel 
extraction kit (Qiagen) or (ii) the Montage PCR96 Filter Plates (Millipore).
(i) Digested plasmid or PCR products were purified using QIAquick® gel extraction kit 
according to the manufacturer’s protocol for PCR product purification using a 
microcentrifuge. The binding buffer, buffer PB, was added to PCR products at a 5:1 (v:v) 
ratio. This mix was placed in a QIAquick column and centrifuged for 1 min at 11,200 x g 
(Biofuge pico, Heraeus). A volume of 750 pi buffer PE was added to the column and 
centrifriged for 1 min at 11,200 x g. The flow-through was discarded and the column was 
centrifriged for a frirther minute to remove traces of the buffer. The column was placed in a
1.5 ml microfrige tube and the DNA was eluted by adding 30 pi of buffer EB and 
centrifriged for one minute. The purified PCR products and digested plasmid were stored at 
-20“C.
(ii) PCR products were also purified using Montage PCR96 Filter Plates (Millipore) 
according to manufacturer’s instructions using a MultiScreen Vacuum Manifold 
(Millipore). Triplicate PCR reactions were pooled and added to each well. The plate was 
placed under vacuum pressure 20 p.s.i for 10 min. A volume of 50 pi of nuclease-free 
water (Promega) was added to the wells and placed on a rotary shaker for 20 min. DNA 
was quantified using a GeneQuant II spectrophotometer (Amersham Bio sciences) at A260 
and stored at -20“C. Template DNA (100 ng) was used in sequencing reactions.
2.9 SEQUENCING BY THE DIDEOXY METHOD
Sequence polymorphism was investigated m regions of eight genes (p/xQ tcfA,Jim2, cyaA, 
vagS, ompQ, bapC and brkA) using various subsets of the 152 B. pertussis isolates. 
Sequences for all of the eight gene targets were determined for the four vaccine strains and
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the type strain (18323^). The four vaccine strains and the type strain were included in this 
study for comparative purposes.
2.9.1 Sequencing PCR reactions
Sequencing of brkA,ptxC, tcfA and vagS was as described by van Loo et al. (2002), with 
minor modifications (this study). The two genes bapC and cyaA were sequenced as 
described in this study. Nucleotide sequences determined by the dideoxynucleotide method 
used the Dye Terminator Cycle Sequencing Quick Start Kit (Beckman Coulter) and the 
products analysed on a CEQ 8000 Genetic Analysis System (Beckman Coulter). 
Sequencing PCR reactions were carried out according to manufacturer’s recommendations. 
The reaction mixture contained 8 pi of Dye Terminator Cycle Sequencing Quick Start Kit 
master mix (Beckman Coulter), 100 ng of purified DNA and a final concentration for each 
primer of 3.2 pM in a total volume of 20 pi. The control DNA template, pUC18, was 
included for each set of sequencing reactions (supplied with Dye Terminator Cycle 
Sequencing Quick Start kit). The primers used were the same as those used for the original 
PCR reaction (see Table 2.4.1). The sequencing PCR parameters were 30 cycles of 96°C 
for 20 sec, 50°C for 20 sec and 60*(C for 4 min followed by holding at 4°C until products 
were taken for ethanol precipitation.
2.9.2 Ethanol precipitation
Ethanol precipitation of the sequencing PCR products was carried out accordmg to the 
manufacturer’s instructions, either in individual 1.5 ml microfuge tubes or in a 96-well 
plate depending on the number of reactions to be sequenced. For plate and tube methods, 5 
pi of stop solution (1.5 M NaOAc pH 5.2, 50 mM Na2EDTA pH 8.0, 4 pg glycogen) was 
added to each reaction followed by 60 pi of 95% ice-cold ethanol. For the tube protocol, 
samples were centrifuged for 15 min at 19,280 x g  (Allegra 21 R Centrifuge and rotor 
F3602, Beckman Coulter). Plates were inverted several times to mix the sequencing 
reactions with stop solution and ethanol, incubated at -20”C for 10 min, then centrifuged 
for 30 min at 1238 x g  (rotor S2096, Beckman Coulter). The 95% ethanol was carefully 
removed and the pellets washed twice with 200 pi of 70% ice-cold ethanol. For the tube 
method, samples were centrifuged for 2 min at 19,280 x g and the plate was centrifriged for 
5 min at 1238 x g. All centrifugations were carried out at 4”C. Samples were vacuum dried
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for 20 min and resuspended in 35 pi of sample loading solution (deionised formamide, 
supplied with Dye Terminator Cycle Sequencing Quick Start Kit, Beckman Coulter).
2.9.3 Sequence analysis
Sequence analyses were performed using software packages BioNumerics and Kodon 
(Applied Maths, Kortrijk, Belgium) and the program BioEdit 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html). For all analyses, sequence data from 
forward and reverse primers were combined and aligned manually. New sequence data 
were aligned with the available sequence(s) for B. pertussis from GenBank, cyaA Y00545, 
tcfA{\) U16754, tcfA{2) AJ009785, tcfAQ) AJ420991, tcfA{A) AJ507643, tcfA{5) 
AJ420992, brM  U12776, vag8{l) U90124 and bap5(l) AF081494.
2.9.4 Gene nomenclature and numbering
The description of the pertactin and pertussis toxin SI gene variants, first described by 
Mooi and colleagues (Mooi etal., 1998; Mooi et a l, 1999; Mooi et a l, 2000), is as defined 
by Fry et a l (2001). Other gene variants described by van Loo et a l  (2002), or novel 
variants found in this study, follow the format of Fry et al (2001), i.e., gene designation 
followed by allele number in parenthesis. Throughout this study, the location of numbered 
positions on the genes is with respect to the GenBank reference sequence mdicated.
2.10 PYROSEQUENCER
2.10.1 Pyroseqiiencer technology
For single nucleotide polymorphism (SNP) analysis, pyrosequencing standard protocols 
(Pyrosequencing AB) were used. This method is based on the technology originally 
described by Ronaghi et a l (1998) and is described in Pyrosequencing technical note 101. 
The sequencing primer was hybridised to single stranded DNA template, which was 
incubated with a mixture of four enzymes: DNA polymerase, ATP sulphurylase, luciferase 
and apyrase, and the substrates, adenosine 5' phosphosulphate (APS) and luciferin (Fig. 
2.10.1.1), The first of the four dNTPs was incorporated into the DNA strand by the action 
of DNA polymerase if it was complementary to the base in the template strand. This 
incorporation was accompanied by the release of pyrophosphate (PPi). ATP sulphurylase
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Figure 2.10.1: Pyrosequencing reaction containing the four-enzyme (DNA polymerase, 
ATP sulphurylase, luciferase and apyrase) mixture with substrates (ATP and luciferin) and 
sequencing primer annealed to template DNA. Once a complementary nucleotide to the 
template strand is incorporated, the reaction shown on the opposite page takes place 
resulting in the production of light. This light results in a peak on the pyrogram, (source: 
Pyrosequencing technical information) and sequence information is obtained from the 
peaks on pyrograms.
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converts PPi to ATP in the presence of the substrate APS, the ATP drives the conversion of 
luciferin to oxyluciferin by the enzymic action of luciferase, and generates visible light in 
amounts that are proportional to the amount of ATP. This light is detected by a charge 
coupled device (CCD) camera and is visualised as a peak in a Pyiogram (Fig. 2.10.1.1). 
The height of each peak in the Pyrogram is proportional to the number of nucleotides 
incorporated. The enzyme apyrase continuously degrades the ATP and unincorporated 
dNTPs (Fig. 2.10.1.1). This switches the light off and regenerates the reaction solution, 
before the next dNTP is added.
Three gene targets ompQ and ptxC) had previously been investigated by van Loo et 
al (2002) for polymorphic regions. Each gene contained a single nucleotide polymorphism 
defining two alleles. The single nucleotide polymorphism of ptxC  was a target for the 
MLST scheme and this polymorphism was investigated for the UK B. pertussis isolates. 
Neither ompQ nor fim2 were included in the MLST scheme due to limited variation. 
However, for tliis study it was informative to investigate if the same ompQ and fim2 alleles 
occurred in the UK B. pertussis population at similar or different frequencies. As the alleles 
and the position of the polymorphisms were known, the real-time sequencing technique, 
Pyrosequencing was applied to detect the allelic frequency of the three genes within the 
UK B. pertussis population as this method is much more rapid than conventional dideoxy 
sequencing. Three B. pertussis isolates, CN137, NCTC10739^ and BP711 were selected for 
the initial investigation of Pyrosequencer technology to determine whether the two known 
ptxC alleles present amongst these three isolates would be detected. It was found that the 
two sequencing techniques were completely concordant and Pyrosequencing was then used 
to determine the allelic frequency of these three genes in further B. pertussis isolates.
2,10.2 Preparation of Pyrosequencer reactions
Single PCR reactions were prepared in place of triplicate reactions required for 
conventional sequencing. Target reaction mixtures contained HotStarTaq"^^ DNA 
polymerase with Q-solution (Qiagen), and 10 pmoles of each primer (MWG-Biotech AG) 
in a final reaction volume of 50 pi. Template DNA (ca. 100 ng) was added and reaction 
mixtures containing no added DNA served as negative controls. Polymerase chain 
reactions for ptxC, ompQ and fm 2  were optimised by comparing different annealing 
temperatures of 50°C, 55®C and 58°C. The optimal temperatmes were 50“C for ptxC and
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55“C for ompQ. Vor fim2 amplification, an annealing temperature of 58“C was used. 
Amplification was performed using a DNA Engine (MJ Research) with the following 
conditions: predenaturation for 10 min at 94°C, then 30 cycles of dénaturation for 2 min at 
94°C, annealing for 2 min at 50-58°C, extension for 1 min at 72°C and a final extension 
step of 10 min at 72°C.
Typically, 20 pi of biotinylated PCR product from a 50 pi PCR reaction was immobilised 
onto streptavidin-coated beads and converted to single-stranded DNA template by 
dénaturation. The biotinylated PCR product is a result of amplification with one of the 
primer pair being labelled with biotin and biotin is known to bind to streptavidin. After 
washing, removal of the unmodified strand (amplified by the non-biotinylated primer) and 
neutralisation, the sequencing primer (0.35 pM final concentration) was annealed to the 
template. Samples were incubated at 80°C for 2 min, allowed to cool to room temperature 
and analysed using the PSQ™ 96MA System (Pyrosequencing AB, Uppsala, Sweden). 
Results were analysed using the Pyrosequencer software and Appendix 9 shows examples 
of Pyrograms for the three targets.
2.11 LIGHTCYCLER ANALYSIS
2.11.1 Target for LightCycler melting curve analysis
During this PhD study, a 6 base pair insertion was identified between the two genes cyaA 
and cyaC after sequencing in two B. pertussis isolates, 99K45 and PICU475. The initial 
sequencing of B. pertussis isolates for cyaA promoter variation was carried out m DBS 
Genomics, Durham University. Forty-six isolates, four vaccine strains and the type strain 
were screened for the presence of this 6 bp insertion using melting curve analysis of the 
LightCycler (LC) (Roche) assays. The LC assay combines real-time PCR with product 
detection using fiuorogenic hybridisation probes that use fluorescence resonance energy 
transfer (FRET) to achieve rapid PCR results. One feature of using this assay is the 
capacity to determine the melting point analysis of PCR products, which allows the 
differentiation of distinct amplified sequences.
2.11.2 LightCycler Assays
The primers, CyaApR and CyaApF, were used for amplification of a 388 bp section of 
cyaA in the LC assay. Suitable probe sequences that are fluorescently labelled were
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designed from the GenBank sequence Y00545. Probes were designed to be situated on the 
same strand and as far from the extending primer as possible, winch delays the 
displacement of the probe by polymerase allowing maximum hybridisation time. The 
spacing between the fluorophores must be ideally be between one to four bases as the 
proximity of the fluorophores allows FRET to be monitored by the LightCycler. The 
probes used here only had one base between them (CyaPins-S: 683-696, CyaP-A: 698- 
726). The long anchor probe (CyaP-A) desgined to detect the wild-type sequence is 
labelled at the 5' end with LightCycler Red 640 aijd the sensor probe (CyaPins-S) designed 
to target the insertion sequence and the single nucleotide difference between the type strain 
and the other B. pertussis isolates is labelled with fluorescein at the 3' end (Fig. 2.11.2.1). 
The melting temperature of the probes CyaPins-S and CyaP-A (Table 2.4.1) (PROLIGO, 
France) were checked using a Tm calculator ensuring that the melting temperature (Tm) of 
the probes was about 5°C higher than that of the CyaApR and CyaApF primers. This 
ensured that the probes have enough time to bind to the target sequence before being 
displaced by the DNA polymerase.
To ensure that the PCR mix and parameters were suitable for use in the hybridisation probe 
assay they were initially optimised by carrying out a SYBR green I assay. This would 
ensure that suitable amplification was occurring without wasting any probe material. A 
final reaction volume of 20 pi contained 2 pi of SYBR green 1 mix (Roche, 10 pi of 
solution A added to the vial containing solution B), 2.5 mM MgCL, with or without 5% 
(v/v) DMSO (Sigma), 1 pM of each primer CyaAPf and CyaAPr (Invitrogen), and 25 ng of 
DNA template. An initial dénaturation step at 94°C for 10 min was followed by 45 cycles 
of dénaturation at 94°C for 10 sec, annealing at 60°C for 10 sec, and extension at 72°C for 
16 sec. This was followed by Melt (95°C 5 sec ramp rate 20°C/sec, 40°C 10 sec ramp rate 
20°C/sec and 95®C 0 sec ramp rate 0.5°C/sec) then Cool programmes. Optimisation had 
determined that 5% (v/v) DMSO in the reaction mix was essential for successful 
amplification to occur.
For melting curve analysis assays, the final volume 20 pi contained 2 pi LC-FastStart DNA 
Master Hybridisation probes mix (Roche, 60 pi of MixB was added to the vial containing
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Figure 2.11.2.1: Schematic diagram of adenylate cyclase toxin gene (cyaA) with the 388 
bp region (bases 570-958) amplified by primers CyaApF and CyaApR (as indicated on 
diagram) shown in greater detail and the probes that target the sequence internal to that 
region. The sensor probe CyaPins-S, targets bases 683-696, will anneal to sequences 
containing the 6 bp insertion at position 691 (highlighted in green) or the single nucleotide 
difference at position 695. The anchor probe, CyaP-A, will anneal to the wild-type 
sequence targeting nucleotides 698-726. CyaPins-S is donor probe labelled with 
fluorescein at its 3' end and CyaP-A is the acceptor probe labelled with LightCycler Red- 
640 at its 5' end. All numbering is relative to that of cyaA GenBank sequence Y00545.The 
arrow that is situated at position 660 indicates the start of the overlap of cyaC GenBank 
sequence (bases 1-91, M57286) with Y00545.
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MixA), 2.5 mM MgCh, 5% (v/v) DMSO, 0.5 \xM of each primer CyaAPf and CyaAPr, 
0.25 pM of probes CyaPins-S and CyaP-A, and 2 pl of 1 ng pf^ DNA. B. pertussis strains 
CN137 (wild-type), NCTC10739^ (single nucleotide difference) and PICU475 (6 bp 
insertion) were used as positive controls and a reaction with no DNA served as negative 
control. The initial dénaturation step at 94°C for 10 min was followed by 45 cycles of 
dénaturation at 94°C for 10 sec, annealing at bO'^ C for 10 sec, and extension at 72°C for 16 
sec. This was followed by Melt (95°C 5 sec ramp rate 20°C/sec, 40°C 10 sec ramp rate 
20°C/sec and 95°C 0 sec ramp rate 0.5°C/sec) then Cool programmes. Melting curve 
analysis was carried out using LightCycler software and the data are converted to melting 
peaks allowing the easy distinction of wild-type ftom mutant species.
2.12 DETERMINATION OF PROTEIN CONCENTRATION
To compare the enzymic activity or cytotoxic activity of CyaA preparations ftom B. 
pertussis cells it was essential that the preparations were compared at the same protein 
concentrations. The protein concentration of B. pertussis urea extracts was quantified using 
the protein assay dye reagent concentrate (Bio-Rad). The working reagent was prepared by 
diluting the concentrate 1 in 5 with sterile distilled water, which was then filtered. Bovine 
serum albumin (BSA, Sigma) was prepared to a stock concentration of 100 mg ml"^  in the 
same buffer that the urea extracts were prepared (section 2.13.3). The concentration of 
BSA used as a positive control in the protein concentration assay was 1 mg ml"\ Four-fold 
dilutions of the BSA and the urea extracts were prepared across the 96-well plates to the 
final dilution of 1 in 512. The final concentration of BSA was 0.488 pg m f\ A blank 
column contained buffer alone. A volume of 20 pi of each dilution was added to 200 pi of 
the diluted Bio-Rad protein assay dye reagent. Plates were incubated at room temperature 
for 5 min before the absorbance at 620nm was measured in a plate reader (Rosys anthos 
2001). A graph of BSA concentration against A^ zonm was plotted using the software 
MicrocaB*^ Origin'*'  ^ version 5.0 (Microcal Software, Inc. Northampton, USA). Protein 
concentrations of each urea extract were determined ftom the standard curve.
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2.13 SODIUM DODECYL SULPHATE POLYACRYLAMIDE GEL 
ELECTROPHORESIS
The presence of CyaA in the urea extracts of B. pertussis and the comparison of the 
intensity of the CyaA band of different urea extracts was visualised using sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE). Gel cassette preparation and 
Mini-PROTEAN® 3 Electrophoresis Module assembly were carried out as described by the 
manufacturer’s instructions (Bio-Rad). The resolving gel containing 7.5% acrylamide 
(Appendix 4.1) was poured between two glass plates and 100% ethanol was used as an 
overlay. The gel was allowed to set for approximately 1 hour at room temperature. 
Stacking gel contahiing 4% acrylamide (Appendix 4.2) in a 1 ml volume was poured on 
top of the resolving gel and a comb was placed within the stacking gel, which was then 
allowed to set. A volume of 10 pi of 2 x sample loading buffer (Appendix 4.3) was added 
to 10 pi of urea extract (various concentrations) and to 10 pi of marker (SeeBlue® Plus2 
Pre-Stained Standard, Invitrogen). The samples, except marker, were placed in a boiling 
bath for 5 min. Samples were run for 30 min at 200V in 1 x electrode buffer (Appendix 
4.6). The gel was removed and stained with Coomassie blue (Appendix 4.4) overnight on a 
rotating platform for protein visualisation. The stain was replaced with destain solution 
(Appendix 4.5) until the background was decolourised.
2.14 CONDUCTIMETRY
2.14.1 Conductimetry apparatus
The adenylate cyclase (AC) enzymic activity in clinical specimens containing B. pertussis 
has been used as a target in diagnostic tests. A conductimetry assay developed in-house 
(DII) to detect B. pertussis AC enzymic activity was investigated for its potential as a 
diagnostic test for pertussis. The assay for AC enzymic activity measured a change in the 
electrical conductance of the reaction solution. The conductimetry equipment was 
developed originally by Mezna and Lawrence (1994) and consists of an eight glass-cell 
system. It has been modified recently for control from a computer with automatic balancing 
and calibration (Lawrence et al., 2002). The enclosed water bath where the glass cells are 
suspended is allowed to heat to, and maintained, at 37°C and the stirrer inside maintains 
constant water temperature (Figure 2.14.1.1).
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Figure 2.14.1.1: Conductimetry apparatus. Apparatus consists of enclosed water bath with 
eight glass cells suspended above a stirring bar. Within each glass cells there is a magnetic 
flea. Thermometer indicates when the water is heated to 37°C and this is kept constant 
throughout assay.
Thermometer
Glass cells ii-
Magnetic flea in 
glass cell
Stirring bar
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The sampling period is 1 s per cell, cycling through the cells, from cell 1 through to cell 8, 
with each cell containing a magnetic flea. This allows continuous mixing of the contents of 
each cell. The conductivity of incomplete assay mixtures (2 ml) is allowed to balance 
before the reactions are initiated by addition of enzyme. Data processing of results includes 
blank subtraction (removes background noise) and on-screen line drawing to measure 
tangents of progress curves and total change.
2.14.2 Conductimetry assay of adenylate cyclase activity
The conductimetry assay was described by Lawrence et al (2002). Buffer (Appendix 5.1) 
containing only 10 mM Bicine and 1.5 mM magnesium acetate (MgAc) was degassed by 
heating for 1-2 min to >90°C and placed under vacuum pressure for ca. 30 sec. Buffer was 
allowed to cool to room temperature before the addition of ATP. A volume of 2 ml of 
buffer, 1 pi of 1 mg ml'* calmodulin (CaM) (Sigma) and 1 pi of 0.5 unit pf* of inorganic 
pyrophosphatase (PPiase) (Sigma) were added to each glass cell. Balancing of the cells was 
allowed to occur before addition of samples containing AC enzyme. After three readings, 2 
pi of 43 ng pf* of purified recombinant adenylate cyclase toxin (rCyaA) was added as a 
positive control (provided by Dr B. Orr, University of Glasgow). The following reaction 
occurs in the cells where the buffer and reagents are present.
Inorganic
AC enzyme pyrophosphatase
(ATP.Mg)^- + Bicine ' -----► cAMP' + (BicineH) + (PPiMg) -----► 2P?‘ +
Calmodulin
This equation predicts no change in conductance unless the pyrophosphate product is 
cleaved to release the magnesium ion from chelation (Lawience et a l, 2002). It is the 
release of the independently mobile ions, P f ' and Mg^”^, that produces the change in 
conductance that is measured by the assay. Total conductance change and tangents to 
reaction curves were measured by an on-screen drawing line drawing routine.
2.14.3 Optimisation for AC enzymic activity of rCyaA and native CyaA assay
For the optimisation of rCyaA and native CyaA assay, ATP and CaM dose response curves 
were carried out. Commercial CaM (Sigma) from bovine brain was compared with CaM 
prepared in-house from porcme testiculai* tissue (Lawrence et al., 2002). Both stock
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preparations of CaM were at concentrations of 1 mg ml'*. To determine the optimal CaM 
concentration for routine use, the effect of different amounts of CaM (Sigma and in-house) 
had on the rate of reaction were compared. Rates of reaction of 2 pi and 1 pi of Img ml"* of 
the CaM (Sigma) were compared with CaM prepared in-house as well as 2 pi-10 pi of 0.1 
mg ml'* and 2 pi and 1 pi of 0.01 mg ml * of CaM (Sigma) being compared. In order to 
determine the optimal concentration of ATP in the assays, buffer was prepai ed with Bicine 
and Mg Ac but without ATP. Various concentrations of ATP (0.2 mM to 1.4 mM) and 
buffer were then added to the glass cells along with the standard amounts of CaM and 
PPiase before cell balancing was carried out. Reactions were started by the addition of 
rCyaA and the reaction rates of various ATP concentrations were compared.
2.14.4 Effect of ATP, CaM and PPiase on conductimetiy assays
Conductimetry assays were carried out without each of the following reagents ATP, CaM 
or PPiase to determine the effect that this would have on the enzymic rate of reaction of 
rCyaA and native CyaA. Buffer was prepared as described in 2.12.2 except that ATP was 
omitted. Various combinations of the reagents were added to the 2 ml of buffer in the glass 
cells to allow reaction rates to be investigated without one of these reagents.
2.14.5 Detection level of rCyaA in conductimetry assays
Assay protocol was followed as described in 2.12.2. The detection level of rCyaA in the 
conductimetry assay was determined by adding decreasing concentrations of rCyaA 
rangmg from 0.216 mg ml * to 0.864 pg ml"* to the glass cells. At the lowest limit of 
detection, the tangents of reaction were compared with and without CaM to ensure that the 
low activity was due to CaM-dependent AC activity.
2.14.6 Calculation of enzymic activity
To determine the total change value (arbitrary units) of the conversion of 1 niM substrate 
(ATP) that would be used to calculate the initial rate of reaction, the following assay was 
carried out. Buffer was prepared with Bicine and MgAc only. Adenosine triphospliate was 
added separately to the conductimetry cells. Final concentrations of ATP in the cells ranged 
from 0.1 mM to 1 mM. A volume of 2 ml of buffer, an appropriate volume of 100 mM 
ATP, 1 pi of 1 mg ml"* CaM (Sigma) and 1 pi of 0.5 U pi"* of PPiase (Sigma) was added to
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each glass cell before balancmg. To start the reaction 2 pi of 0.216 mg ml"* rCyaA was 
then added. For a substrate concentration of 1 mM giving a total change of x units and an 
initial slope of y units per minute, the initial rate was: initial rate == (y/x) pmoFml/min 
(Lawrence et al, 2002).
2.14.7 Testing of inhibitory reagents
Commercial nonionic detergents (PIERCE and Novagen) and urea (Sigma) were 
investigated as potential lysis agents of Bordetella spp. (Table 2.14.7.1). Before the 
nonionic detergents and urea could be used as lysis agents, they had to be tested to 
determine if they affected the conductimetry assay by inhibiting or enhancing the reaction. 
Reaction rates of spiked samples containing 2 pi of rCyaA in the presence of various 
amounts of nonionic detergents, ranging from 2 pi to 300 pi (0.05%-1.5%) in 2 ml were 
compared with the rate of reaction of 2 pi of rCyaA alone. Recombinant adenylate cyclase 
toxin was added to cells which contained concentrations of urea ranging from 0.25 M to 8 
M urea and the rates of reaction were compared to that of the positive control. To 
determine if there was a volume effect regarding the addition of larger volumes of lysate 
(300 pi) an assay was carried out using 2 pi -  300 pi of a non-inhibiting solution (assay 
buffer) containing 2 pi of rCyaA. The rates of reactions were compared to that of the 
addition of 2 pi CyaA alone.
2.15 CONDUCTIMETRY OF ADENYLATE CYCLASE TOXIN ENZYMIC 
ACTIVITY OF IN J5. pertussis
2.15.1 Optimisation of preparation of j5. pertussis cell lysates
The method developed for the detection of CyaA activity from lysed cells of Bordetella 
spp. was adapted from the manufacturer’s instructions supplied with B-PER™ (PIERCE) 
reagent. Initially, assays were carried out using the B. pertussis strain BP348pRMBl, an 
AC-overexpressor (Brownlie et al., 1988). BP348pRMBl was grown on BG plates and 
incubated for 72 h at 37°C. Cell growth was used to prepare a turbid suspension of freshly- 
grown bacteria in saline and 200 pi was spread on BG agar and incubated overnight at 
37°C to obtain a confluent layer of growth. Suspensions of bacteria from this overnight 
growth were prepared to 2 x 10  ^cfu ml * in saline, initially by comparison with an opacity 
rod, which was then later determined to be equivalent to ca. ODeoonm 0.46.
Table 2.14.7.1. Potential lysis agents for B. pertussis.
Lysing agent Description Source
Urea Powder, dissolved in 
deionised distilled water
Sigma
B-PER^'^ Bacterial Protein 
Extraction Reagent
Nonionic PIERCE
BngBuster^^ Protein 
Extraction Reagent
Nonionic Novagen
Triton X-100 Nonionic, 10% solution PIERCE
Triton X-114 Nonionic, 10% solution PIERCE
Brii 35 Nonionic, 10% solution PIERCE
Brii 58 Nonionic, 10% solution PIERCE
Tween-20 Nonionic, 10% solution PIERCE
Tween-80 Nonionic, 10% solution PIERCE
NP40 Nonionic, 10% solution PIERCE
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Foiu' nonionic detergents, Triton X-100, NP40, Brij 35 and Brij 58 were used for the 
optimisation of preparation of bacterial cell lysates.
1. A volume of 300 pi of nonionic detergent alone was tested to determine if the detergent 
would have an effect on the reaction curves of enzymic reactions.
2. Bacterial suspensions were frozen (-70°C for 5 min) then allowed to thaw at room 
temperature. Cells were pelleted by centrifugation for 10 min at 6,600 x g  (Biofuge pico, 
Heraeus), and the supernate was tested for AC activity to determine if enzymic activity was 
lost during this step.
3. Pellets were resuspended in 300 pi of the four different nonionic detergents and then 
tested for AC activity.
4. Pellets that were resuspended in the nonionic detergents were mixed at 4°C on a rotary 
shaker for different times (10 min, 30 min and Ih), then tested for AC activity to determine 
if length of mixing time had an effect on the lysis of bacterial cells. A control containing 2 
pi of rCyaA in 300 pi of nonionic detergent was allowed to mix for 30 min at 4°C and 
tested for AC activity. This control would determine if AC activity decreased during the 
mixing step.
5. The nonionic detergents that were known not to cause inhibition of the assay were used 
in the B. pertussis lysis protocol. BP348pRMBI, AC over-expressor, and NCTC10739^ 
were tested for AC activity using the conductimetry assay as described in 2.15.5. Tangents 
of reactions were compared to determine which condition provided optinial lysis as shown 
by detection of highest level of AC activity.
2.15.2 Detection of AC activity from B, pertussis grown in SS medium
B. pertussis was grown in 5 ml volumes of SS shaking at 150-200 rpm for 48 h at 37°C. 
The resulting culture, supernate and cell pellet, which was resuspended in 1 ml of assay 
buffer (no ATP) were tested for AC activity as B. pertussis is known to secrete CyaA into 
the growth medium. Conductimetry assay was carried out as described in 2.14.5, except 
that 300 pi of each sample was added to the glass cells to start the reaction. A method for 
desalting SSX medium was investigated because of the inhibitory properties of this 
medium (see section 3.7.3), using PD-10 desalting columns (Amersham Biosciences) and 
following the manufacturer’s instructions. The gel in the PD-10 column was equilibrated 
with 25 ml of the conductimetry buffer (no ATP), then 2.5 ml of the culture was added to
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column and the flow-through was discarded. Uninoculated SS alone was also added to one 
column. Elution buffer (3.5 ml) was added and 3 ml of eluted sample was collected. The 
presence of CyaA in the desalted samples (5 pl-200 pi) was detected using the 
conductimetry assay.
2.15.3 Preparation of B, pertussis urea extracts
The amount of CyaA expressed at different times during growth of^. pertussis BP338 was 
determined. The extraction of CyaA from Bordetella was adapted from the method 
described by Westrop et a l (1994). The growth cuive of BP338 had previously been 
determined. Volumes of 250 ml of SS liquid medium were inoculated with BP338 to an 
ODeoonm of 0.01 and at 32, 56 and 73 h and the resulting cultures were Gram stained to 
ensure that no contaminating bacteria were present. The cultures were pelleted by 
centrifugation at 9,000 x g  for 20 min (centrifuge Sorvall® RC-5B with rotor Soiwall® 
GSA). The resulting cell pellets were stored at -20^C. For the production of urea extracts, 
cell pellets were thawed and resuspended in 2 ml of 10 mM Trlcine pH 8, 0.5 mM EDTA 
pH 8, 0.5 mM EGTA pH 8, 4 M urea and 1 mM PMSF (Sigma). Suspensions were stirred 
for 1 h at 4‘^ C on a rotary shaker and then centrifuged for 30 min at 15,000 x g  (centrifuge 
Sorvall® RC-5B and rotor Sorvall® SS-34). The protein concentrations of urea extracts 
were quantified using a Bradford’s assay described in 2.12 and urea extracts were stored at 
-20°C. Adenylate cyclase toxin enzymic activity of the urea extracts was determined by the 
protocol described in section 2.15.5.
The supernates from cultures in CL, from which the cells were harvested for production of 
urea extracts, were desalted using PD-10 columns as described in 2.15.2. This would detect 
AC activity that may have been secreted into the medium. A positive control containing 2 
pi of crude rCyaA in 2.5 ml of conductimetry assay buffer was added to a PD-10 column. 
This would determine if AC activity was lost during the desalting process. Spiked samples 
containing desalted supernate and 2 pi of crude rCyaA was also tested for AC activity. 
These would show the presence of any inhibitoiy products.
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column and the flow-through was discarded. Uninoculated SS alone was also added to one 
column. Elution buffer (3.5 ml) was added and 3 ml of eluted sample was collected. The 
presence of CyaA in the desalted samples (5 pl-200 pi) was detected using the 
conductimetry assay.
2.15.3 Preparation ofB, pertussis urea extracts
The amount of CyaA expressed at different times during growth of B. pertussis BP338 was 
determined. The extinction of CyaA from Bordetella was adapted from the method 
described by Westrop et al (1994). The growth curve of BP338 had previously been 
determined. Volumes of 250 ml of SS liquid medium were inoculated with BP338 to an 
ODeoonm of 0.01 and at 32, 56 and 73 h and the resulting cultures were Gram stained to 
ensure that no contaminating bacteria were present. The cultures were pelleted by 
centrifugation at 9,000 x g  for 20 nun (centrifuge Sorvall® RC-5B with rotor Sorvall® 
GSA). The resulting cell pellets were stored at -20°C. For the production of urea extracts, 
cell pellets were thawed and resuspended in 2 ml of 10 mM Tricine pH 8, 0.5 mM EDTA 
pH 8, 0.5 mM EGTA pH 8, 4 M urea and 1 mM PMSF (Sigma). Suspensions were stirred 
for 1 h at 4°C on a rotary shaker and then centrifuged for 30 min at 15,000 x g  (centrifuge 
Sorvall® RC-5B and rotor Sorvall® SS-34). The protein concentrations of ui'ea extracts 
were quantified using a Bradford’s assay described m 2.12 and urea extracts were stored at 
-20°C. Adenylate cyclase toxin enzymic activity of the urea extracts was determined by the 
protocol described in section 2.15.5.
The supernates fr om cultures in CL, from which the cells were harvested for production of 
urea extracts, were desalted using PD-10 columns as described in 2.15.2. This would detect 
AC activity that may have been secreted into the medium. A positive control containing 2 
pi of crude rCyaA in 2.5 ml of conductimetry assay buffer was added to a PD-10 column. 
This would determine if AC activity was lost during the desalting proeess. Spiked samples 
containing desalted supernate and 2 pi of crude rCyaA was also tested for AC activity. 
These would show the presence of any inhibitory products.
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2.15.4 Concentration of urea extracts
Amicon* Ultra centrifugal filter device columns (Millipore) with a 30,000 molecular 
weight cut-off were used to concentrate urea extracts of B. pertussis BP338 and 99K45. 
Approxhnately 2 ml volumes of urea extract were added to the columns and centrifuged at
4,000 X g  for 4 min at 4“C (Multifuge 3S-R, Hereaus). The urea extracts were concentrated 
to about 500 pi. Volumes of 10 pi of concentrated samples were compared to 10 pi of 
unconcentrated samples for CyaA content by SDS-PAGE. Remaining samples were stored
at -20°C.
2.15.5 Conductimetry assay of B. pertussis CyaA
The assay procedure is described in section 2.14.2. After degassing the buffer, it was 
allowed to cool before the addition of ATP. A volume of 2 ml of buffer, 1 pi of 1 mg ml ' 
CaM (Sigma) and 1 pi of 0.5 U p f ' PPiase was added to each glass cell. Balancing was 
allowed to occur before addition of B. pertussis lysate or otlier Bordetella spp. lysate. Once 
balanced, 300 pi of the lysate was added to glass cells. A volume of 2 pi of 43 ng pi of 
purified rCyaA and/or 300 pi BP338 lysate were added as positive controls and, for some 
assays, 300 pi BP347 lysate was included as a negative control.
2.16 CYTOTOXICITY ASSAY
Two B. pertussis isolates were found to contain a 6 bp insertion between cyaA and cyaC. 
The gene cyaC activates the adenylate cyclase protoxin enabling the molecule to carry out 
several biological activities one of which is its cytotoxicity activity. The 6 bp insertion is 
situated very close to cyaC relating to the start of the cyaC GenBank sequence, which may 
affect the expression of this gene. Whether this sequence variation has an effect on CyaA 
cytotoxic activity was therefore examined. The cytotoxic activity of B. pertussis urea 
extracts were determined using the CellTitre 96® Non-Radioaetive Cell Proliferation Assay 
(Promega). The assay is dependent on the reduction of the tétrazolium salt (3-(4,5- 
dimethylthazol-2-yl)-2,5-diphenyl tétrazolium bromide) by the mitochondrial 
dehydrogenase of viable cells to form an insoluble purple formazan product (MAXline™ 
Microplate Readers, application note 5). Mouse macrophage-derived (J774.2) cells were 
suspended in phenol red-fl-ee RPMI medium (Gibco) supplemented with 10% foetal calf 
serum (Gibco), 200 mM L-glutamine, 100 pg ml streptomycin and 100 U ml'' penicillin.
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Cell viability was checked using Trypan Blue exclusion. Live cells were counted using a 
haemocytometer, then the suspension was pelleted by centrifugation at 250 x g (Multifuge 
3S-R, Hereaus) for 5 min. The pellet was resuspended in an appropriate volume of phenol 
red-free RPMI medium to give a final concentration of 5 x 10^  cells ml'*. Suspended cells 
(50 pi) were added to a 96-well plate and then incubated at 37°C for 1 h. Meanwhile, the 
urea extracts were prepared to a starting concentration of 1500 pg ml'*. Doubling dilutions 
of the urea extracts were prepared in phenol red-free RPMI medium. A volume of 50 pi of 
phenol red-free media and 1% Triton X-100 (Sigma) were added to the cells serving as a 
negative control and a positive control, respectively. A volume of 50 pi of diluted urea 
extracts were added to the cells, with final concentrations ranging from 750 pg ml'* to 3 pg 
ml'*, and incubated at 37°C for 2 h. A volume of 15 pi of MTT dye (Promega) was added 
to each well that contained cells with CyaA and this plate was further incubated at 37°C for 
2 h. Following this incubation, 100 pi of solubilisation/stop solution (Promega) was added 
to each well and this was incubated overnight at 37°C. The plate was read using a plate 
reader (Rosys anthos 2001) at OD540nm- Percentage cell killing was calculated using the 
following formula:
Percentage killing = 1- test sample O D - positive control ODnegative control - positive control ODg^ o,,,^ xlOO
Protein concentration was plotted against percentage killing to determine the protein 
concentration required to give 50% killing of the macrophages using software MicrocaB^ 
Origin"^  ^version 5.0.
2.17 CONSTRUCTION OF BIOLUMINESCENT VECTORS CONTAINING THE 
cyaA PROMOTER
Constructs containing a promoterless bio luminescent reporter gene, lux or gfp, with the 
cyaA promoter region inserted upstream were developed in order to determine when in the 
growth cycle cyaA is optimally expressed and the effect of different growth conditions 
(including modulating signals) on expression. Information from these assays would aid in 
the optimisation of the conductimetry assay for use as a diagnostic tool. Bioluminescent 
reporters provide the ability to quantify gene expression at high sensitivity over a large 
dynamic range in real time and non-destructively. Some reporter systems have the problem
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of background expression due to host enzymes but with bioluminescent reporters this is 
much less of a disadvantage as naturally bioluminescent bacteria are rare outside the 
marine environment (Winson et al., 1998).
The lux genes that are required for luminescence are arranged in a single operon, 
luxCDABE. The reporter lux genes were derived from Photorhabdus (Xenorhabdus) 
luminescens, these genes are functional at temperatures as liigh as 45 °C and therefore more 
suitable than the working temperatuies of those derived from Vibrio harveyi (<37^C) and 
V, fischeri (<30°C) (Winson et ah, 1998). Winson et a l (1998) reported the use of 
lucifersases to report on gene expression throughout the bacterial culture growth curve 
using an automated photometer/luminometer (Lucy 1, Anthos Labtech, Salzberg, Austria). 
This would allow real-time determination of cyaA expression thioughout the B. pertussis 
growth. The gene, gfp, encoding green fluorescent protein is originally from the jellyfish 
Aequorea victoria which can be produced expressed in prokaryotic and eukaryotic cells 
(Chalfie et a l, 1994). Exogenous substrates and cofactors are not required for this 
fluorescence thus allowing its use for monitoring gene expression and protein localisation 
in living cells. Unlike lux expression, gfp expression cannot be monitored in a real-time 
fashion, cyaA expression could only be detected by measuring the fluorescence intensity at 
different time points.
Two plasmids were used for the cloning study: pSB395 (containing a promoterless lux 
operon) and pPROBE-AT' (containing a promoterless gfjp) (Table 2.2.2.1). Plasmid 
pSB395 contains an EcoBJ site upstream of luxC that was used for promoter cloning. The 
plasmid pPROBE-AT' contains several unique restriction sites, Kpnl and Sad  sites were 
chosen for restriction analyses.
2.17.1 Ligation
Ligation of purified cyaA PCR product (amplified with primers CyaAl and CyaA6/CyaA8) 
with the commercial A-T cloning vector pGEM®-T Easy (Promega) was carried out 
following the manufacturer’s protocol. Standard reactions and positive control reactions 
were prepared. The standard reactions contained Rapid Ligation Buffer, 5 ng of pGEM®-T 
Easy vector, 2 pi of the cleaned PCR product, 3 U of T4 DNA ligase, and sterile deionised
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water was added to give a final volume of 10 pi. The positive reaction was prepared as that 
described for the standard reaction but 2 pi (8 ng) of control insert DNA was used in place 
of the PCR product. Reactions were incubated overnight at 4°C and then stored at -20®C.
Ligation of purified cyaA PCR product (amplified with primers CyaAl and CyaA6/CyaA8) 
with the vectors pPROBE-AT' or pSB395 digested with KpnllSaci and EcoRl respectively, 
was carried out using the Fast-Link™ DNA Ligation and Screening Kit (Epicentre). The 
manufacturer’s protocol was followed for ligation of insert DNA with cohesive ends. The 
total reaction volume (15 pi) contained 1 x Fast-link ligation buffer, 1 mM ATP, 2 pi of 
digested and purified vector DNA, 7 pi of digested and purified insert DNA and 1 pi (2 U) 
of Fast-Link DNA ligase. The last reagent added to the ligation reaction was DNA ligase. 
Reactions were incubated overnight at room temperature. These ligation reactions were 
used to transform competent E. coli strain SMIO X pir.
2.17.2 Preparation of electroporation-competent cells
E. coli cells were used to inoculate 10 ml LB and grown overnight at 37^C, shaking at 150- 
200 rpm. The overnight culture was diluted 1 in 100 in 500 ml of fresh LB m a 2 1 dimpled 
flask and was incubated at 37°C, shaking at 150-200 rpm until an ODeoonm of 0.5-0.7 was 
obtained. The flasks were chilled on ice for 30 min and the cells were then harvested by 
centrifugation at 2,500 x g  for 15 min at 4®C (centrifuge Sorvall® RC-5B with rotor 
Sorvall® GSA). The cell pellets were resuspended in 500 ml of chilled sterile distilled 
water and cells were pelleted as before. The pellet was resuspended in 10 ml of cold 10% 
(v/v) glycerol. Aliquots of 40 pi were added to 1.5 ml microfuge tubes which were snap 
frozen in liquid nitrogen and then stored at -70°C for up to approximately six months.
2.17.3 Electroporation
A volume of 1 pi of plasmid preparation or ligation reaction was added to 40 pi of E, coli 
competent cells and this was placed in a Gene Puiser® (E. coli Puiser®) Cuvette (Bio-Rad) 
with a 0.2 cm electrode gap. The mixture was gently shaken to the bottom of the 
electroporation cuvette, which was then placed in a Bio-Rad Gene Puiser™ connected to a. 
Bio-Rad Pulse Controller. The following conditions were used: 2.5 kV, 200 Ohms and 25 
pFD (Faraday). Luria Bertani broth (0.75 ml) was then added to the cuvette and this was
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incubated at 37“C with shaking at 150-200 rpm for 1 h. Aliquots of 200 pi volumes were 
then spread on to LB plates containing the appropriate antibiotics and incubated overnight 
at 37°C. Resulting single colonies were re-streaked on to LB agar with appropriate 
antibiotics and incubated overnight. Plasmid and glycerol stocks were prepared from the 
resulting colonies.
2.17.4 Bacteriophage (ffmd>4) preparations
The bacteriophage ffin04 (provided by Dr M. Lynch) was prepared for use in plate mating 
assays (section 2.15.4). Bacteriophage ffrn04 lyses E. coli cells but B. pertussis is resistant 
to fifmd)4. The E. coli strain SMIO % pir containing plasmid pSB395 was grown overnight 
in 5 ml of LB at 37°C with shaking at 150-200 rpm. The culture was diluted 1 in 100 in 
fresh LB broth and this was prepaied as four replicates to produce enough phage stocks. 
The resulting culture was grown for 2 h a t 37^C shaking at 200 rpm. Bacteriophage ffm04 
(50 pi) was added to the culture and this was incubated at 37°C shaking for ca. 2 h until the 
culture became much less turbid. This was due to lysis of E. coli cells by the phage. A few 
drops of chloroform were added to kill any remaining non-lysed cells. The chloroform and 
lysed culture were mixed by swirling. The chloroform layer was allowed to settle and the 
top layer was aspirated in to a fresh tube. B. pertussis BP338 (100 pi) and E. coli SMIO X 
pir pSB395 (100 pi) suspensions were spread on to BG agar and LB agar respectively. 
Aliquots (20 pi) of each phage preparation were spotted on to both plates. The presence of 
plaques was checked on the plates after 24 h for E. coli and 72 h for B. pertussis. This 
ensured that the fresh phage preparation was effective in lysing E. coli cells and that B. 
pertussis was resistant to the phage. The bacteriophage stocks were stored at 4°C.
2.17.5 Conjugation
The first method that was used for plate mating E. coli with B. pertussis was based on a 
method communicated by Dr M. Lynch. B. pertussis BP338 and E.coli SMIO X pfr, a DNA 
mobilising strain, transformed with the vector pSB395 were grown on BG and LB and 12.5 
pg ml'^ of tetracycline (pSB395 confers tetracycline resistance) respectively. Colonies oiB. 
pertussis were frioculated in 5 ml of SSX medium and grown at 37®C for 72 h. Colonies of 
E. coli were inoculated in 5 ml of LB and 12.5 pg ml'  ^ o f tetracycline and incubated at 
3TC  overnight. Five x 1 ml of each inoculated broth was centrifriged for 1 min at 11,200 x
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g  (Biofiige pico, Heraeus). The supernates were aspirated and pellets were resuspended in 1 
ml of growth media. Suspensions were centrifuged for 1 min at 11,200 x g (Biofuge pico, 
Heraeus). Pellets were resuspended in 100 pi of growth media and mixed in a 1:1 ratio of 
donor:recipient. Aliquots (10 pi) of this mixture were placed on freshly-made dry BG agar 
and were incubated at 37°C for 24 h. The bacterial growth resulting from each aliquot of 
bacterial mix was scraped from the plate and suspended in 100 pi of LB. A volume of 100 
pi of bacteriophage (ffm04) preparation was added to the resuspended cells and gently 
pipetted to mix the suspension. The suspensions were incubated at room temperature for 30 
min and then spread on to dry BG plates containing the following selective antibiotics, 12.5 
pg ml'  ^ of tetracycline and 40 pg ml"^  of cephalexin (chosen to select against E. coli). The 
only bacteria that should be present after the plate mating should be B. pertussis containing 
pSB395. Plates were incubated at 37°C for 72 h. Resulting cultures were checked by the 
Gram stain method. Plates were checked the following day and contaminating E. coli cells 
were present. It was assumed that the E. coli had outgrown B. pertussis even in the 
presence of cephalexin. Therefore the above protocol was altered to include the method 
described by Stibitz and Carbonetti (1994).
Conditions for culture were the same as those described previously, however B. pertussis 
was incubated in SS for 48 h instead of 72 h and E. coli SMIO X pir was grown in 10 ml of 
LB instead of 5 ml. The resulting ODôoonm for E. coli SMIO X pir culture was 1.0 and for B. 
pertussis 0.8. Five x 1 ml o f each inoculated broth was centrifuged for 1 min at 11,200 x g 
(Biofuge pico, Heraeus). The supernates were aspirated and pellets were resuspended in a 
total of 1 ml of growth media. Suspensions were centrifriged for 1 min at 11,200 x g 
(Biofuge pico, Heraeus). Pellets were resuspended in 100 pi of growth media and mixed in 
a 1:10 mix of donor:recipient. Aliquots (10 pi) of the mixture were added to freshly-made 
dry BG agar containing 10 mM magnesium sulphate (MgS04) and were incubated at 37^C 
for 7 h. The bacterial growth resulting from each aliquot of bacterial mix was scraped from 
the plate and suspended in 100 pi of LB. A volume of 100 pi of phage prepai'ation was 
added to the resuspended cells and gently pipetted to mix the suspension. The suspensions 
were incubated at room temperature for 30 min and then spread on to dry BG containing 
the following selective antibiotics, 12.5 pg ml'  ^ of tetracycline and 40 pg ml'  ^ of 
cephalexin. Plates were incubated at 37°C for 72 h. Presumptive B. pertussis colonies were
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subcultured on to BG with 12.5 pg ml'  ^ of tetracycline and incubated for 72 h. Resulting 
cultures were Gram-stained to ensure that it was B. pertussis present. Glycerol stocks and 
plasmid preparations were prepared from the B. pertussis cultures.
2.17.6 Bioluminescence assay
Colonies oîB. pertussis BP338 containing pSB395 with the cyaAl-6 insert (pSBl-6), as a 
result of conjugation, were investigated for then ability to produce light using a 
luminometer, Lucy-1. B. pertussis wild-type BP338 and BP338 pSBl-6 colonies were 
inoculated in 5 ml SS liquid medium and incubated for 48 h at 37°C, shaking at 150-200 
rpm. The bacteria were diluted to ODeoonm 0.05 in fresh SS liquid medium in 96-well white 
microplates. White or black microplates are available for use with Lucy-1, however white 
plates were chosen due to the requirement of increased light output. The plate was placed 
in Lucy-1 and assayed for 72 h to determine luminescence of the bacteria.
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3.0 Results
3.1 SEQUENCE VARIATION IN B. pertussis VIRULENCE-ASSOCIATED GENES
Sequence variation was determined in regions of eight vii'ulence-associated genes (ptxC, 
tcfA,fim2, brkA, vagS, ompQ, bapC and cyaA) in a selection of historical and recent UK 
isolates of B. pertussis. The regions that were sequenced for determination of genotypic 
variation were either the open reading frame {bapC and brkA), polymorpliic sites determined 
by previous studies (ptxC, tcfA ,fm 2, vagS, and ompQ) or a region deteimined to contain 
sequence variation by a BLAST search of the Tohama-I genome (BX470248) and the 
GenBank sequence (Y00545) {cyaA). The three B. pertussis strains used to produce the UK 
whole-cell pertussis vaccine (CN2992, CN5476 and CN3099), the strain used to produce 
components for the acellular pertussis vaccine (Tohama-I) and the type strain 18323^ 
(NCTC10739^) of B. pertussis were included for compamtive purposes.
3.1.1 Electrophoretic analysis of PCR products
Amplified PCR products to be sequenced were separated on 2% (w/v) agarose gels to 
confirm successful amplification of a product of expected size. For each gene target, 
amplified products of the expected size were obtained with the primer pairs listed in Table
2.4.1 (Figs. 3.1.1.1a and 3.1.1.1b).
3.1.2 Summary of frequency of gene polymorphisms in UK B. pertussis isolates
Sequence information on eight genes, tcfA, cyaA,fim2, ompQ, vag8, brkA and bapC, 
and also on the promoter region of cyaA, cyaApr, was obtained with one or a combination 
of the following methods: LightCycler hybridisation assay, conventional dideoxy DNA 
sequencing or Pyrosequencing. The sequencing results are summarised in the Table 3.1.2.1. 
The sequence information for genes ptxA and prnA has been described in previous studies 
(Fry et ah, 2001; Packard et aL, 2004). Table 3.1.2.1 shows the overall frequency of each 
allele of each gene target together with the appropriate GenBank accession numbers. The 
variation reported for each gene will be described individually.
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Figure 3.1.1.1a. Electrophoretic analysis following amplification of B. pertussis gene 
targets bordetella resistance to killing protein A {brkA), virulence-activated gene 8 {vagS) 
and tracheal colonisation factor {tcfA).
Lane PCR primers Gene target Product size pi
M lOObp ladder (Invitrogen) not app
1 BrkAF and BrkAR5 brkA 570 bp
2 BrkAF2 and BrkAR4 brkA 614 bp
3 BrkAF7 and BrkAM2 brkA 653 bp
4 BrkAMl and BrkAR3 brkA 644 bp
5 BrkAF3 and BrkARl brkA 511 bp
6 BrkAF6 and BrkAR6 brkA 679 bp
7 92KF and 92KR4 vag8 681 bp
8 92KF7 and 92KR2 vag8 754 bp
9 KF5 and 92KR vag8 413 bp
10 TcfAF and TcfAR.4 tcfA 543 bp
11 TcfAF2 and TcfAR3 tcfA 651 bp
12 TcfAFl and TcMRl tcfA 525 bp
13 TcfAF and TcfAR5 tcfA 762 bp
14 TcfAF2 and TcfiVR3 tcfA 576 bp
15 TcfAF3 and TcfiAR3 tcfA 634 bp
16 TcfAM and TcfAR6 tcfA 652 bp
17 TcfAF4 and TcfAR5 tcfA 380 bp
Figure 3.1.1.1b. Electrophoretic analysis following amplification of B. pertussis gene 
targets adenylate cyclase toxin gene {cyaA), pertussis toxin S3 subunit {ptxC), outer- 
membrane protein Q {ompQ), fimbrial antigen 2 ifim2) and bordetella autotransporter 
protein C {bapC).
Lane PCR primers Gene target Product size predicted
M 100 bp ladder (Invitrogen) n/a
18 CyaA3F and CyaA3R cyaA 569 bp
19 CyaA5F and CyaA5R cyaA 621 bp
20 CyaA4F and CyaA4R cyaA 329 bp
21 CyaA2F and CyaA2R cyaA 519 bp
22 CyaAl F and CyaAl R cyaA 550 bp
23 CyaApF and CyaApR cyaA 388 bp
24 PtxS3f and PtxAJKS S3R ptxC 247 bp
25 ptxS3-3270F and ptxS3-3658R ptxC 388 bp
26 ompQ-1377F and ompQ-1533R ompQ 156 bp
27 fim2-632F and fim2-900R fim2 268 bp
28 BapC IF and BapClR bapC 529 bp
29 BapC2F and BapC2R bapC 677 bp
30 BapC3F and BapC3R bapC 489 bp
31 BapC4F and BapC4R bapC 561 bp
32 BapC5F and BapC5R bapC 418 bp
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Table 3.1.21. Frequency of gene polymorphisms in United Kingdom isolates oïB. 
pertussis.
Gene I Allele Number of isolates
Frequency
(%)
GenBank
Accession
no.
B. pertussis 
strain
ptxA 136
ptxA{\) 122 89.7 AJ006155 287
ptxA(2) 14 10.3 AJ006157 Tohama
ptxC 138^ ------------- ptxC(l) 83 60.1 M13223 3779
ptxC(2) 55 39.9 AJ420987 NK
tcfA 138
tcfA(l) 0 0 U16754 18323'
tcf4(2) 124 89.8 AJ009785 B596
tcfAO) 2 1.4 AJ420991 NK
tcfA(4) 9 7.1 AJ507643 NK
tcfA(5) 1 0.7 AJ420592 NK
tcfA(6)* 2 1.4 AY375533 DCH154
cyaA 42
cyaA(l) 0 0 Y00545 18323'
cyaA(2)* 42 100 BX470248 Tohama-I
ompQ 42
ompQ(l) 0 0 U16266 18323'
ompQ(2) 42 100 AJ420990 NK
vay;8 9
vaj^8(l) 0 0 U90124 18323'
va^8(2) 9 100 AJ420993 NK
brkA 9 100 U12276 Tohama
bapC 9
bapC(l) 9 100 AF081494 Taberman
bapC(2Y 0 0 18323'
prnA 138
prnA{\) 72 52.1 AJ011091 B391
prnA(2) 62 44.9 AJ011092 B345
prnAO) 4 3 AJ011093 B343
fim2 80
fim2(l) 60 75 Y00527 Wellcome 28
fim2{X) 20 25 AJ420988 NK
cyaApr 46
cyaApr(l) 0 0 Y00545 18323'
cyaApr{2Y 43 93.4 BX470248 Tohama-I
cvaAprOY 2 6.6 PICU475
* Alleles identified in this study, NK= not known.
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3.1.3 Pertussis toxin SI (ptxA) and S3 {ptxC) genes
The sequence variation for the pertussis toxin SI subunit gene {ptxA) has been reported 
elsewhere (Fry et a l, 2001; Packard et a l, 2004) and is to be included here as it is one of 
the MLST targets. Five ptxA types (pW (l)-(6)) aie found amongst B. pertussis isolates 
world-wide. There are two ptxA types found amongst UK B. pertussis isolates, j?W (l) and 
ptxAQ). The summary table (Table 3.1.2.1) shows the frequency of both ptxA alleles found 
in UK isolates from 1920-2002 with then respective GenBank numbers. The majority of 
isolates (n=122; 89.7%) were ptxA{\) (AJ006155) and 10.3% (n=14) were ptxA{2) 
(AJ006157). For trend analysis of each virulence-related gene, the isolates have been divided 
into seven groups according to the year of isolation: six groups of approximately 10 years 
from 1920-1999 and the most recent isolates, 2002, as a separate group (Fig. 3.1.3.1). 
These time groups were chosen for convenience and to facilitate comparison of the UK B. 
pertussis population with other populations (see section 4.2). Isolates were not available for 
aU years and it should be noted that within some of the decades only a few years are 
represented. For example, the groups titled 1990-1999 only contain isolates from 1998 and 
1999. For actual dates of isolation see Table 2.1.1.2 and Appendix 6. Figui'e 3.1.3.1 depicts 
theptxA{\) andptxA(2) trends throughout this time period.
There has been an increasing predominance of ptxA{l) with the concurrent decrease of 
ptxA(2) until all B. pertussis isolates wereptxA(\). BothptxA alleles were found from 1920- 
1989 and from 1990-2002 only ptxA{\) was found amongst UK isolates. The three whole­
cell vaccine strains were ptxA{\) or ptxA(2) (CN3099 and CN5476 were ptxA(l) and 
CN2992 was ptxA(2y) and the ACV strain as ptxA{2), The B. pertussis type strain was 
ptxA(4). The pubHshed genome sequence of B. pertussis strain Tohama-I (BX470248) 
contained ptxA{2) .
The pertussis toxin S3 subunit gene {ptxC) alleles had previously been defined by a single 
nucleotide polymorphism at position 3625 (M l3223, van Loo et aL, 2002): ptxC{\) (TGÇ, 
Cys) and ptxC(2) (TGT, Cys). Pertussis toxin subunit C sequences of 138 UK isolates were 
obtained by Pyrosequencing as well as by conventional dideoxy sequencing (see Appendix 9 
for examples of Pyrograms). Pertussis toxin subunit C sequences of three B. pertussis 
isolates were obtained originally by conventional sequencing and these were also analysed by
1 0 2
Figure 3.1.3.1: Trends in pertussis toxin SI subunit (ptxA) alleles in UK isolates of B. 
pertussis from 1920-2002. Information from previous studies (Fry et aL, 2001; Packard et 
aL, 2004).
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Pyrosequencing to ensure that both methods were able to detect the same alleles of these 
isolates. Both techniques were found to agree and the isolates were sequenced routinely for 
ptxC  variation by Pyrosequencing. Only the two known ptxC allele types were identified in 
the UK isolates. The summary table (Table 3.1.2.1) shows the frequency of each allele, 
60.1% (n=83) forptxC{\) and 39.9% (n=55) forptxC(2) together with respective GenBank 
numbers M l3223 and AJ420987. The trends in ptxC allelic variation found amongst UK 
isolates from 1920-2002 are shown in Fig. 3,1.3.2. As before, the isolates have been divided 
into seven time groups: six groups of approximately 10 yeai’s from 1920-1999 and the most 
recent isolates, 2002, as a separate group (Fig. 3.1.3.2). These time groups were chosen as 
not aU years had representative isolates (see Appendix 7). When the results were analysed 
according to date of isolation, it was determined that there has been an apparent shift in the 
predominant aUele of ptxC (Fig. 3.1.3.2). From 1920 until 1998, all isolates (n-53) were 
/7/xC(l). During 1998 and 1999, 22 of 51 (43%) isolates wereptxC(2) (Fig. 3.1.3.2). Of 34 
isolates from 2002, 33 wereptxC(2) and one was ptxC(l). The four vaccine strains and the 
type strain were all ptxC(l) (Appendix 8). The published genome sequence was of B. 
pertussis strain Tohama-I which wasptxC(l).
3.1.4 Tracheal colonisation factor gene {tcfA)
Nucleic acid sequence of the tracheal colonisation factor {tcfA) gene was determined by 
eonventional sequencing for 138 isolates, four vaccine strains and the B. pertussis type strain 
between bases 688-1339 (U16754). Five tcfA {tcfA{\)-{5)) alleles based on the variation 
found within this region have been found amongst other B. pertussis populations (van Loo 
et aL, 2002) (Table 3.1.2.1). Of the five sequence types previously described for this region 
four, tcfA{2), tcfA{3), tcfA{4) and tcfA{5), were found amongst the UK B. pertussis 
population (Fig. 3.1.4.1). A novel tcfA type, designated tcfA{6), not previously reported, 
was also found amongst the UK isolates (Fig. 3.1.4.1). Sequencing of the isolates containing 
this novel aUele was repeated to ensure that tins was not due to sequencing errors. The 
aUele tcfA{6) has a 15 bp deletion resulting in bases missing between nucleotides 932-946 
(U16754) (Fig. 3.1.4.1). This tcfA aUele sequence was deposited in GenBank under 
accession number AY375533. Allele tcfA{\) contains a 75 bp fragment not foxxnd in alleles 
tcfA(2-4 and 6) (Fig. 3.1.4.1), and is not represented in the UK clinical isolates or the four
104
Figure 3.1.3.2: Trends in pertussis toxin S3 subunit iptxC) alleles in UK isolates of B. 
pertussis from 1920-2002.
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Figure 3.1.4.1: Primary structure of a c. 467 bp region of the B. pertussis tracheal 
colonisation factor gene {tcfA) showing the six types described to date, designated tcfA{\) 
to tcfA{5) (van Loo et aL, 2002) and tcfA{6) (this study). Numbering is with respect to 
tcfA{\), U16754. Nucleotide polymorphisms are shown and associated amino acid changes 
are indicated beneath the relevant codon. Dots indicate identity, and codons are separated 
by dashes. In tcfA{\), (N)?  ^indicates a region of 75 bp, which is absent from the remaining 
alleles. Deletions are indicated by X. The arrow below tcfA{5) indicates an inserted G, 
which changes the reading frame and results in premature translational termination two 
codons downstream.
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vaccine strains. The tcfA{\) allele has only been found in tvyo of eight American B. pertussis 
isolates from the pre-vaccination era (van Loo et aL, 2002) and this is the same as the tcfA 
GenBank sequence (U16754) of & pertussis strain 18323^ originally deposited by Finn and 
Stevens (1995). The tcfA alleles tcfA(2-4 and 6) also differ from one another by nonsilent 
nucleotide differences, whereas tcfA(5) is predicted to encode a truncated Tcf protein by 
virtue of a nucleotide addition which alters the reading frame to create a premature 
translational stop codon.
The summary table (Table 3.1.2.1) displays the overall frequencies of each tcfA allele found 
in the UK B. pertussis population from 1920-2002 together with their respective GenBank 
numbers. The allele tcfA{2) was predominant amongst the UK B. pertussis population (124 
of 138; 89.9%). To determine if there has been shift in tcfA variation, the tcfA sequence 
types were grouped according to the period of isolation (Fig. 3.1.4.2). There appears to 
have been no particular trend, but different tcfA alleles have appeared throughout time 
period studied. However, these were found only at low frequency. Therefore, tcfA(2) has 
been the predominant allele in all time groups (Fig. 3.1.4.2). During 1950-1959, 1960-1969 
and 2002, the only allele detected was tcfA(2). The two isolates that had the tcfA allele 
tcfA(3) were from a pertussis case in paediatric intensive care isolated in 1999 (Crowcrofr et 
aL, 2003), and from an unvaccinated individual who was less than two months old, in 1999. 
Nine isolates from 1970-1999 were tcfA{A). The tcfA{5) isolate was from 1942. The two 
strains with the novel tcfA type, tcfA(6), were isolated in 1983. All UK vaccine strains were 
tcfA(2) and the type strain was tcfA(l) (Appendix 8). The genome sequence of Tohama-I 
carried the tcfA{2) allele.
3.1.5 Adenylate cyclase toxin gene {cyaA)
Sequence variation was investigated using conventional dideoxy sequencing in 42 UK 
isolates of B. pertussis, together with the four vaccine strains and the type strain 
NCTC10739^ in the region (2512 bp) of the cyaA gene encoding the immunodominant 
moiety. The CyaA protein that this gene encodes is being investigated for possible inclusion 
in future generation pertussis AC Vs and for its use in multipurpose vaccines. Therefore, it is 
important to determine its potential for antigenic variation. Variation or lack of variation in 
the B. pertussis cyaA gene has not been described previously.
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Figure 3.1.4.2: Trends in tracheal colonisation factor {tcfA) alleles in UK isolates of B. 
pertussis from 1920-2002.
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Only one allelic type was detected amongst UK B. pertussis isolates from 1920-2002 (Table
3.1.2.1). The allelic type of cyaA found in the type strain of B. pertussis sequenced in this 
study was designated cyaA{\). The two allele types, cyaA(l) and cyaA(2) differ by only a 
single nucleotide at position 4403 corresponding to a synonymous mutation; cyaA{l) has the 
codon CTA (Leu) and cyaA(2) has the codon CTG (Leu). Comparison of the cyaA sequence 
from the type strain (NCTC10739^) determined in this study with that of the same strain 
obtained from GenBank (Y00545) (Glaser et aL, 1988) showed one other nucleotide 
difference at position 3981 (Y00545). This difference was a C nucleotide rather than the G 
nucleotide present at this position in the GenBank sequence. In our study, sequencing from 
forward and reverse primers covering this region was done in triplicate with concordant 
results. All other isolates analysed in this study, including the four vaccine strains, and 42 
isolates of B. pertussis isolated in the United Kingdom from 1920-2002 belonged to the 
distinct allelic type designated cyaA(2) (Table 3.1.2.1, Appendix 8). The genome sequence 
of Tohama-I was also found to be cya^(2). Thus, no polymorphism was foimd in the 
isolates and there was no allelic variation between the vaccine strains and the isolates in a 
potentially important, immunodominant region of cyaA.
3.1.6 Outer-membrane protein Q gene {ompQ)^ virulence-activated gene 8 {vagS), 
bordetella resistance to killing protein gene A (brkA) and bordetella autotransporter 
protein C gene (bapC).
Sequence polymorphism of ompQ was investigated in 42 UK isolates chosen from different 
time periods and in the four vaccine strains. Alleles of ompQ were determined by 
Pyrosequencing and examples of pyrograms are shown in Appendix 9. This real-time 
sequencing method was used as ompQ variation had been determined previously by van Loo 
et al. (2002) and was defined as a single nucleotide polymorphism. Pyi'osequencing offers a 
more rapid method for determining single nucleotide variation amongst samples than 
conventional sequencing. There are two known ompQ alleles (van Loo et al., 2002) and 
only one of these was foimd in the UK B. pertussis population. The two alleles of ompQ are 
defined by a nonsilent single nucleotide polymorphism at position 1465 (U16266), ompQ(\) 
(CTG, Leu), found only in the type strain, and ompQ(2) (CCG, Pro) found to be present in 
all 42 UK isolates and the four vaccine strains (Appendix 8, Table 3.1.2.1). The B. pertussis 
Tohama-I genome sequence was determined to be ompQ(2).
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Nine isolates selected from each of the different time periods, the four vaccine strains and 
the type strain (NCTC10739^) were investigated for variation in (all or part o^ the vag8, 
brkA and bapC genes by conventional DNA sequencing. Two alleles of vag8 have been 
reported by van Loo et a l  (2002), therefore the same polymoiphic sites were targeted to 
directly compare allelic variation of the strain panel used for tliis PhD study and Dutch B. 
pertussis isolates. There was no sequence variation in vag8 between UK isolates and the UK 
vaccine strains, but there were three single nucleotide differences in this gene between the 
type strain and the other strains (Appendix 8). These differences occurred at positions 510, 
782 and 2697 (U90124) (CGT, Arg; GTC, Val; CGC, Arg) vag8{\), in the type strain, and 
(CGC, Arg; GÇC, Ala; CGT, Arg) vag8{2) in all other strains and the Tohama-I genome 
sequence.
The recently described putative autotransporter gene, bapC, has not been investigated for 
sequence variation. This gene encodes an autotransporter protein, which is a potential 
virulence factor and protective antigen. Therefore it is important to investigate its potential 
for antigenic variation. There was a single nucleotide difference at position 2159 
(AF081494), (CCT, Pro) bapC{\) in ah of the UK isolates, the four vaccine strains and the 
Tohama-I genome sequence, compared with (CCC, Pro) bapC(2) in the type strain 
(Appendix 8, Table 3.1.2.1).
The gene brkA that encodes an autotransporter has been investigated for sequence variation 
and none was found amongst Dutch B. pertussis isolates (van Loo et al., 2002). It was 
considered informative to determine if this was also observed amongst UK B. pertussis 
isolates. No sequence variation was found in brkA between the UK isolates, the four vaccine 
strains, the Tohama-I genome sequence or the type strain (Appendix 8, Table 3.1.2.1).
3.2 MULTILOCUS SEQUENCE TYPING
Multilocus sequence types (MLST-1 to -9) based on point mutations in the three genes 
ptxA, ptxC, and tcfA have been described by van Loo et al. (2002). This scheme was 
applied to 136 UK B. pertussis isolates from 1920-2002 and the four vaccine strains. The 
various combinations of the three genes ptxA, ptxC, and tcfA that contribute to different 
MLSTs are listed m Table 3.2.1.
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Table 3.2.1. Multilocus sequence types (MLSTs) of B. pertussis defined by alleles of genes 
coding for pertussis toxin SI subunit iptxA), S3 subunit (ptxC), and tracheal colonisation 
factor (tcfA) (van Loo et a l, 2002; this study).
MLST Alleles
MLST-1 ptxA{3), ptxC(\), tcfA{2)
MLST-2 ptxA (2), pixC{ 1 ), tcfA (2)
MLST-3 ptxA{\), ptxC{ 1 ), tcfA(2)
MLST-4 ptxA( 1 ), ptxC( 1 ), tcfA (3)
MLST-5 ptxA(l), ptxC{2), tcfA(2)
MLST-6 ptxAfi),ptxC{V), tcfA{A)
MLST-7 ptxA{\),ptxC{\), tcfA{5)
MLST-8 ptxA{2), ptxCÇZ), tcfA(2)
MLST-9 ptxA(l),ptxC(\), tcfA(l)
MLST-10* pixA(l), ptxC(\), tcfA(6)
MLST-11* ptxA(2), ptxC{\), tcfA(5)
* Novel MLSTs found in this study.
I l l
The MLSTs listed are based on those previously described by van Loo et al. (2002) and this 
list has been expanded to include two novel MLSTs based on allelic combinations found 
during this study. MLST-10 had not been previously described and includes the discovery of 
a new tcfA allele, tcfA{6), and MLST-11 is based on a unique combination of previously 
described alleles.
3.2.1 Temporal analysis of multilocus sequence types of Bordetella pertussis in the UK
The temporal trends in MLST frequencies in the UK were examined by dividing the panel of 
B. pertussis isolates into seven time periods: 1920-1949, 1950-1959, 1960-1969, 1970- 
1979, 1980-1989, 1990-1999 and 2002 (Fig. 3.2.1.1). As explained earlier, isolates were not 
available for all years and, for ease of describing the trends and for comparison with other B. 
pertussis populations, the isolates were split into these time groups. Seven distinct MLST 
types were identified in a collection of 136 UK isolates: MLST-2, 3, 4, 5, 6, 10 and 11.
The earliest available UK isolate from 1920 was MLST-2. Three MLSTs, MLST-2, MLST- 
3 and MLST-11, were observed prior to the widespread introduction of pertussis 
vaccination in the UK in the 1950s. Of the 23 isolates from the pre-vaccination era, 10 were 
MLST-2 {ptxAfl), ptxC{\), tcfAÇf) and 12 were MLST-3 {ptxA{\\ p txC {\\ tcfAflj) while 
an isolate from 1942 was a novel MLST type, MLST-11 (ptxA{2), ptxC{\), tcfA{S)) (Fig.
3.2.1.1). MLST-2 persisted into the time period 1980-1989 but has not been seen in isolates 
from the panel since 1985 (there were no isolates available from 1986 to 1997). MLST-3 
was found in aU time periods studied, the most recent of wliich was from 2002. Nine isolates 
from 1970-1999 were MLST-6 (ptxA(l), ptxC(l), tcfA(4)) (Fig. 3.2.1.1). Another novel 
MLST type was identified in two clinical isolates from 1983, namely MLST-10 defined as 
ptxA(l), ptxC(l), tcfA(6). MLST-4 (ptxA(l), ptxC(l), tcfA(3)) was seen only in two isolates, 
from 1999.
In the recent isolates from 2002, only two MLST types were found, MLST-5 (n=31), 
detected only from 1990 onwards, and a single representative of the MLST-3 type (Fig.
3.2.1.1). It is important to note that MLST-5 was not present in the four* UK vaccine strains. 
Two of the three UK WCV strains were MLST-3 (CN5476 and CN3099) and the other was
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Figure 3.2.1.1; Temporal trends in the frequency of multilocus sequence types (MLSTs) in 
the UK B. pertussis population.
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MLST-2 (CN2992) (Fig. 3.2.1.L Appendix 8). The ACV strain, Tohama-I, was MLST-2 
and the type strain oîB. pertussis was MLST-9 (Appendix 8).
3,2.2 Correlation of MLST with pertactin {prnA) types
The variation found in the pertactin (prnA) gene amongst UK isolates has been described 
elsewhere (Fry et a l, 2001; Packard et a l, 2004). In previous work, the prnA gene was 
used alongside the ptxA gene as markers to determine if allelic shift has occurred amongst B. 
pertussis isolates world-wide (section 1.13.2). Several prnA alleles, have been described, 
prnA(\~%) (Mooi et a l, 2000), ^ m ^(9) (AF218785) andprnA{\ 1) (AJ507642).
These alleles differ by the number of repeats found in the molecule’s immunodominant 
regions 1 and 2 or, with prnA(7) a point mutation upstream of region 2. Three known prnA 
alleles, prnA(l-3), have been identified amongst 138 UK B. pertussis isolates within the 
panel (Table 3.1.2.1). The prnA trends are depicted in Fig. 3.2.2.1 and it is shown that a 
shift in prnA type has occurred over time. All isolates and the four vaccine strains fi'om 
1920-1979 were prnA{\) and the non-vaccine prnA alleles were first identified in isolates 
from the 1980s. The predominant allele amongst recent UK isolates fiom 1990-1999 and 
2002 is the non-vaccine prnA allele, prnA(2), The B. pertussis Tohama-I genome sequence 
containedprnA{\) and the type strain wasprnA{6).
Multilocus sequence types of 136 UK B. pertussis isolates and the foui’ vaccine strains were 
compared to their previously determined prnA types and the distribution of these three prnA 
types within the various MLSTs. MLST-2 (n—13), -6 (n=9), -10 (n=2) and -11 (n=l) 
isolates were allprnA{V), MLST-3 isolates (n=12) were prnA{\) during the pre-vaccination 
era but contained representatives of all three UK prnA {prnA{\yprnA(3)) alleles after 1980. 
However, a greater number of MLST-3 isolates were associated with prnA{\) (Fig. 3.2.2.2). 
Of the two MLST-4 types, one was prnA(2) and the other was prnA(3). The majority of 
MLST-5 isolates (n=29) were linked with prnA{2), and one was prnA{3). Two of the three 
WCV strains were MLST-3 prnA(l) and the other was MLST-2 prnA(l). The ACV strain 
was MLST-2prnA(l) and the type strain of B. pertussis was MLST-9 prnA(6).
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Figure 3.2.2.1: Trends in pertactin (prnA) alleles in UK isolates of B. pertussis population 
from 1920-2002. Information from previous studies (Fry et al., 2001; Packard et al., 2004).
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Figure 3.1.2.2: Variation in pertactin (prnA) type in MLST-3 isolates from the UK B. 
pertussis population.
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3.3 POLYMORPHISM IN THE GENE ENCODING FIMBRIAE ANTIGEN 2 {fim2)
Variation in the fim2 gene has been described pi-eviously in Dutch B. pertussis isolates (van 
Loo et ah, 2002). Tsstofim2 alleles were reported in Dutch isolates from the pre-vaccination 
era. After the introduction of vaccination only the fim2{\) allele was apparent. In the present 
study, polymorphism was investigated for eighty UK B. pertussis isolates fr om 1920-2002 
and was detected at position 701 (Y00527) using the real-time sequencing technique 
Pyrosequencing. This method was used for detection of the single nucleotide polymorphism 
amongst UK isolates as it is much more rapid for attaining such results than dideoxy 
sequencing. The two alleles found in the UK B. pertussis population were fim2{V) (AGA, 
Arg) and fim2(2) (AAA, Lys) (Table 3.1.2.1), in agreement with those found by van Loo et 
al. (2002). Table 3.1.2.1 shows that 60 of 80 isolates (75%) were flm2{\) and 25% were 
fm2{2). The trends in fim2 allelic variation found amongst the UK isolates from 1920-2002 
is shown in Fig. 3.3.1. The isolates have been divided into five time groups; two groups of 
approximately 30 years from 1920-1985, isolates from 1998, isolates from 1999 and the 
most recent isolates, from 2002, as separate groups (Fig. 3,3.1). These time groups were 
chosen as isolates were not available for all years. Allele fim2(2) was only found among UK 
isolates from 1998-1999 (Fig. 3.3.1). The four- vaccine strains, the Tohama-I genome 
sequence and the B. pertussis type strain were fim2{\) (Appendix 8). During 1998, 9 of 18 
B. pertussis isolates were fim2{2) and in 1999, 11 of 26 isolates were fîm2(2) . Interestingly, 
this allele was only linked to isolates that were serotype 1,2, determined by a previous study 
(Fry et ah, 2001), and all were MLST-3. The allele fim2{l), conversely, was associated with 
isolates that were all possible combinations of serotypes (1, 1,2, 1,2,3, 1,3).
3.4 INCLUSION OF FIMBRIAE ANTIGEN 2 {fim2) AND PERTACTIN (prnA) 
GENES IN MULTILOCUS VIRULENCE GENE SEQUENCE TYPING (MVGST) 
SCHEME
The MLST scheme developed by van Loo et al. (2002) was based on the allelic variation of 
the three gene tar gets ptxA, ptxC and tcfA, with each gene exhibiting a degree of variation 
suitable for use as gene markers. However, two other genes, fim2 and prnA, Irad also 
demonstrated variation and therefore had potential for use in strain discrimination. The 
genes fim2 and prnA were not included in the original MLST scheme because only Dutch B. 
pertussis isolates from the pre-vaccination era had shown variation in fim2 and the var iation
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Figure 3.3.1: Trends in fimbrial antigen 2 (fim2) alleles in UK isolates of B. pertussis from 
1920-2002.
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of prnA was not deemed suitable. This is due to prnA variation not being a result of single 
nucleotide polymorphisms, but due to insertion and deletion of repeat units and this is a 
process that is expected to occur relatively frequently as well as reversibly (van Loo et al., 
2002). However, the variation of prnA had been used in previous sequence typing studies 
(see section 1.13.2) as it was considered a suitable gene target, and was therefore included 
here. It should also be noted that the known alleles of the MLST gene marker tcfA also 
differ due to the presence of an insertion and a deletion as well as single nucleotide 
differences. Sequence variation offlm2 was only observed during the pre-vaccination era for 
Dutch isolates \mXfim2 variation may differ with different B. pertussis populations. Tliis was 
shown for the UK B. pertussis population as variation was observed during 1998-1999. 
Inclusion offim2 in a sequence typing scheme would further discriminate the same MLST 
isolates from the same time periods as well as between B. pertussis populations.
Tliree variations of the van Loo et al. (2002) MLST scheme, designated here as Multilocus 
Virulence Gene Sequence Typing (MVGST), are described in this section. The first scheme, 
MVGST(l), is based on a combination of sequence types of ptxA, ptxC, tcfA and prnA, 
MVGST(2) is based on a combination of sequence types of ptxA, ptxC, tcfA and fim2 and 
MVGST(3) is based on a combination of sequence types of ptxA,ptxC, tcfA, prnA and fim2. 
There were seven MLST types found within the UK B. pertussis population using the 
original scheme (section 3.2). Sequence variation o f prnA was knovm for 138 5. pertussis 
isolates and fim2 variation was known for 80 UK B. pertussis isolates. The inclusion ofprnA 
expanded the original scheme to eleven types. The inclusion o f fim2 resulted only in six 
types but not all isolates had been investigated for fim2 variation. The inclusion o f both prnA 
and ftm2 yielded ten sequence types which is a lower number of sequence types than that 
found with the MVGST(l) scheme, again due to the smaller number of isolates investigated 
for fim2 variation. The temporal trends of particular types of B. pertussis according to the 
different MVGST schemes are described later. As before, the isolates were divided into 
seven time groups: six groups of approximately 10 years from 1920-1999, and the most 
recent isolates, 2002, as a separate group. The trends for each of the MLST schemes were 
examined for these same time groups, allowing comparison between the original MLST 
scheme and the three MVGST schemes described here.
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The integration ofprnA sequence types alone, in MVGST(l), yielded the greatest number of 
sequence types found amongst UK B. pertussis isolates but this can be partially attributed to 
prnA variation being known for a greater number of isolates than fim2 variation. Table 3.4.1 
lists the eleven combinations of MVGST(l) types found amongst the UK B. pertussis 
population. The MVGST(l) trends are depicted in Fig. 3.4.1.
There were thiee MVGST(l) sequence types found during the pre-vaccination era, 
MVGST(1)~1 to -3 and this was similar to that seen with the original MLST scheme where 
three types were found during the same time period. Two sequence type MVGST(1)-1 
{ptxA{2),ptxC{\\ tcfA(2\prnA(V)) and MVGST(l)-2 (ptxA(\\ptxC{\), tcfA{2\ prnA{\)) 
were present during 1920-1949 at similar frequencies whereas MVGST(l)-2 dominated 
during the 1950s and 1960s. Lastly, MVGST(l)-3 iptxA{\), p txC {\\ tcfA{5), prnA{\)) was 
seen only in one B. pertussis isolate, from the period 1920-1949. The four UK vaccine 
strains were MVGST(1)-1 or MVGST(l)-2. During the 1970s and 1980s when the pertussis 
vaccination rate in the UK had declined, there was the appearance of sequence types not 
found during 1920-1969 (Fig. 3.4.1). During the 1970s, two sequence types were apparent, 
MVGST(l)-2 and MVGST(l)-4 (ptxA(\), ptxCil), tcfA{A), prnA{\%  with the vaccine 
stram type, MVGST(l)-2, predominating. From 1980s onwards this scheme is apparently 
more discriminatory than the original MLST scheme. Six sequence types were found during 
1980-1989 compared to the four types found using the original scheme. Two predominating 
types were found, MVGST(l)-2 and MVGST(l)-4 with MVGST(1)-1 found in very few 
isolates (Fig. 3.4.1). Three types not seen previously were present amongst isolates from 
1980-1989: MVGST(l)-5 (ptxA{\\ ptxC{\), tcfA{2), prnA{2)), MVGST(l)-6 (ptxA{l), 
ptxC{l), tcfA(2\ prnA{3)) and MVGST(l)-7 (ptxA(\), ptxC(\), tcfA(6), prnA{\)) (Fig.
3.4.1). Seven sequence types were found with this scheme (MVGST(l)) amongst B. 
pertussis isolates from the 1990s compared to four types found using the original scheme. 
The sequence type, MVGST(l)-2 was one of the predominating sequence types. Three 
types, MVGST(l)-4, -5 and -6, were present at low frequencies and there was the 
appearance of three types not seen previously, MVGST(l)-8, -9 and -10 (Fig. 3.4.1). 
MVGST(l)-8 (ptxA(l), ptxC(2), tcfA(2), prnA(2)) was a sequence type predominating 
during this time period and was present in a greater number of UK B. pertussis isolates than 
MVGST(l)-2. The two sequence types, MVGST(l)-9 (ptxA{\), ptxC{\), tcfA(3), prnA{2))
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Table 3.4.1. Miütilocus virulence gene sequence types (1) (MVGST(l)) of UK isolates of 
B. pertussis defined by alleles of genes coding for pertussis toxin SI subunit iptxA), S3 
subunit (ptxQ, tracheal colonisation factor (tcfA) and pertactin (prnA).
Sequence types Alleles
MVGST(1)-1 ptxA(2), ptxC(l), tcfA(2), prnA(l)
MVGST(1>2 ptxA(l), ptxC(l), tcfA(2\ prnA(\)
MVGST(l)-3 ptxA(\), p txC (\\ tcfA(5\ prnA(\)
MVGST(1>4 ptxA{\), p txC (\\ tcfA(A\ prnA(V)
MVGST(1>5 ptxA{\\ p txC (\\ tcfA{2), prnA(2)
MVGST(l)-6 ptxA(l), ptxC(l), tcfA(2), prnA(3)
MVGST(l)-7 ptxA(l), ptxC(l), tcfA(6), prnA(l)
MVGST(l)-8 p txA (\\ ptxC(2\ tcfA(2), prnA(2)
MVGST(l)-9 ptxA (l\ ptxC(l), tcfA(3), prnA(2)
MVGST(1)-10 ptxA(\), ptxC(l), tcfA(3), prnA(3)
MVGST(1)-11 ptxA(\), ptxC(2\ tcfA(2), prnA(3)
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Figure 3.4.1: Temporal trends in the frequency of multilocus virulence genes sequence
types (1) (MVGST(l)) types in the UK B. pertussis population (135 B. pertussis isolates).
Key:
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and -10 (ptxA{\), ptxC{\), tcfAQ), prnA(3)), were detected in a lower number of B. 
pertussis isolates. During the most recent time period examined, 2002, three sequence types 
(MVGST(l)-2, -8 and -11) were identified, compared with two with the original MLST 
(Fig. 3.4.1). One of these types was not seen in previous time periods, MVGST(1)-11 
{ptxA{\), ptxCil), tcfA{2), prnA(3)). The predominating type was MVGST(l)-8 and 
MVGST(1)“2 and -11 were each found in one B. pertussis isolate.
The scheme MVGST(2) based on the gene variation of ptxA, ptxC, tcfA and fim2, yielded 
the least number of sequence types compared to MVGST(l) and MVGST(3). Regarding 
greater variation foxmd with the MVGST(l) scheme this was presumably related to a smaller 
number of isolates having been investigated for fim2 variation. The six MVGST(2) types 
that were found amongst B. pertussis isolates are described in Table 3.4.2. The MVGST(2) 
trends from 1920-2002 are shown in Fig. 3.4.2. Two types were found amongst B. pertussis 
isolates fi'om 1920-1949, MVGST(2)-1 {ptxA{2\ ptxC{\), tcfA{2\ fim2{\)) and 
MVGST(2)-2 (ptxA{\), ptxC{\), tcfA(2), fim2(l)) with MVGST(2)-1 found in a slightly 
greater number of isolates (Fig. 3.4.2). The four UK vaccine strains were MVGST(2)-1 or - 
2. Only these two types were found until the 1970s when there was the appearance of 
MVGST(2)“3 (ptxA{l), ptxC(l), tcfA{4), fm 2 (l)). The vaccine strain types, MVGST(2)-1 
and -2, were found amongst isolates fiom 1980s. During 1990-1999, there were four types 
found, MVGST(2)-2, -4 (ptxA(l), ptxC(l), tcfA{2), fm 2{2 )\ -5 iptxA{\), ptxC{\), tcfA{3), 
fim2{\)) and -6 (ptxA{\), ptxC(2), tcfA(2),fim2{\)). Two types, MVGST(2)-4 and -6, were 
the predominating types during the 1990s (Fig. 3.4.2). During 2002, only one type, 
MVGST(2)-6, was apparent.
When the sequence typing scheme MVGST(3), based on variation of all five genes, ptxA, 
ptxC, tcfA, prnA and fim2 known to exhibit sequence variation amongst the UK B. pertussis 
population, was used, ten types were identified and these are fisted in Table 3.4.3. Figure
3.4.3 shows the MVGST(3) trends found amongst UK B. pertussis isolates. Two sequence 
types were found amongst B. pertussis isolates from 1920-1969, MVGST(3)-1 (ptxA{2), 
ptxC{\), tcfA{2), prnA{\), fim2{\)) and MVGST(3)-2 {ptxA{\), ptxCfi), tcfA(2), prnA{V), 
fïm2{\)) (Fig. 3.4.3). The four UK vaccine strains were also MVGST(3)-1 or -2. During 
1970-1979 MVGST(3)-2 and -3 {ptxA{\), pixC{\), tcfA{A),prnA{\),fim2{\)) were present.
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Table 3,4.2. Multilocus virulence gene sequence types (2) (MVGST(2)) of UK isolates of 
B. pertussis defined by alleles of genes coding for pertussis toxin SI subunit {ptxA), S3 
subunit (ptxC), tracheal colonisation factor (tcfA) and fimbrial antigen 2 (fiml).
Sequence types Alleles
MVGST(2)-1 ptxAfl), ptxC{\\ tcfA{2), fiin2{\)
MVGST(2)-2 ptxA(l), ptxC(l), tcfA(2), fim2(\)
MVGST(2)-3 ptxA(lX ptxC(l), tcfA(4),fim2(l)
MVGST(2)-4 ptxA(l), ptxC(l), tcfA{2),’fim2{2)
MVGST(2)-5 ptxA{\\ ptxCiX), tcfA{3),fim2{l)
MVGST(2)-6 ptxA{\\ ptxC(2), tcfA(2), fim2{\)
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Figure 3.4.2: Temporal trends in the frequency of multilocus virulence genes sequence 
types (2) (MVGST(2)) types in the UK B. pertussis population (80 B. pertussis isolates).
Key:
MVGST(2)-1 ■ Vaccine strains: (CN2992, Tohama-I)
MVGST(2)-2 □ Vaccine strains: (CN3099, CN5476)
MVGST(2)-3 □
MVGST(2)-4 ■
MVGST(2)-5 □
MVGST(2)-6 ■
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Table 3.4.3. Multilocus virulence gene sequence types (3) (MVGST(3)) of UK isolates of 
B. pertussis defined by alleles of genes coding for pertussis toxin SI subunit {ptxA), S3 
subunit (ptxC), tracheal colonisation factor (tcfA), pertactin (prnA) and fimbrial antigen 2 
(fim2).
Sequence types Alleles
MVGST(3)-1 ptxA(2% ptxC(l), tc/A(2), prnA(l), fm 2 (l)
MVGST(3)-2 ptxA(l), p txC (\\ tcfA(2\ prnA(\\ fim2(l)
MVGST(3)-3 pixA(l),ptxC(\), tcfA(4\ prnA(l),fim2(\)
MVGST(3)-4 ptxA(l), ptxC(l), tcfA(2), prnA(2),fim2(l)
MVGST(3)-5 ptxA(\), ptxC(l), tcfA(2), prnA(3\ fim2(l)
MVGST(3)-6 p txA (\\p txC (\\ tcfA(2\ prnA(\), fm 2(2)
MVGST(3)-7 ptxA(\), ptxC(\), tcfA(2), prnA(2), fîm2(2)
MVGST(3)-8 p txA (l\ ptxC(2\ tcfA(2\ prnA(2\ fim2(l)
MVGST(3)-9 p txA (l\p txC (l\ tcfA{3), prnAQ\fim2{\)
MVGST(3)-10 ptxA{\), ptxC(\), tcfA(3),prnA(2),fim2(l)
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Figure 3.4.3: Temporal trends in the frequency of multilocus virulence genes sequence 
types (3) (MVGST(3)) in the UK B. pertussis population (80 B. pertussis isolates).
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The vaccine strain types, MVGST(3)-1 and -2, were found amongst isolates from 1980- 
1989.
Tills method was found to be the most discriminatory for isolates from 1990-1999 compared 
to MVGST(l), MVGST(2) and the original MLST. Eight sequence types were found 
amongst isolates from this time period. The sequence type, MVGST(3)-2 was present in a 
low number of isolates and MVGST(3)-4 to -10 were present during this time period and 
were not apparent in other years (Fig. 3.4.3). Sequence types MVGST(3)-4 {ptxA{\), 
ptxC {\\ tcfA{2\ prnA(2), /?w2(l)), MVGST(3)-5 (ptxA(l\ ptxC{\), tcfA{2), prnAQ), 
flm 2{\)\ MVGST(3)-9 {ptxA{l\ ptxC{\), tcfA{3\ prnA(3), fim2{\)) and MVGST(3)-10 
(ptxA(l), ptxC(l), tcfAQ), prnA(2), fîm 2(l)) were each found only in one B. pertussis 
isolate. MVGST(3)-7 (ptxA{V), ptxC{\), tcfA{2), prnA(2), fim2{2)) was also found in a 
small number of isolates. Two types predominated: MVGST(3)-6 (ptxA{\), ptxC{\), tcfA{2), 
prnA(l),fim2(2)) and MVGST(3)-8 (ptxA(l), ptxC(2), tcfA{2), prnA(2), fim2{l)) amongst 
isolates from the 1990s. During the most recent time period examined, 2002, all isolates 
were MVGST(3)-8 (Fig. 3.4.3).
It was found that with the inclusion of prnA the number of sequence types increased 
compared to using only ptxA, ptxC and tcfA, thus discriminating amongst B. pertussis 
isolates that belonged to a particular MLST according to the original scheme. AH three 
schemes showed that a shift in UK B. pertussis population occurred between the pre­
vaccination era and the present day. A larger number of sequence types were identified 
amongst isolates from the 1980s and 1990s with the MVGST(l) and MVGST(3) schemes 
compared to the number found using the original MLST scheme. However, each scheme has 
demonstrated that novel sequence types were present in B. pertussis isolates from 2002 that 
were not found amongst isolates from the pre-vaccination era or the immediate post­
vaccination era and wliich also differed from the sequence types of the four UK vaccine 
strains.
3.5 cyaA PROMOTER
3.5.1 Polymorphism in the cyaA promoter region
One of the objectives of this investigation was to study the expression of the cyaA gene that
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encodes the virulence factor CyaA under different growth conditions. For this, the promoter 
region of the cyaA gene was successfully cloned upstream of the promoterless lux operon 
contained on the plasmid, pSB395, and the promoterless gfp gene contained on the plasmid 
pPROBE-AT', which would be used as reporters for cyaA expression. The type strain of B, 
pertussis has been previously described to have three times more adenylate cyclase enzymic 
(AC) activity and to express three times more CyaA protein than the strain Tohama-I (Guiso 
et al., 1991). It was therefore desirable to determine if sequence variation existed in the 
promoter region of cyaA between the type strain and other isolates that might explain the 
difference in expression.
The region was amplified using primers CyaAl and CyaA6, which targeted bases 287-1165 
(Y00545), containing the cyaA promoter region. This amplified region was sequenced for 
ten UK B. pertussis isolates (including the non-UK B, pertussis type strain, NCTC10739^) 
from different time periods and B. pertussis Tohama-I derivative strain BP338 that has been 
used in conductimetiy analysis and is the host strain for the lux and gfp plasmid cloning 
work (section 3.9). The four vaccine strains were not included in the original investigation 
for sequence variation. The available GenBank sequence for cyaA gene is of the B. pertussis 
type strain (18323^) and sequencing results were aligned with this control sequence for 
analyses. The type strain NCTC10739^ was sequenced for this region to ensure that this was 
the same as that of the submitted GenBank sequence. There was a single nucleotide 
difference between the GenBank sequence Y00545 and that of strain NCTC10739^ 
identified at position 840 and this latter sequence was designated cyaApr{\). Strain BP338 
was also sequenced in this region and a single difference was found between BP338 
sequence and NCTC10739^ at nucleotide position 695 (Fig. 3.5.1.1). Only one of the ten 
isolates in the panel was cyaApr{\). Seven were of the same cyaApr sequence type as that of 
BP338, cyaApr{2). There were two isolates, PICU475 and 99K45, of the panel of 10 
isolates, that contained a 6 bp insertion at nucleotide position 692 (Y00545) which lies 
between cyaA and the cyaC gene upstream of cyaA promoter. It should be noted that the 6 
bp insert does not actually overlap with the cyaC GenBank sequence (M57286) as this 
insertion is situated approximately 31 bases fi'om the start of cyaC (Fig. 3.5.1.1). However, 
it is situated close to the start of the cyaC sequence. This sequence type was designated 
cyaAprQ). Sequencing of strains 99K45 and PICU475 for the same region using primers
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Figure 3,51,1. Alignment of the adenylate cyclase toxin (cyaA) promoter region of B, 
pertussis strains (NCTC10739^, CNI 37, PICU475 and 99K45) with the GenBank 
sequence of the type strain (Y00545), B. parapertussis strains (NCTC5952), and B. 
bronchiseptica strain (NCTC452). The areas highlighted in green are differences in 
sequence compared to that of the cyaA promoter sequence predominantly foxmd 
amongst isolates and this is represented by CNI 37. The -10 and -35 areas are 
highlighted in yellow and grey respectively. The binding sites of phosphorylated BvgA 
(BvgA-P) predicted by Karimova et aL, 1996 are highlighted in blue. The numbering on 
the diagram is relative to that of Y00545. The bold letter and arrow at position 660 
indicates the start of the accessory gene (cyaC) GenBank sequence M57286. The 
overlap between M57286 and the sequence amplified is bases 1-91 (M57286).
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CyaAl and CyaA6 was repeated. The primers CyaApR and CyaApF were designed to 
amplify a smaller region of 388 bp targeting bases 570-958 (Y00545) and tliis was also 
sequenced.
The amplified regions were sent to DBS Genomics, University of Durham; MBSU, 
University of Glasgow for sequencing and this was also canied out in RSIL to ensure that 
sequencing error had not occuired. The results firom the repeated sequencing were 
concordant with that of the original sequencing. B. parapertussis (NCTC5952) and R. 
bronchiseptica (NCTC452) were also sequenced for this region as these two species are 
known to express the gene cyaA. Sequence differences were found between all tliree 
Bordetella species (Fig. 3,5.1.1). However, neither the B. parapertussis strain nor the B. 
bronchiseptica strain contained the 6 bp insertion. There is overlap between the GenBank 
sequences of cyaA and cyaC and the gene cyaC starts within Y00545 at position 660 and 
the 6 bp insertion is situated at position 691 (Fig. 3.5.1.1).
3.5.2 Screening the cyaA promoter region in B. pertussis isolates with LightCycier 
assay
The LightCycier (LC) hybridisation probe assay was used as an alternative to conventional 
sequencing to screen 42 isolates, the four vaccine isolates and the type strain for the 
presence of the 6 bp insertion between cyaA and cyaC. The LightCycier was used as an 
alternative to conventional sequencing to ensure that this 6 bp insertion in PICU475 and 
99K45 was not a sequencing error and it is also much more rapid. Due to the differences in 
sequences of the cyaA promoters, there were differences in melting temperatures of each 
sequence type, thus making this target suitable for screening with the LC hybridisation probe 
assay. Different sequence types are indicated by different melting curves. The primers used, 
CyaApR and CyaApF, targeted bases 570-958 (Y00545) amplifying a total of 388 bp for the 
LC assay. Figure 3.5.2.1 shows an example of LightCycier melting curve analysis.
There were three positive controls, the B. pertussis type strain {cyaApr{\)), CN137 
{cyaApr(2)), PICU475 {cyaAprQ))^ included in each LC assay performed to ensure that all 
three sequence types were capable of being detected easily. The three sequence types, 
cyaApr(\)-{3\ were easily discriminated from one another by melting curve analysis
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Figure 3.5.2.1: Melting curve analysis of LightCycier assay of B. pertussis isolates 
PICU287, 519, 522, 523 and 524. The yellovy cursor indicates the melting curve of the B. 
pertussis type strain NCTC10739^, the green cursor highlights the melting curves of the 
PICU287, 519, 522, 523 and 524 isolates and the blue cursor highlights the melting curve 
of PICU475 which is known to contain the 6 bp insertion.
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resulting in three individual peaks. The peak indicated with the yellow cursor represents that 
of the type strain (positive control) and it has a melting temperature of 58°C. The peaks 
indicated with the green and yellow cursors represent the wild-type B. pertussis isolates 
(CN137 as positive control) and PICU475 (positive control) respectively with melting 
temperatures of 63.9°C and 67.5°C respectively. Table 3,1.2.1 summarises the frequency of 
the cyaApr alleles found amongst UK isolates. No further sequence variation was found in 
this region and only the two isolates, 99K45 and PICU475, which had the known 6 bp 
insertion, were confirmed using the LC assay, Thi*ee alleles have been identified, cyaApr(iy 
(3) and only the B. pertussis type strain was cyaApr{\), The majority of UK B. pertussis 
isolates, including the four vaccine strains, were cyaAprÇL) (43 of 46; 93.4%). The other UK 
isolates, 99K45 and PICU475, were cyaAprQ) (6.6%), The Tohama-I genome sequence 
was cyaApr{2). Four* other PICU isolates (PICU287, PICU519, PICU522, PICU523 and 
PICU524) were screened using the LightCycier assay to check for the 6 bp insertion to 
determine if B. pertussis isolated from other young infants admitted to paediatric intensive 
care units (PICUs) infected with pertussis had this sequence variation present between the 
genes cyaA and cyaC. None of the other PICU isolates contained this sequence variation. 
There were no family contact samples of PICU475 containing B. pertussis available for 
similar analyses to determine if the family contacts also had B, pertussis isolates with this 6 
bp insertion.
The two isolates PICU475 and 99K45 were MLST-4 but they differed in their prnA types: 
PICU475 was prnAQ) and 99K45 was prnA{?>). This MLST type is based on the tcfA allele 
tcfA(3). Moreover, these strains are the only two isolates of the selected panel of 138 
isolates, vaccine strains and the type strain that have the tcfA(3) allele. In view of this 
finding, it was desirable to determine if there was a link between isolates that were tc/A(3) 
and the 6 bp insertion situated between cyaA and cyaC. Other tc/A(3) isolates (n=3) were 
provided by Prof F. Mooi, National Institute of Public Health and the Environment, 
Bilthoven, The Netherlands. The region of interest was amplified using CyaApR and 
CyaApF primers, already used for the LC assay, and the amplified DNA was sent to the 
sequencing unit at DBS Genomics, University of Durham. Sequencing data were analysed 
using BioNumerics (Applied Maths). None of these isolates contamed the 6 bp insertion. 
Therefore, there is no linkage between tcfA(3) and the presence of the 6 bp insertion.
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3.6 CONDUCTIMETRY ASSAYS OF rCyaA
The enzymic (AC) activity of adenylate cyclase toxin has been used as a diagnostic tool in 
radioisotopic assays that detect cAMP levels in clinical samples from pertussis patients or B. 
pertussis cultures. A novel conductimetric assay developed by Dr A. Lawrence (University 
of Glasgow) has been used to detect AC activity from recombinant CyaA (rCyaA). The 
method of preparation of rCyaA wiU be described briefly as this was used to optimise the 
assay. It was kindly supplied by Dr B. Orr. The CyaA protoxin (containing the AC activity) 
and CyaC (which is required for activation of cytotoxic activity of CyaA) were expressed on 
separate compatible plasmids, pGW44 and pGW54, respectively (MacDonald-FyaU, 2002). 
The E. coli strain BL21/DE3 was the host strain for these expression vectors. Urea extracts 
of BL21/DE3 expressing active CyaA were prepared and rCyaA was extracted and purified 
using a combination of two protein purihcation methods, DEAE sepharose (anionic 
exchange) chromatography and phenyl sepharose (hydrophobic interaction) 
chromatography. This section will report the optimisation of the conductimetry assay 
measuring AC activity from rCyaA, its detection limit and the effect of inhibitory substances. 
It will also describe the development of a protocol for the measur ement of AC activity from 
B. pertussis urea extracts and cell lysates and the optimisation of this assay.
3.6.1 Optimisation of rCyaA and native CyaA assay protocols
There are two reagents, ATP and CaM, used in this assay for detection of AC activity from 
CyaA that affect the rate of reaction. It was important for this investigation to determine the 
concentration of each reagent that provided the optimal reaction rate of AC activity. The 
reagent pyrophosphatase (PPiase) was not considered to be a rate-limiting reagent due to 
the rate of reaction not being affected by the amount that is added, as the conversion of ATP 
to cAMP with the release of PPi is the rate-limiting step. It is only when very active stock 
rCyaA is used that there may not be enough PPiase to catalyse the second reaction 
optimally. One way to overcome this is to ensure that dilutions of stock rCyaA ar e used. The 
optimal ATP concentration was determined by measuring AC enzymic activities with ATP 
concentrations ranging from 0.2-1.4 mM ATP. The optimal concentration of ATP was 
found to be 0.5 mM for assays detecting AC activity from rCyaA as increasing the 
concentration above this level did not affect the reaction rate. The optimal CaM 
concentration was determined in a similar way with both CaM from a commercial source
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(Sigma) and CaM prepar ed in-house. The optimal amount was determined to be Ipl of Img 
ml'^  of either CaM source but due to supply limitations, the commercial preparation was 
preferred.
The optimal ATP concentration for assays of native CyaA was determined as described 
above. The optimal concentration of ATP was found to be 1 mM to be used for assays 
detecting AC activity from B. pertussis cell lysates prepared in the non-ionic detergent 
Triton X-100. The optimal CaM concentration was also determined as described above. This 
was determined to be 1 pi of 1 mg ml“’ of either preparation and again the commercial 
preparation was preferred.
3.6.2 Determination of AC enzymic activity
To calculate the AC enzymic activity in international units (lU) per mg of protein, the total 
conductance change must be known. Total conductance change in arbitrary units for a 
substrate concentration of 1 mM (ATP) was 2200 (Fig. 3.6.2.1) and this value was used in 
calculating the specific activities of AC.
Example of calculation for determining AC activity expressed in international units (lU) mg' 
Stock preparation of rCyaA concentration was 0.216 mg protein ml''. This was used at a 1 
in 10 dilution (0.0216 mg protein ml ') and 2 pi were added to a final volume of about 2 ml 
therefore in the conductimetry cell there was a final concentration of 0.0216 pg protein ml ' 
of CyaA.
initial reaction rate = (y/x) pmoFmFmin
initial reaction rate = tangent of reaction (y) (containing 0.0216 pg ml'*) (units per min) / 
total change value (x) (arbitrary units)
For example:
-  26 ( y ) /2200 (x)
= 0.0118 pmoles/ml/min
To convert pmoles/ml/min to pmoles/min/pg protein 
= 0.0118 pmoles/ml/min / 0.0216 pg protein ml *
= 0.55 pmoles/min/pg protein
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Figure 3.6.2.1: Standard curve for total conductance change (arbitrary units) for ATP 
concentrations from 0.1 mM to 1 mM.
Key;
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To convert p,moles/ml/min to lU (international imits)/mg 
= 550 lU mg"^  protein
3.6.3 Determination of detection limit of AC assay
This was determined by testing various dilutions of recombinant CyaA in the optimised 
reaction to give logarithmic scale of tangents of the reaction curves. At the lowest dilutions, 
it was necessary to determine if the reaction was genuine and not due to background. This 
was achieved by determining the rate of reactions with and without CaM. No reaction 
occurred when CaM was absent. With this information, the detection level for AC activity of 
purified recombinant CyaA in the cell was 0.864 ng protein ml"\
3.6.4 Requirement for ATP, CaM and PPiase in AC assays
Reactions in the conductimetric assay containing different reagents and the effect it had on 
the enzymic reaction of purified CyaA were compared. A reaction that contained CaM and 
ATP but no PPiase showed a negative reaction (Fig. 3.6.4.1). With reactions that contained 
no ATP, the progress curves remained at the baseline and no increase in conductivity took 
place (Fig. 3.6.4.2). Reactions that did not contain CaM showed only a slight increase in 
conductivity (Fig. 3.6.4.2). Thus rCyaA had very low AC activity in the absence of CaM, 
but AC activity was greatly activated by CaM. Therefore the assays were CaM-specific, as 
expected.
3.6.5 Effect of different lysis agents on AC enzymic activity
The AC enzymic activity of B. pertussis CyaA has been detected in the culture supernate 
and is also known to cell-associated. Hewlett et al. (1976) reported that up to 20% of AC 
activity is detected in the culture supernate whereas the remaining activity is cell-associated 
with 91-93% of it being extracytoplasmic. Initially, a suspension of whole-cells of B. 
pertussis BP348pRMBl fi-eshly grown on BG agar was originally tested for AC activity in 
the conductimetry assay. No AC activity was detected after adding whole cells to the 
conductimetiy cell, which implied that any CyaA on the cell surface was at undetectable 
levels. Therefore it was important for this study to develop a protocol for the lysis of B. 
pertussis cells that would maintain sensitivity of the assay and minimise the introduction of 
inhibitory substances. Urea and several nonionic detergents were investigated for then
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Figure 3.6.4,1: Enzymic (AC) activity without the addition of pyrophosphatase (PPiase). 
Conductimetry assay determining the effect of PPiase on AC activity. The first and last 
cells were the blank controls consisting of buffer with CaM and PPiase and no reeombinant 
adenylate cyclase toxin (rCyaA). Cells 2-4 contained all reagents and rCyaA. Cells 5-7 
contained assay buffer with CaM and CyaA with no PPiase.
Key:
1 —  Blank
2 —  rCyaA+ATP+CaM+PPiase
3 —  rCyaA+ATP+CaM+PPiase
4 —  rCyaA+ATP+CaM+PPiase
5 ___ rCyaA+ATP+CaM
6 —  rCyaA+ATP+CaM
7 —  rCyaA+ATP+CaM
8 —  Blank
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Figure 3.6.4.2: Enzymic (AC) activity without the addition of calmodulin (CaM) or ATP. 
Conductimetry assay determining the effect of CaM and ATP on AC activity. The first cell 
was the blank control as for Fig. 22a. Cell 2 contained the positive control, assay buffer 
with all reagents and rCyaA. Cells 3-5 contained assay buffer with ATP, PPiase and rCyaA 
but no CaM. Cells 6-8 contained assay buffer with CaM, PPiase and rCyaA but no ATP.
Key;
1 — Blank
2 —  rCyaA+ATP+CaM+PPiase
3 —  rCyaA+ATP+PPiase
4 —  rCyaA+ATP+PPiase
5 —  rCyaA+ATP+PPiase
6 —  rCyaA+CaM+PPiase
7 —  rCyaA+CaM+PPiase
8 —  rCyaA+CaM+PPiase
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potential as lysis agents of B. pertussis. It was important to determine the potential 
inhibitory effect of these agents in conductimetry assays.
The maximum concentration of urea that could be present m the glass cell without any 
noticeable inhibition of AC enzymic activity was 0.25 M (Fig. 3.6.5.1). Two commercially- 
available agents that contain nonionic detergents, B-Per® Bacterial Protein Extraction 
Reagent and BugBuster™ Protein Extraction Reagent were also tested. Both of these 
detergents caused inhibition even at low amounts (2 pi). The seven nonionic detergents 
tested (Table 6) did not inhibit the AC enzymic activity (the effects of Tween-20 are shown 
in Fig. 3.6.5.2) over the concentration range of 0.01% to 1.5% and with a final 
concentration of 43.2 ng ml"^  of rCyaA. By comparing the tangents of the progress curves, it 
was determined that AC activities were approximately similar and therefore no significant 
inliibition had occurred. It was also determined that there was no volume effect when adding 
different volumes of a known non-inhibiting reagent.
3.7 CONDUCTIMETRY ASSAY OF AC ENZYMIC ACTIVITY IN B. pertussis 
SAMPLES
3,7.1 Optimisation of R. pertussis CyaA protocol
The seven nonionic detergents, for wliich no inhibition of AC activity was found, were 
further investigated to determine which one provided optimal lysis of B. pertussis for 
detection of enzymic activity. Initially, lysis agents were tested on strain BP348pRMBl, an 
overexpressor of AC (Brownlie et al, 1988), then tested on strain NCTC10739^ (reported 
to express AC activity 3-fold greater than that of Tohama-I) and strain BP338. Cell 
suspensions of 2 x 10^  cfu ml"' of B. pertussis strain BP348pRMBl were prepared in saline 
and lysed with the seven different non-ionic detergents.
To aid in lysis of the cells, the ceU suspension was maintained in detergent at 4°C for 
different lengths of time (10 min, 30 min, 1 h) on a rotary shaker. It was found that the 
inclusion of the mixing stage did improve lysis and 30 min was the time chosen for mixing of 
cells with detergent.
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Figure 3.6.5.1; Effect of urea concentration of enzymic (AC) activity of recombinant 
adenylate cyclase toxin (rCyaA). The first cell contained the positive control (rCyaA). Cell 
2 contained the blank control consisting of buffer alone. Cells 3-8 contained decreasing 
concentrations of urea, with final concentrations ranging from 8M to 0.25 M urea.
Key:
1 — Positive control
2 — Blank
3 — 8M urea
4 — 4M urea
5 — 2 M urea
6 — 1 M urea
7 — 0.5 M urea
8 — 0.25 M urea
p »  c * l»  C e tf ig u i*  U*k>
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Figure 3.6.5.2: Effect of a nonionic detergent (Tween-20) on enzymic activity. Cell 1 was 
the blank control. Cell 2 contained the positive control, 2pl of rCyaA alone. Cell 3-8 
contained increasing concentrations of Tween-20. The final concentrations in cells 3-8 
ranged fi-om 0.01%-1.5%.
Key;
1 —  Blank
2 —  Positive control
3 —  0.01% Tween-20
4 —  0.05% Tween-20
5 —  0.1% Tween-20
6 —  0.25% Tween-20
7 —  1% Tween-20
8 —  1.5% Tween-20
E l*  C « fc  V!*<» C oD flgu»  t M i
r WOM
143
In some assays, an extra control was included consisting of 86 fxg protein of positive control 
rCyaA added to 300 pi of nonionic detergent (Tween-20, Tween-80 or Brij 35) which was 
also mixed for 30 min at 4°C. This control was included in the assays to determine if any AC 
activity was lost during this mixing stage of the lysis protocol. It was tested in three assays 
and it was found that there was a loss of about 30% of AC activity. For example, the 
positive control had a tangent of 116 while that with Brij 35 had a tangent of 82, after the 
nuxiiig step.
Table 3.7.1.1 lists the non-ionic detergents investigated, the final concentration of each 
lysing agent in the conductimetry cell, the number of lysed cells of B. pertussis strains in the 
conductimetry cell and the tangent value of each progress curve. This table was derived after 
different volumes of cell suspension (10-300 pi), lysed with non-ionic detergent, were added 
to the conductimetry cell to determine the optimal amount of BP348pRMBl lysate and 
NCTC10739^ lysate to add as the source of AC activity in the assay. Three of the non-ionic 
detergents, Triton X-100, Brij-58 and NP-40, appeared to provide the best lysis of B. 
pertussis cells accordmg to the tangent values of the AC activity progress cui'ves. The 
tangent values of each progress curve for these three detergents did not differ greatly. 
However, from the comparison of the activity of BP348pRMBl and NCTC10739^ lysates, 
Triton X l^OO was foimd to provide optimal lysis of B. pertussis cells. As expected, strain 
BP348pRMBl, the recombinant overexpressor strain, showed greater AC activity than the 
type strain NCTC10739'^.
By adding different numbers of 5. pertussis lysed by Triton X-100, the detection limit of AC 
enzymic activity fi'om the AC overexpresser (BP348pRMBl) was equivalent to c. 10^  cfu in 
2 ml m the conductimetiy cell and the detection limit of AC activity fi'om the type strain 
(NCTCI0739^) was c. 10^  cfu in 2 ml in the conductimetry cell. The protocol was optimised 
and is described as follows: B. pertussis cells fi:om an overnight lawn plate on BG agar were 
suspended in saline to an ODeoonm 0.46 (approximately 2 x 10^  cfu ml“^ ). Suspensions were 
centrifuged for 10 min at 6,600 x g  (Biofuge pico, Heraeus). Pellets were resuspended in 
300 pi of 10% Triton X-100 and suspensions were allowed to mix for 30 min at 4^C. The 
mixed suspensions were used immediately for the conductimetry assays. This method of 
lysing B. pertussis cells with Triton-XlOO developed in tliis investigation was not considered
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Table 3.7.I.I. Effect of non-ionic detergents on AC activity of& pertussis cell suspensions
Nonionic
Detergent
Strain Final
concentration of 
lysis agent in cell
No. of bacterial 
cells in
conductimetry
cell
Tangent
Triton X-100 BP348pRMBl 0.05% 3,3x10' 4
1.5% IxlO" 40
NCTC10739'* 0.5% 3.3x10“ 5
1.5% 1x10" 13
Brij 58 BP348pRMBl 0.05% 3.3x10" 1.3
1.5% 1x10" 35
NCTC10739‘ 0.5% 3.3x10* 4
1.5% 1x10" 9
Brij 35 BP348pRMBl 0.05% 3.3xl0" 1.5
1.5% 1x10" 16
NCTC10739' 0.5% NT NT
1.5% NT NT
Triton X-114 BP348pRMBl 0.05% 3.3x10' 3
1.5% 1x10" 18
NCTC10739' 0.5% 3.3x10“ 5
1.5% 1x10" 11
NP40 BP348pRMBl 0.05% 3.3xlO" 2
1.5% 1x10" 38
NCTC 10739' 0.5% 3.3x10* 0
1.5% 1x10" 18
Tween-20 BP348pRMBl 0.05% 3.3x10" 0
1.5% 1x10" 8
NCTC10739'' 0.5% NT NT
1.5% NT NT
Tween-80 BP348pRMBl 0.05% 3.3x10" 0
1.5% 1x10" 8
NCTC10739‘ 0.5% NT NT
1.5% NT NT
NT = not tested, this is due to a low tangent value for AC activity of BP348pRMBl, the 
AC over-expresser strain, as a result of inefficient lysis of the B. pertussis cells. Therefore 
this detergent was not tested for its ability to lyse B. pertussis strain NCTC10739^.
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sensitive enough for diagnostic use directly from clinical specimens due to the large number 
of bacterial cells required for detection of AC enzymic activity.
Using the optimised lysis method, lysed cells of B. pertussis BP338 strain grown in two 
different ways, on BG agar and in SS liquid medium, were compared as sources of AC 
activity to be detected by the conductimetry assay. This would determine whether there was 
an optimal method of growing the bacteria to be used as a source of AC activity. B. 
pertussis BP338 was grown either on BG agar for 72 h at 37^C or inoculated into 5 ml SS 
hquid medium (Appendix 1.2) and grown for 72 h at 37®C with shaking at 150-200 rpm. 
After incubation, lawn plates of B. pertussis cells were prepared by restreaking from BG 
agar and incubated overnight. Alternatively, a volume of 1.25 ml of culture grown in SS was 
used to inoculate 5 ml of fresh SS liquid medium and incubated overnight at 37°C with 
shaking at 150-200 rpm. Bacteria gi'own on the lawn plates were suspended to 2 x 10^  cfu 
mf* in saline and lysed with Triton X-100 as described on the previous paragraph. Bacteria 
from the overnight SS liquid medium were centrifuged and suspended to 2 x 10^  cfu mf^ in 
saline and lysed as described previously with Triton X-100. A volume of 300pl of lysed cells 
was analysed for AC activity using the conductimetry assay. Cells that were grown on BG 
agar were found to have greater AC activity than cells grown in SS liquid medium, tangents 
of progress curves were 55 and 3 respectively. An explanation for this large difference in AC 
activity is difficult to determine, but may relate to CyaA accumulating in cells grown on BG 
lawn plates and the possibility that in SS liquid medium, a significant proportion of CyaA is 
secreted and lost.
3.7.2 Requirement for ATP, CaM and PPiase in R. pertussis lysate AC assays 
B, pertussis strain BP338 lysates were used and reactions that did not contain one of the 
reagents, ATP, CaM or PPiase, were compared. This would determine if the enzymic 
activity detected by the assay was CyaA activity or background enzymic reactions from the 
B. pertussis cell lysate. The strain BP338 is a derivative of Tohama-I and is a widely used 
laboratory strain. BP338 was favoured in place of the B. pertussis type strain NCTC10739^, 
as it is likely to be more representative of B, pertussis isolates. BP338 cells from an 
overnight lawn plate grown on BG agar were suspended in saline to a suspension of 2 x 10^  
cfii ml‘‘ and the cells were lysed with the nonionic detergent Triton X-100. A volume of 300
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jil of cell lysate was used immediately as a source of AC activity. The reaction containing 
CaM and ATP, but no PPiase, still showed a progress curve, although the tangent of the 
reaction was 15 compared to a tangent of 25 for the positive control in this experiment, 
which contained ATP, CaM and PPiase (Fig. 3.7.2.1). This imphed that the BP338 cell 
lysate contained PPiase activity. With the reaction that contained CaM and PPiase, but no 
ATP, the progress curves remained at the baseline, i.e. there was no increase in conductivity 
(Fig. 3.7.2,1). Reactions that contained ATP, PPiase and no CaM had a much slower rate of 
reaction, the tangent of which was 5 compaied to a tangent of 25 for the positive control 
reaction that contained all reagents (Fig. 3.7.2.1). This implied that BP338 cell lysate also 
had some CaM-like stimulating activity because the tangent was greater than that obtained 
with rCyaA in the absence of CaM (Fig. 3.6.4.2).
In another experiment using a lysate of B. pertussis strain BP347 lysate, reactions that did 
not contain one of the reagents, ATP, CaM or PPiase, were compared. The B. pertussis 
strain BP347 is a mutant strain that is known not to express vhulence-activated genes 
including CyaA. This strain was included in assays as a negative control for the detection of 
AC activity. BP347 cells from an overnight lawn plate grown on BG agar were suspended in 
saline to a suspension of 2 x 10^  cfu ml"’ and the cells were lysed using the nonionic 
detergent Triton X-100. A volume of 300 pi of cell lysate was used immediately. The 
reaction that contained BP347 lysate with ATP, PPiase and CaM had a progress curve that 
was slightly raised above the baseline, tangent = 1 (Fig. 3.7.2.2). The BP347 reaction that 
did not contain CaM had a reaction rate marginally faster that the reaction containing no 
ATP, but noticeably lower that BP347 reaction with CaM, ATP and PPiase (Fig. 3.7.2.2). 
The reaction lacking PPiase had a rate similar to that of the complete reaction, again 
indicating that BP347 had endogenous PPiase activity. There was no slight raise above the 
baseline for the BP347 lysate reaction that did not contain ATP (Fig. 3.7.2.2).
The work indicated that, the conductimetric assay was suitable for specific measurement of 
AC activity as the activity detected in the BP338 lysate in the absence of ATP was 
negligible. However, a noticeable reaction occurred if CaM was excluded which might 
suggest that the assay was unsuitable for specifically measuring CaM-dependent CyaA. AC 
activity m the BP347 lysate was negligible in the absence of CaM indicating that the assay is
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Figure 3.7.2.1: Enzymic (AC) activity of B. pertussis BP338 cell lysate without the 
addition of calmodulin (CaM), ATP or pyrophosphatase (PPiase). The first cell, and cells 7 
and 8 contained the blank control. Cell 2 contained the positive control. The third cell 
contained assay buffer with all reagents and BP338 cells lysed in Triton X-100. Cells 4, 5 
and 6 contained assay buffer with all but one of the regents, CaM, ATP and PPiase 
respectively.
Key:
1 —  Blank
2 —  rCyaA+ATP+CaM+PPiase
3 —  BP338+ATP+CaM+PPiase
4 —  BP338+ATP+PPiase
5 —  BP338+CaM+PPiase
6 —  BP338+ATP+CaM
7 —  Blank
8 —  Blank
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Figure 3.7.2.2: Enzymic (AC) activity using BP347 cell lysate without the addition of 
calmodulin (CaM), ATP or pyrophosphatase (PPiase). The first and last cells contained the 
blank control. Cells 2 and 3 contained that described for Fig. 3.7.2.1. Cell 4 contained 
assay buffer with all reagents and BP347 cells lysed in Triton X-100. Cells 5, 6 and 7 
contained everything except one reagent, CaM, ATP and PPiase respectively.
Key:
1 —  Blank
2 —  rCyaA+ATP+CaM+PPiase
3 — BP338+ATP+CaM+PPiase
4 —  BP347+ATP+CaM+PPiase
5 —  BP347+ATP+PPiase
6 —  BP347+CaM+PPiase
7 —  BP347+ATP+CaM
8 —  Blank
1 2 J
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suitable for detection of CyaA even if the cell lysate contains some CaM-like molecule.
3.7.3 Detection of B. pertussis CyaA from SS medium
B, pertussis is known to secrete a proportion of CyaA into the culture supernate (Hewlett et 
ah, 1976; Brownlie et al., 1985). Previous work, section 3.6.5, did not detect any AC 
activity in a whole-cell suspension prepared from BP348pRMBl grown on BG agar. 
However, it was important to determine if growth in liquid media released more CyaA 
protein. A loopfol of B. pertussis previously grown on BG agar was used to inoculate 5 ml 
of liquid (SS) medium, which was then incubated for approximately 72 h. This culture 
provided samples to be tested for AC activity using the conductimetry assay. Samples that 
were tested were 300 pi of the growth culture, 300 pi of pelleted cells resuspended in 1 ml 
of conductimetry buffer and 300 pi of SS medium alone. The progress curves are shown in 
Fig. 3.7,3.1. The positive control (final concentration in conductimetry cell was 10.8 ng 
protein ml'  ^ of rCyaA) exhibited AC activity of 510 lU mg'  ^ protein. There was little 
enzymic activity detectable with the cell pellet resuspended in buffer as the source of AC 
activity. The tangent of the reaction curve was equivalent to 1.3. Spiked samples (300 pi of 
the previously mentioned samples and 10.8 ng ml“^ of rCyaA) were also introduced for this 
assay to determine if there were any inhibitory effects from the samples. Only the spiked cell 
pellet resuspended in buffer showed AC activity equivalent to that of rCyaA alone (440 
mg) (Fig. 3.7.3.1) which suggested that inhibitory reagents were present in SS liquid 
medium.
Investigation of desalting the SS medium to remove inhibitory substances was carried out. 
FD-10 columns (Amersham) were used as a method to desalt the samples. B. pertussis 
NCTC10739^ was grown in SS medium for 72 h and the culture was desalted using the 
columns. Different volumes (5-200 pi) of the desalted culture were added to the 
conductimetry assay to determine AC activity of the samples. Activity was only observed 
with the addition of 200 pi of desalted sample but this was very low. In another assay, a 
loopful of B. pertussis NCTC10739^ grown on BG agar was used to inoculate CL liquid 
medium, which was then incubated for 72 h. The cultures were set up in duplicate, 
designated 1 and 2. The supernates from cultures grown in CL liquid medium were desalted 
using PD-10 columns and a volume of crude rCyaA was also placed through the column to
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Figure 3.7.3.1: Enzymic (AC) activities in different fractions of B. pertussis cultures after 
growth in SS Uquid medium. Cell 1 was the blank control. Cell 2 contained the positive 
control consisting of assay buffer with all reagents and recombinant adenylate cyclase toxin 
(rCyaA). Cells 3-8 contained the test samples, see key below for description.
Key;
1 —  Blank
2 —  Positive control
3 —  Cell pellet from SS resuspended in assay buffer
4 —  Cell pellet from SS resuspended in assay buffer spiked with rCyaA
5 ■— SS whole culture
6 —  SS whole culture spiked with rCyaA
7 —  SS medium, uninoculated
8 —  SS medium, uninoculated spiked with rCyaA
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determine whether AC activity was lost during the desalting process. The cells from the 
culture had already been pelleted for preparation of urea extracts. The positive controls in 
the assay contained final concentrations of 5 pg protein ml'^  of crude rCyaA alone and 5 pg 
protein ml'^  of crude rCyaA that had been through a PD-10 column. The supernates that had 
been desalted were tested alone and as spiked samples to ensure that no inhibitory 
substances remained. The progress curves of desalted supernates fi'om cultures 1 and 2 are 
shown on Fig. 3.7.3,2. The rCyaA that had been through the desalting process had a similar 
activity to the rCyaA that had not, therefore no AC activity was lost during the desalting 
process. The spiked samples also had an activity shmlai' to that of the positive control, 
therefore no inhibition was occurring with the desalted samples. No activity was observed 
with the culture supernates alone (Fig. 3.7.3.2),
3.7.4 AC activity during growth curve of B, pertussis
To aid in the optimisation of the conductimetry assay it was important to determine at which 
point during the B. pertussis growth curve maximum AC activity was obtained as this 
information would increase the sensitivity of detection if the cells were to be grown fi:om 
clinical specimens. For this assay, specimens of 1.6 ml of BP338 cells grown in 5 ml SS 
liquid medium was used to inoculate 250 ml of fi-esh SS liquid medium to attain a starting 
ODeoonm of 0.01. This culture was incubated for 73 h at 37®C, with shaking at 150-200 rpm. 
Throughout this time, OD^ oomn values were taken to determine the time points of early log 
phase, late log phase and late stationary phase. Cells were pelleted fi'om BP338 cultures at 
the three time points, early log phase (32 h), late log phase (56 h) and late stationary phase 
(73 h). Urea extracts of BP338 were prepared fi'om cells fi’om the tliree different growth 
phases. Preparation of urea extracts of B. pertussis cells was used here rather than B. 
pertussis cells lysed with Triton X-100 due to the inability to visualise CyaA by SDS-PAGE 
with the latter method. Samples produced a smear on gel and it was not possible to 
determine whether bands were present at 200 kDa or to compare the intensity of CyaA 
bands between samples to predict which crude sample would have greater AC activity in the 
conductimetry assay. The protein concentrations of the urea extracts by the Bradford’s assay 
were: early log phase urea extract, 157 pg ml'*; late log phase urea extract, 1791 pg ml"*; 
and the stationary phase urea extract, 462 pg ml*. Two protein concentrations of the BP338 
urea extracts were tested for AC enzymic activity, 100 pg ml* and 10 pg ml"’; 300 pi of each
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Figure 3.7.3.2: Enzymic (AC) activities in the desalted culture supernates from 72 h B, 
pertussis cultures grown in CL medium. The first cell contained assay buffer alone. Cell 2 
contained assay buffer and all reagents with rCyaA as positive control. Cell 3 contained the 
positive control that has been placed through the PDIO column. Cells 5 and 7 contained 
desalted supernates alone and cells 4 and 6 contain spiked desalted supernates.
Key:
1 —  Blank
2 —  Positive control
3 —  Positive control through PDIO
4 — desalted supernate spiked no. 1
5 —  desalted supernate no. 1
6 —  desalted supernate spiked no. 2
7 —  desalted supernate no. 2
8 —  Blank
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sample was added to the conductimetry cell. A positive control containing a final 
concentration of 54 ng protein ml * of rCyaA was included. Urea inhibition of AC activity 
detection was reported previously in section 3,6.5 where it was shown that the final 
maximum concentration of urea in the assay was 0.25 M before inhibition was demonstrated. 
Therefore, as the urea extracts were stored in a solution containing 4 M urea, it was 
important to include a sample containing a final concentration of 54 ng protein ml'* of rCyaA 
with the sample maximum concentration of urea as in those urea extracts. The maximum 
concentration of urea that was determined to be present in the samples at 100 pg protein ml'
* of the early exponential phase uiea extracts was 2.5 M urea. The urea concentration of 
urea extracts of cells fi'om late exponential and stationary phases were 0.2 M and 1,1 M, 
respectively. The rCyaA with 2.5 M urea control had a reduction in AC activity compared to 
that of rCyaA alone (Fig. 3.7.4.1). Therefore, urea inhibition of AC activity was occurring. 
The activity of the urea extract from the late exponential phase could be calculated due to 
the lower urea concentration and was determined to be 0.97 lU mg'* of protein. Activities of 
urea extracts fi-om early exponential and late exponential phases were analysed at a lower 
protein concentration to reduce the urea concentration.
Due to the possibility of urea inhibition, urea extracts at 10 pg protein ml * were assayed as 
there would be no inhibitory effect at this dilution. The urea concentrations of early 
exponential, late exponential and stationary phases were 0.25 M, 0.02 M and 0.08 M, 
respectively. A positive control of rCyaA alone (final concentration 54 ng protein ml'*) and 
rCyaA with the maximum amount of urea (final concentration 54 ng protein ml * and 0.25 M 
urea) were included (Fig. 3.7.4.2). Comparison of the AC activities of rCyaA alone with 
rCyaA and 0.25 M urea showed that there was no inhibitory effect of urea in this assay. 
Analysis of AC activities in urea extracts at 10 pg protein ml * over the growth curve of 
BP338, showed that activity was only detected fi-oni the stationary phase (ca. 73 h growth). 
The activity of BP338 urea extract from the stationary phase was 1.5 lU mg'* protein. 
Therefore urea extracts of B. pertussis cells fiom the stationary phase should be used for 
comparison of AC activities and cytotoxic activities between B. pertussis strains (see section 
3.9).
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Figure 3.7.4.1; Enzymic (AC) activity of urea extracts of B. pertussis BP338 (100 pg 
protein ml’*) from early exponential, late exponential and stationary phase. Cells 1 and 2 
contained negative (assay buffer only) and positive (rCyaA with assay buffer and aU 
reagents) controls respectively. Cells 3-6 contained urea extracts from the different growth 
phases of B. pertussis to test for AC activity.
Key:
1 —  Blank
2 —  Positive control
3 Positive control (with urea)
4 —  Early exponential phase BP338
5 —  Late exponential phase BP338
6 —  Stationary phase BP338
HB
\ÜJ
i
1 2 3
155
Figure 3.7.4.2. Enzymic (AC) activity of urea extracts of B. pertussis BP338 (10 jig protein 
mf^) from early exponential, late exponential and stationary phase. Cells 1 and 2 contained 
negative (assay buffer only) and positive (rCyaA \vith assay buffer and all reagents) 
controls respectively. Cells 3-6 contained urea extracts from the different growth phases of 
B. pertussis to test for AC activity.
Key:
1 Blank
2 —  Positive control
3 Positive control (with urea)
4 —  Early exponential phase BP338
5 —  Late exponential phase BP338
6 —  Stationary phase BP338
a1 2 3 4 5 6
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3.7.5 Detection of AC activity in other Bordetella species
Lysates of other Bordetella spp. namely B. parapertussis^ B, bronchiseptica^ B. avium, B. 
hinzii, B. holmesii and B, trematum were prepared using the method described in section 
3.7.1, developed for lysing B. pertussis cells with Triton X-100. The B. pertussis strains 
BP338 and BP347 were included in the majority of assays as positive and negative controls, 
respectively. AC activity was detected only in B. parapertussis (NCTC5952, NCTC10853) 
and B. bronchiseptica (BBC 17). It was noted that AC activity was not detected in B. 
bronchiseptica strains NCTC452 and NCTC458. The two B. parapertussis strains tested 
had different AC activities, the progress curve of NCTC5952 had a tangent of 31 and 
NCTC10853 had a tangent of 58 (Fig. 3.7.5.1), B. parapertussis NCTC10853 was also 
observed to be much more haemolytic on BG sandwich plates (indicative of the production 
of CyaA). In this assay it should be noted that the negative control B. pertussis strain, 
BP347, does appear to have activity and this may be due to the presence of contaminating 
AC activity or due to the fact that it has been demonstrated that the conductimetry can be 
to, some extent, non-specific.
Conductimetry assays determining the AC activity of B. bronchiseptica BBC 17 had shown 
that there was a difference in AC activities of strains grown from different glycerol stocks, 
designated 1 and 2. The AC activity of B. bronchiseptica BBC 17 (from glycerol stock 2) 
strain used for intranasal infection of mice and the passaged strain recovered from lung 
culture at seven days after challenge (M. Lynch, personal communication) were also 
investigated (Fig. 3.7.5.2), The tangent of the AC enzymic activity reaction curve of the 
original strain was 12, but, after isolation from the mouse lungs, the tangent of AC enzymic 
activity reaction curve was 58, about 21% increase in specific activity (Fig. 3.7.5.2). It was 
also noted that the strain that had been passaged in the mouse model was noticeably much 
more haemolytic on BG sandwich plates. This result emphasises that Bordetella expressing 
AC enzymic activity must express it most when in the appropriate host or may be selected 
for by host passage, which is reflected in the greater activity found in passaged isolate. 
Expression must decrease when the strain is propagated in a laboratory envnonment. AC 
activity was not detected in any of the strains of the following species B. avium, B. hinzii, B. 
trematum and B. holmseii. These species were also noted to not be haemolytic on BG 
sandwich plates.
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Figure 3.7.5.1: Comparison of enzymic (AC) activities of B. parapertussis (NCTC5952 
and NCTC10853) lysates with that of B. pertussis BP338. The blank control was in cell 1. 
B. pertussis BP338 was used as a positive control in cell 2, Cell 3 contained BP347 as a 
negative control. Cells 4 and 5 contained NCTC5952 and NCTC10853 respectively.
Key:
1 — Blank
2 —  BP338
3 —  BP347
4 —  NCTC5952
5 —  NCTC10853
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Figure 3.7.5.2; Comparison of enzymic (AC) activities of B. bronchiseptica isolates 
(BBC 17 stocks (1) and (2)) with the activity of BBC 17 from glycerol stock 2 passaged 
through the mouse. Cell 1 was the blank control. Cell 2 contained BBC 17 from glycerol 
stock 2 (BBC 17(2)) from mouse model. Cells 3-8 contained BBC17 from two different 
glycerol stocks (1 and 2).
Key:
1 — Blank
2 —  BBC 17 passaged
3 — BBC17(1)
4 — BBC17(1)
5 —  BBC17 (1)
6 —  BBC17(2)
7 — BBC17(2)
8 —  BBC17 (2)
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3.8 PHENOTYPIC ANALYSIS OF PICU475 AND 99K45
3.8.1 Comparison of AC activities of cell lysates 99K45, PICU475 and BP338
B. pertussis strains 99K45 and PICU475 from 1999 were the only two isolates from a panel 
of 46 to contain a 6 bp insertion between the cyaA and cyaC genes (see section 3.3). The 
presence of this 6 bp insertion was determined by sequencing and LightCycler melting curve 
analysis. It was desirable to determine if this insertion had any effect on expression of AC 
enzymic activity. The AC enzymic activity was compared between four B. pertussis strains: 
BP347, BP338, PICU475 and 99K45, Lysates of the fom* strains were prepared using the 
non-ionic detergent Triton X-100 from suspensions of 2 x 10  ^ cfu ml"^  (see section 3.7.1) 
and these were immediately added to the conductimetry assay to determine differences in 
AC activity. The positive control rCyaA in the conductimetry cells was at a final 
concentration of 43 ng protein ml’*. Strain 99K45 had increased CyaA activity compared to 
BP338 (tangents 48 and 23 respectively), and in another assay PICU475 had CyaA activity 
similar to that of BP338 (tangents 21 and 19 respectively) (Fig. 3.8.1.1). The tangent of the 
positive control, rCyaA, was slightly lower than that of previous assays, whereas the tangent 
of the BP338 preparation was similar to that obtained previously. Strain 99K45 did not 
appear more haemolytic on BG agar compared to BP338 and P1CU475. Lysates of B. 
pertussis cell suspensions using the non-ionic detergent Triton X-100 could not be analysed 
by SDS-PAGE to visualise the presence and intensity of a CyaA band. It was important to 
visualise and quantify CyaA from these B. pertussis strains, therefore urea extracts of 
BP338, 99K45 and PICU475 were prepared.
3.8.2 Comparison of AC activities of urea extracts of 99K45 and BP338
Previous analysis of the B. pertussis growth curve had determined that the greatest CyaA 
expression occurred from cells taken from stationary phase. Therefore B. pertussis strains 
BP338 and 99K45 were grown in 250 ml of SS liquid medium for 73 h at 37°C with shaking 
at 150-200 rpm. It was observed that the PICU475 strain did not grow as well in liquid (SS) 
medium as BP338 and 99K45, therefore urea extracts (see section 2.13.3) were prepared 
only for the latter two B. pertussis strains. The AC activity of the urea extracts were 
determined at 10 pg protein ml’* by the conductimetry assay. Activity of the samples was 
low, their activities were about 1.5 lU mg’* protein, which was similar to that previously 
found for the BP338 stationary phase urea extract from the growth cuiwe analysis. This
160
Figure 3.8.1.1: Enzymic (AC) activities of lysates of B. pertussis strains BP338, BP347, 
99K45 and PICU475. Cell 1 was the assay blank control consisting of assay buffer and 
reagents only. The positive control (rCyaA) was in cell 2. Cell 3 contained BP338 lysate 
used as the B. pertussis AC activity positive control and cell 4 contained BP347 lysate as 
the negative control for B. pertussis AC activity. Cells 5-8 contained the test samples, see 
key below for description.
Key:
1 —  Blank
2 —  Positive control
3 —  BP338 lysate
4 —  BP347 lysate
5 —  99K45 lysate
6 —  99K45 lysate duplicate
7 —  PICU475 lysate
8 —  PICU475 lysate duplicate
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result does not agree with that of the previous assay with B. pertussis cells freshly grown on 
BG agar and lysed with Triton X-100, where 99K45 had greater AC activity. However, due 
to the low activity of these extracts it is probably not possible to accurately determine any 
differences in AC activity.
3.8.3 SDS-PAGE analysis of urea extracts
The AC activity of the urea extracts was low and it was required to make the B. pertussis 
urea extracts as active as possible and this was done by concentrating the samples. Urea 
extracts were concentrated using AMICOM® columns with 30,000 molecular weight cut­
off. From the protein assay it was determined that the unconcentrated urea extract of 99K45 
was 389 pg ml'* and this was concentrated to 1945 pg ml'*. The unconcentrated sample of 
BP338 was 719 pg ml * and that of the concentrated sample was 2170 pg ml *. SDS-PAGE 
analysis was used to visualise the presence and intensity of CyaA in unconcentrated and 
concentrated urea extracts of BP338 and 99K45. A volume of 10 pi of each urea extract 
was used and the intensity of bands at c. 200 kDa, indicating the presence of CyaA, were 
compared (Fig. 3.8.3.1). The concentrated urea extracts of BP338 and 99K45 had a greater 
band intensity of CyaA on the gel and these were used in the following cytotoxicity assay. 
These concentrated samples were not analysed for AC activity with the conductimetiy assay 
due to the small volume available for the cytotoxicity assay.
3.8.4 Comparison of cytotoxic activities of 99K45 and BP338
Investigation of the potential effect of the 6 bp insertion on expression of AC or AC activity 
was inconclusive, as no clear differences in AC activity between BP338 and 99K45 were 
detected. As tins insertion Is situated very close to the cyaC gene (according to the GenBank 
sequences of cyaA and cyaC) it was of interest to determine if tliis would have any effect on 
the cytotoxic activity of CyaA by virtue of limitation of expression of cyaC whose product 
CyaC is required to activate pro-CyaA. The urea extracts of BP338 and 99K45 were 
investigated for differences in their cytotoxic ability by determining their effect on the killing 
of the mouse macrophage-Hke cell-line J774.2 by the MTT assay. The urea extracts of 
BP338 and 99K45 exhibited cell killing only at high protein concentrations, with that of 
99K45 being more active than that of BP338 (Fig. 3.8.4.1). The 50% cell killing by the 
99K45 extract was achieved at the concentration o f609 pg mT* whereas that of BP338 was
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Figure 3.8.3.1: SDS-PAGE analysis of BP338 and 99K45 urea extracts unconcentrated and 
concentrated using AMICON® columns. Each lane contained 10 pi of concentrated or 
unconcentrated sample.
Lane
M SeeBlue® Plus2 Pre-Stained Standard (Invitrogen)
1 BP338 unconcentrated
2 BP338 concentrated
3 99K45 unconcentrated
4 99K45 concentrated
M
250kDa
98kDa
64kDa
50kDa
36kDa
16kDa
6kDa
163
Figure 3.8.4.1. Cytotoxicity assay of urea extracts of B. pertussis strains 99K45 and 
BP338 on J774.2 mouse macrophage cells. Each point on the opposite graph represents 
the mean of the two values.
Key:
BP338
99K45
1 0 0 -
80 -
60 -
40 -
20 -
700 800400 500 600300200100
Protein concentration (ug ml-1)
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not able to kiU 50% of cells in this assay (Fig. 3.8.4.1).
3.9 STUDY OF cyaA EXPRESSION WITH REPORTER GENES lux AND gfp
For investigation of the diagnostic potential of the conductimetry assay, it was important to 
determine when optimal expression of cyaA occurred during the growth of B. pertussis. 
Reporters such as lux (codes for luciferase and luciferin, winch are required for the light- 
emitting reaction) and green fluorescent protein {gfp) genes provide the ability to study gene 
expression. The lux reporter, with the use of a luminometer, allows this to be done in a real­
time fashion and quantitatively. The gfp reporter allows gene expression to be followed by 
fluorescence microscopy or fluorimetry. This system would supplement the previous work 
using selected growth curve time points for investigation of cyaA expression, by determining 
the AC promoter activity in more rapid and informative ways. The use of lux and gfp 
reporters would also facilitate studies on the expression of this essential virulence factor 
when B. pertussis was grown under a variety of different growth conditions such as in the 
presence of modulating factors, or in the intracellular' envir onment.
3.9,1 Amplification oîB. pertussis cyaA
The region of DNA that was amplified for use in cloning studies included the promoter 
region of cyaA. Primers CyaAl and CyaA6 amplified the region including nucleotides 287- 
1165 (Y00545) whereas primers CyaAl and CyaA8 targeted and amplified nucleotides 287- 
1396 (Y00545) (Fig. 3.9.1.1). Boiled lysates of B. pertussis strain BF338 were used as the 
source of DNA template. Visualisation of the resulting PCR products by gel electrophoresis 
ensured that the target region had been successfirlly amplified and were of the expected size 
(see Fig. 3.9.1.2). PCR products of the expected sizes (878 bp and 1109 bp respectively) 
were obtained with these primer pairs. Negative controls containing water in place of 
template DNA were included in the PCR reaction to ensure that no contammatmg B. 
pertussis DNA was present (Fig. 3.9.1.2).
From gel lanes 1 and 3 contairimg the negative controls, it can be seen that no product is 
present thus confirming that the PCR has worked successfixUy. The sizes obtained were the 
same as those predicted fi-om GenBank cyaA sequence (Y00545), The PCR products were 
purified and used for digestion and ligation reactions.
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Figure 3.9.1.1: Schematic diagram of cyaA (Y00545) amplified by primers CyaAl and 
CyaA6/8, the overlapping region of cyaC (M5726) is shown. Numbering relates to that of 
the GenBank sequences. The 6 bp insertion and CDS start sites are indicated. The black 
arrows indicate the direction of gene transcription. The BvgA-P binding sites and the -35 
and -10 regulatory regions are indicated on cyaA. See Fig. 3.5.1.1 for nucleotide positions.
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Figure 3.9.1.2. Electrophoretic analysis on 1% (w/v) agarose gel of adenylate cyclase toxin 
(cyaA) promoter amplified with primers CyaAl and CyaA6 or CyaAl and CyaA8.
Lanes Predicted product size
M 1 kb ladder (Invitrogen) n/a
1 negative control for CyaAl/CyaA8 PCR n/a
2 CyaA 1 /CyaAS PCR product 1109 bp
3 negative control for CyaAl/CyaA6 PCR n/a
4 CyaA 1/CyaA6 PCR product 878 bp
M 1 2 3 4 M
1018 bp
506,517 bp
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3.9.2 Cloning of B. pertussis cyaA into constructs
CyaAl“6 and cyaAl-8 PCR products were purified, then ligated into the pGEM®-T Easy 
vector (Promega). E. coU XL-2 cells were transformed with 1 pi of the ligation reaction 
product and grown on SGAL^m/lb Agar Blend media containing 50 pg mf^ of ampicillin 
for blue and white colony screening to determine which cells had been successfully 
transformed with the construct. Single wliite colonies were selected and subcultured on LB 
agar containing 150 pg ml“^ of ampicillin. The resulting colonies were grown in LB broth 
with 150 pg ml'* of ampicillin for preparation of glycerol stocks and plasmid preparation.
For fixrther cloning into the promoterless gfp vector, pPROBE-AT', the orientation of the 
cyaAl-6/1-8 insert in pGEM®-T Easy had to be determined. The enzyme Pstl was chosen as 
that would be predicted to produce a fragment of the size corresponding to cyaA 1-6 and 
cyaA 1-8 in one orientation, but not in the other as a Pstl site was included in primer CyaAl 
(Fig. 3.9.2.1). If no fragment was present fi'om digestion with Pstl then the cyaAl-6/1-8 
insert was not in the desired orientation. The restriction enzymes that were chosen for 
cloning into pPROBE-AT' (Fig. 3.9.2.2) were the enzymes KpnllSacl. The forward primer 
CyaAl contains a Kpnl site and the pGEM®-T Easy contains a Sad  site, and both of these 
sites are present in the multi-cloning site of pPROBE-AT'.
The cyaAl-6 and cyaAl-8 inserts were removed fi'om pGEM®-T Easy vector with 
restriction enzymes Kpnl and Sad  in a double digestion reaction. Electrophoretic separation 
of the digested fragment and vector was visualised on 1% (w/v) agarose gels. The insert was 
extracted and purified fi'om the agarose gel for use in fixrther cloning assays with the vector 
pPROBE-AT' (Fig. 3.9.2.2). The pPROBE-AT' was digested with the enzymes Kpnl and 
Sad  and this was visualised using gel electrophoresis to ensure that successful digestion had 
occurred. The digested vector was purified before ligation with the digested insert such that 
the cyaAl-6 or the cyaAl-8 fragment was inserted upstream of the gfp gene in the correct 
orientation. A volume of 1 pi of the ligation reaction was used to transform E. coli XL-2 
and SMIO X pir strains by electroporation. There were many E. coli colonies resulting from 
transformation with the ligation reaction after electroporation. Representative colonies were 
subcultured and used for plasmid preparation.
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Figure 3.9.2.1: Desired orientation of cyaAl-6/cyaAl-8 insert as anti-sense to lacZ in 
pGEM®-T Easy vector (Promega), drawn using Redasoft^^ Visual Cloning 2000.
T7 prom oter
f1 ori CyaAl (5') 
Kpn\, Pst\
arrpicHlin
pŒM-T Easy Vector
3015 bp
CyaA6/8 (3’)
PstVSacX 
SP6 promoter
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Figure 3.9.2.2. Promoterless gfp construct, pPROBEAT', showing multi-cloning site (mes) 
with restriction sites used for cloning of J^wI/SiarcI-digested cyaA promoter product, drawn 
using Redasofl™ Visual Cloning 2000.
; mob
arrpidlin
pPROBEAT
6810 b p
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cyaAl-6/1-8
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170
Correct orientation of the cyaA 1-6 or cyaAl-8 fragment was not required for cloning with 
the vector pSB395 as this vector only contains one restriction site, EcoRI (Fig. 3.9.2.3). The 
cyaAl-6 and cyaAl-8 inserts were removed from pGEM®-T Easy vector with restriction 
enzyme EcoKL. Electrophoretic analysis of the digestion reaction was visualised on 1% 
(w/v) agarose gels. The insert was extracted and purified from the agarose gel for use in 
further cloning assays with the Zz^-containing plasmid pSB395. The vector was digested and 
purified before further cloning by ligation of the digested pSB395 with the digested insert 
such that the cyaAl-6 or cyaAl-8 fr agment was inserted upstream of the promoterless lux 
operon. A volume of 1 pi of the ligation reaction was used to transform E. coli XL-1 MRF' 
and SMIO X pir strains by electroporation. Only two colonies were present after 
transformation of pSB395 containing the cyaAl-6 insert by electroporation. These were 
subcultured and used for plasmid preparation.
3.9.3 Confirmation of reporter constructs in E, coli
Purified plasmid preparations of putative cyaAl-6 and cyaAl-8 constructs in E, coli were 
checked by restriction analysis and PCR. Restriction analysis of pPROBE-AT' plasmid 
preparations from E. coli XL-2 and SMIO % pir transformants was carried out to ensure that 
the construct was present with its insert. The ligation was successful only with the cyaAl-6 
insert with pPROBE-AT' as determined by restriction analysis of the plasmid preparation. 
The plasmid preparations from cells suspected to contain pPROBE-AT' with cyaAl-8 insert 
contained only the vector, and no insert was visualised. Fig. 3.9.2.1 shows digestion of 
pPROBE-AT' constructs containing cyaA 1-6 fragment from plasmid preparation of E. coli 
XL-2 cells. Lanes 1-12 contain digestion reactions of individual colonies resulting from 
transformation with pPROBE-AT' containing the cyaA 1-6 ligation reaction. After double 
digestion with KpnVSacl, the insert was seen as a band of 878 bp for cyaAl-6 (Fig. 3.9.3.1). 
The plasmid constructs could be used for transfer to B. pertussis to study the expression of 
cyaA under different growth conditions.
Ligation reactions of the cyaA 1-6 insert and pSB395 were successful whereas ligation 
reactions with the cyaAl-8 insert were not; tliat is, colonies were present only after 
transformation of E. coli cells with the cyaA 1-6 and pSB395 ligation reaction. Therefore, 
further studies with the lux plasmid were carried out using cyaAl-6. The nature of the lux
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Figure 3.9.2.3. Promoterless lux construct, pSB395, with EcoRi restriction site used for 
cloning of Æ’coRI-digested cyaA promoter product, drawn using Redasoft™ Visual Cloning 
2000.
luxCDABE operon
pSB395
16300 bp
tetracycline
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Figure 3.9.3.1: Electrophoretic analysis on 1% (w/v) agarose gel of digested plasmid 
preparations from E. coli XL-2 blue transformed cells containing pPROBE-AT' with 
cyaA 1-6 insert. Purified plasmid (pPROBE-AT') preparations from individual colonies 
were digested with Kpnl and Sad  and then analysed for the presence of cyaA 1-6 insert. 
The expected size is c. 878 bp.
Lanes
M 1 kb ladder (Invitrogen)
1-12 Plasmid preparations double-digested with Kpnl and Sad
M I 2 3 4 5  6 7 8 9  10 II 12
1636 bp
1018 bp
506, 
517 bp
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plasmid, pSB395, with the cyaAl-6 insert in E. coli XL-1 and E. coli SMIO X pir cells was 
also checked by PCR to ensure that the cyaA promoter was in the correct orientation to 
allow expression of the promoterless lux operon. To overcome the lack of orientation of the 
inserts in pSB395, a reverse primer was designed to target the ImC  gene (the first gene of 
the lux operon) and the forward CyaAl primer from the previous PCR amplification of this 
insert was used. Boiled lysates of the resulting E. coli colonies from transformation by 
electroporation were used as DNA templates. A negative control containing water in place 
of DNA template was included to ensure that no contaminating DNA was present.
PCR reactions were analysed by agarose gel electrophoresis (Fig. 3.9.3.2). If a PCR product 
was present, it ensured that transformation had been successfiil and that the cyaAl-6 insert 
was present in the correct orientation for expression of the lux operon. PCR products of the 
correct size, 878 bp, were found for two of the transfoi*med E. coli SMIO % pir colonies 
resulting from electroporation with the ligation reaction (gel lanes 2 and 3, Fig. 3.9.3.2). The 
plasmid pSB395 containing the cyaAl-6 insert in the correct orientation could be used for 
transfer to B. pertussis to study the expression of cyaA in different growth conditions. The 
transformed E. coli SMIO X pfr containing pSB395 with cyaA 1-6 insert was checked for 
luminescence using the luminometer Lucy-1. No light output was detected but this was 
expected due to cyaA expression occurring only under the control of the bvg locus, which is 
not present m E. coli.
3.9.4 Plate mating of E. coli and B, pertussis
The pSB395 plasmid containing the cya A1-6 insert was introduced into B. pertussis BP338 
from E. coli SMIO X pir by conjugation. This method was also used as an attempt to 
introduce the gfp plasmid, pPROBE-AT' containing the cyaAl-6, from E. coli SMIO X pfr 
strain to B. pertussis BP338 but this was not successful. Therefore this method will be 
described for pSB395 with the cyaAl-6 insert. It was found through optimisation of the 
plate-mating method that the E. coli would easily outgrow B. pertussis and one way that this 
could be overcome was to increase the donor: recipient ratio and make the incubation time 
shorter. The protocol that was found to result in B. pertussis cells containing the plasmid 
pSB395 with the cyaAl-6 insert was a combination of two protocols methods, described by 
M. Lynch (personal communication) and Stibitz and Carbonetti (1994). The optimised
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Figure 3.9.3.2: PCR products of E. coli SMIO X pir cells containing the plasmid 
pSB395 with the cya A1-6 insert in the correct orientation. DNA from boiled lysates of 
E. coli cells were amplified with primers CyaAl and LUXCr. PCR products, pSB-16, 
were analysed on 1% (w/v) agarose gel and reactions that gave products of expected 
size were considered to contain the cyaAl-6 insert in the correct orientation to allow 
expression of the lux operon.
Lanes Predicted product size
M 1 kb ladder (Invitrogen) n/a
1 negative control n/a
2 pSB 1 -6 PCR product 878 bp
3 pSB 1-6 PCR product 878 bp
M 1
1636 bp 
1018 bp
506,517 bp
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method is described in section 2.15.4. Briefly, the method involved preparing a 
donor:recipient (1:10) mix of E. coli and B. pertussis cultures. This bacterial mix was 
incubated on BG agar for 7-8 hours. The bacteriophage, f&n04, was then added to this mix 
to lyse E. coli cells. After conjugation, cultures were plated on BG containing cephalexin 
and tetracycline, which counterselected against E. coli donor cells and selected for B. 
pertussis cariying the pSB395 construct, respectively. Only six colonies resulted from the 
conjugation and these colonies were selected and individually subcultured on BG agar with
12.5 pg ml^ of tetracycline. The resulting cultures were used for preparation of glycerol 
stocks and subcultured in SS liquid medium for plasmid preparation.
The six B. pertussis-Vke, colonies containing pSB395 with the cyaA 1-6 insert were grown in 
SS liquid medium and were Gram-stained to check if they were potential contaminants 
before plasmid preparation. Two colonies were clearly B. pertussis isolates from which 
plasmid preparations were made and PCR analysis was carried out. Boiled lysates of the B. 
pertussis colonies were used as DNA template and, if pSB395 with the cyaAl-6 insert was 
present, a PCR product would be obtained using CyaAl and LUXCr primers. A negative 
control containing water in place of DNA template was included to ensure no contaminating 
DNA was present. The positive control consisting of boiled lysate of E. coli containing 
pSB395 with cyaAl-6 insert, which was also included to ensure that the PCR analysis had 
not failed due to technical error. Electrophoretic analysis on 2% (w/v) agarose gels was used 
to visualise the PCR products. From Fig. 3.9.4.1 it can be seen that only one of the two 
plasmid preparations has a PCR product that could be visualised on the gel, however the 
size of the band is higher than expected. The E. coli preparation that was used in the plate- 
mating has a PCR product of much greater intensity than that of B. pertussis.
3.9.5 Detection of bioluminescence from pSB395 with cyaA promoter insert in B, 
pertussis
Once the presence of the cyaA promoter inserted upstream of the lux reporter in the correct 
orientation was confirmed, glycerol stocks were prepared and used to prepare cell 
suspensions for bioluminescence assay using the luminometer Lucyl. E. coli with the lux 
construct containing the cyaA promoter and BP338 wild-type were included as controls as 
they were not expected to be bio luminescent. BP338 wild-type and BP338 with the lux
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Figure 3,9.4.1. Electrophoretic analysis on 1% (w/v) agarose of purified plasmid from B. 
pertussis BP338 cells and E. coli SMIO % pir cells containing the construct pSBl-6. The 
PCR product pSBl-6 consists of vector pSB395 and adenylate cyclase toxin {cyaA) 
promoter region amplified with primers CyaAl and CyaA6. Purified plasmid from E. coli 
SMIO X pir containing the construct pSBl-6 PCR was also included as a positive control. 
The purified plasmid preparations of confirmed B. pertussis cells and E. coli cell were 
amplified using LUXCr and CyaAl primers to ensure that the vector and insert were 
present.
Lanes Predicted product size
M 1 kb ladder (Invitrogen) n/a
1 negative control n/a
2 B. pertussis pSBl-6 no.l 878 bp
3 B. pertussis pSBl-6 no.2 878 bp
4 E. coli pSBl-6 878 bp
M1636 bp ------^
1018 bp ------►
506, 517 bp ----- ^
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construct, pSBl-6, were both haemolytic on BG sandwich plates. It was important to check 
that B. pertussis strains containing the lux plasmid with cyaA 1-6 insert were as haemo lytic 
as the wild-type strain so as to ensure that the introduction of the plasmid had not affected 
the expression of cyaA from the chromosome and it still was in the Bvg^ phase. B. pertussis 
cells were grown in 5 ml of SS liquid medium before inoculation of fresh SS medium in the 
96-well plates. However, the B. pertussis strain containing pSB395 with the cyaA promoter 
cloned upstream of the /wx operon was not light-producing when assayed by the 
luminometer. Boiled extracts of B. pertussis pSBl-6 cells grown on BG agar for 72 h were 
re-checked using PCR with CyaAl and ItixC primers. No PCR products were visualised 
using gel electrophoresis. These findings will be discussed in Section 4.6.
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4.0 Discussion
4.1 SEQUENCE VARIATION AND CONSERVATION
4.1.1 Strain collection used for sequencing
The strain collection used for determining genotypic variation of B. pertussis isolates 
during the coui’se of this PhD study was carefully selected to be representative of the UK 
B. pertussis population ifom the pre-vaccination era to the present day, but with 
constraints due to strain availability. In the culture collection held at RSIL, isolates were 
not available for all years, or in some cases, few were available for a particular time 
period. The total number of B. pertussis isolates held at RSIL from 1920-2002 was 446. 
These isolates were from several collections held witliin the UK: CAMR, NCTC, 
Wellcome collection. University of Glasgow and University of Manchester. The strain 
collection is presumed to be representative of B. pertussis isolates from the UK, but 
there are only a few isolates available from Scotland, Wales and Northern Ireland. Only a 
limited number of isolates were available for a particularly interesting period, from 1974- 
1983 when there was a decline in vaccination uptake levels in the UK. Even though there 
was a limited number of isolates available from this period, unusual tcfA types and 
MLSTs were detected. No B. pertussis strains from 1986-1997 were available in this 
study therefore it is difficult to be precise about trends of genes such as ptxC  where the 
shift in allele type was not apparent until 1998. Thus it remains unknown at present when 
the appearance of the ptxC  allele, ptxCÇl), actually occurred. This problem relating to 
gaps in the strain collection and limited numbers of isolates appears to have been 
encountered in other, similar studies that have been carried out elsewhere. Lack of 
isolates in the Dutch strain collection were apparent for the time period 1952-1965 (van 
Loo et aL, 2002). The MLST scheme developed by van Loo et al. (2002) was applied to 
only 10 Italian strains, 13 Japanese strains, 27 Finnish strains and 18 US strains. This US 
strain panel also included a number of isolates (n=10) from the pre-vaccination era. 
Therefore it is difficult to compare the MLST trends of these countries with those in the 
UK and The Netherlands that have used larger strain collections. The foiu' vaccine strains 
and B. pertussis type strain NCTC10739^ were included in the present study as reference 
strains to help identify vaccine and non-vaccine allele types and to increase the 
probability of identifying polymorphic sites, as the type strain has been shovm to be an 
atypical strain (Musser et al., 1986; Gerlach et al., 2001).
179
4.1.2 Isolate numbers chosen for individual targets
Different numbers of B. pertussis isolates were used for investigation of gene variation in 
different virulence factors (see section 2.1,1 for further information). Isolates stored in 
RSIL had previously been sequenced for prnA and ptxA as well as being serotyped (Fry 
el aL, 2001), therefore isolates that showed differences in these properties were known. 
The gene cyaA was the original target for investigation of sequence variation amongst 
UK B. pertussis isolates. Forty-seven of these isolates were selected from the strain 
collection held at RSIL and ranged in date of isolation from 1920 -  2002. They included 
strains with known ptxA and prnA differences as well as distinct serotypes. The subset 
also contained the four vaccine strains and the type strain to be used as reference strains 
and to determine if a shift in sequence types from the vaccine strains had occurred. The 
subset panel was considered to be representative of UK isolates. Limited variation was 
suspected after sequencing regions of the cyaA gene in only 20 B. pertussis isolates due 
to the lack of variation between the atypical type strain and these other isolates. 
However, another 27 isolates were sequenced.
The only difference in the ompQ gene reported previously was between the type strain 
and Dutch R  pertussis isolates (van Loo et al., 2002). However, it was still important to 
determine whether this lack of variation also applied to UK isolates (discussed in section 
4.1.6). The same set of isolates used for investigating cyaA variation were chosen for 
single nucleotide polymorphism sequencing of ompQ with the Pyrosequencer as this 
technique is much more rapid for identifying single nucleotide polymorphisms than 
conventional sequencing. Only a limited numbers of isolates (n=14) were chosen for 
brkA and vag8 as previous sequencing studies had shown httle variation (van Loo et al., 
2002), but it was still important to determine if any variation was present amongst UK B. 
pertussis isolates (discussed in section 4,1.6). Using the subset of 47 isolates was 
considered to be too time-consuming when limited variation has aheady been 
demonstrated in other B. pertussis populations. Regions of hapC were initially amplified 
and sequenced for five isolates to ensure that primers had amplified the desired region 
and to determine any potential regions of polymorphism. The number of B. pertussis 
isolates investigated for bapC variation was increased to 14 and showed that only a 
single nucleotide difference existed between the type strain and the other strains 
including the vaccine strains. These limited numbers (n==14) used isolates chosen from 
the time period 1920 to 1999 as well as the vaecine strains, for the investigation of brkA,
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vag8 and bapC gene variation. It was intended that this subset would highlight any 
variation in sequence type throughout this time, if any change had occurred with time 
and if such change coincided with the introduction of whole-cell vaccination or the drop 
in vaccination rate and the resurgence of pertussis.
A larger number of UK B. pertussis isolates were selected for deterrnining aUehc 
frequencies of ptxC, tcfA and fim2 genes in the different time periods. These three gene 
targets had previously demonstrated variation (van Loo et al., 2002). Gene variation of 
ptxC and tcfA was investigated for 138 UK isolates in order that these allele types could 
be used in conjunction with the known variation of ptxA in the strains. The MLST 
scheme of van Loo et al. (2002) (based on these three genes) could then be applied to 
UK isolates and the data compared with the MLST trends found in B. pertussis 
populations in other countries. Eighty UK B. pertussis isolates, as well as the four 
vaccine strains and the type strain, were selected for investigation offim2 variation. Gene 
variation offim2 had been reported in Dutch isolates, but only from the pre-vaccination 
era (van Loo et al., 2002) and it was important to determine if this was the case for UK 
isolates. An initial investigation of 42 isolates with the four vaccine strains and the type 
strain had revealed that B. pertussis isolates from 1998 and 1999 contained the two 
known fim2 alleles, fm 2 {\)  and fim2fX). The number of UK isolates was expanded to 
include more isolates from 1998 and 1999 as the initial investigation showed this was 
when variation occurred and that only serotype 1,2 isolates from this time period 
appeared to have the fim2Q) allele.
Due to the restricted availabihty of strains from different time periods and different 
geographic locations of the UK (Appendix 6), this study may provide only a hmited 
insight into the epidemiology of B. pertussis in the UK from 1920-2002. For 
convenience, isolates were divided into seven time groups: 1920-1949, 1950-1959, 
1960-1969, 1970-1979, 1980-1989, 1990-1999 and 2002. In fact, the actual dates of 
isolation within these groups were 1920, 1941-1949, 1950-1956, 1963-1967, 1977- 
1979, 1982-1985, 1998-1999 and 2002. For discussion of each virulence-related gene 
and the MLST scheme actual dates of isolation will be used. The number of isolates used 
here would have to be increased to determine if there is a link between a particular 
sequence type and vaccination status or severity of pertussis. However, valuable 
information regarding strain variation has resulted from this investigation and highlights
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the fact that a shift in the genetic makeup of the UK B. pertussis population has 
occurred. Therefore it is important to continue surveillance of gene variation, particularly 
in relation to the introduction of the ACV that consists of limited antigenic components 
and the likelihood of its more widespread and increased use.
4.1.3 Pertussis toxin subunit S3 gene
A total of 138 UK B. pertussis isolates from the pre-vaccination (1920, 1941-1956), 
post-vaccination era (1963-1985) and recent (1998-1999, 2002) time periods were 
mvestigated for pixC  allelic variation. The two known ptxC alleles found in the UK and 
in other B. pertussis populations differed by a single silent nucleotide difference. There 
has been an apparent shift with time from ptxC{\) to ptxC(2); that is ptxC{\) was the 
only ptxC allele found in UK isolates from 1920-1985 and ptxC{2) became apparent from 
1998 onwards, 22 of 51 (43%) from 1998-1999, and was the predominant allele in 
2002, 33 of 34 (97%). Analysis of the published Tohama-I genome sequence 
(BX470248) was confirmed it contained the allele ptxC{l). The allele ptxC(l) was the 
only ptxC  allele present during the pre-vaccination era and this has been reported for 
other countries, The Netherlands and the US (van Loo et a l, 2002). The allele ptxC{2) 
was present in Dutch isolates between 1990 and 1999 (32 of 85 isolates, 38%) and in the 
US B. pertussis population (7 of 10, 70%) from the same time period (van Loo et aL,
2002). The Japanese isolates from 1990-1999 had both ptxC  alleles but the fiequency of 
ptxC(2), 2 of 13 isolates (15%), was lower than that of UK, US and Dutch B. pertussis 
populations. Finnish and Italian B. pertussis populations differed from the other countries 
in that, from 1990-1999, only ptxC{\) was found.
4.1.4 Tracheal colonisation factor gene
A total of 138 UK B. pertussis isolates fiom the pre-vaccination (1920, 1941-1956), 
post-vaccination era (1963-1985) and recent (1998-1999, 2002) time periods were 
investigated for tcfA allelic variation. The four vaccine strains and the type strain were 
also investigated. Of the five known tcfA alleles (van Loo et al., 2002), tcfA{\)-tcfA{5), 
four alleles tcfA(2)~tcfA(5) were found amongst UK B. pertussis isolates. A novel tcfA 
allele, designated tcfA{6), was foimd during this study. The allele tcfA{\) contains a 75 
bp segment not seen in the other alleles. There are single non-silent nucleotide 
differences between tcfA{2), tcfA(3i) and tcfA{A). The allele tcfA{5) contains an extra G 
nucleotide resulting in the premature translational termination which leads to expression
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of a truncated protein. The novel allele tcfA{6) found during this study contains a 15 bp 
deletion not present in the other alleles. All of these described differences occur within 
the sequence that encodes the N~terminal region of Tcf. The majority of UK isolates 
including the four vaccine strains and the reported Tohama-I genome sequence were 
tcfA{l). The type strain was tcfA{\) and tc/M(3)- tcfA{6) were foxmd in a small number of 
isolates. The predominant tcfA allele type, tcfA(2), found in this study has also been 
reported in isolates from The Netherlands, Finland, Italy, Japan and the USA and tcfA{2) 
was predominant in all countries except Italy (van Loo et aL, 2002). Of ten Italian B. 
pertussis isolates studied, six (60%) were tcfAQ) and four (40%) were tcfA(2) . The 
allele tcfA(3) was not found in the US or Japanese B. pertussis populations. In the three 
other countries, the allele tcfA{3) has been reported in isolates from the period 1990- 
1999 only. This allele is apparently also more predominant in The Netherlands than in the 
UK, in that 27 of 85 (31.8%) Dutch B. pertussis isolates from 1990-1999 were tcfA(3), 
compared to 2 of 51 (4%) UK B. pertussis isolates from 1998-1999. Eight of nine UK 
tcfAifL) isolates were from 1977-1983, and the other was from 1999. The allele tcfAiff) 
has not been reported in B. pertussis isolates from The Netherlands, Finland, Italy, Japan, 
or the USA, but has been seen in at least one isolate from Australia (AJ507643). The UK 
isolate from 1942 that was tcfA{5) was unusual as this allele has previously been reported 
only in isolates from the United States from 1990-1999 (van Loo et aL, 2002). It may be 
significant that the unusual alleles {tcfA{4) and tcfA{6)), except for one isolate, occurred 
during the late 1970s to the mid 1980s, following a drop in vaccine uptake rate that 
resulted in two epidemic peaks of pertussis in the UK around 1979 and 1983.
4.1.5 Adenylate cyclase toxin gene
A total of 42 UK B. pertussis isolates from the pre-vaccination (1920, 1941-1956), post- 
vacciaation era (1963-1985) and recent (1998-1999, 2002) time periods were 
investigated for allelic variation in cyaA. Sequence variation was investigated for the 
region that encodes the immunodominant moiety, bases 3586-6098 (Y00545) i.e. a total 
of 2512 bp were sequenced. The same region was also sequenced for the foui’ vaccine 
strains and the type strain. Only two cyaA types were confirmed in this study and the 
type strain (NCTC10739^) was the only strain found with allele type cyaA(\). This 
variation existed as a single silent nucleotide difference at position 4403 (Y00545) in the 
region that encodes the immunodominant moiety (Fig. 2.4.1). There was also a single 
nucleotide difference at position 3981 (Y00545) in the previously deposited sequence,
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Y00545, when compared to the sequence data of NCTC 10739^ for the same region. The 
strain used for the sequence data in Y00545 was B. pertussis strain 18323^. These type 
strains may have existed as independent cultures for a considerable time, which may 
explain the single nucleotide difference. Another explanation for this discrepancy is that 
there was a sequencing enor at position 3981 in the previously deposited sequence, 
Y00545. The cyaA sequence was deposited in GenBank in 1988 and the earlier 
sequencing techniques used may have led to this error. The cyaA sequence of 
NCTC 10739^ was confirmed by sequencing in triplicate during this study. Since the 
cyaA{2) sequence is found in all other strains and is also present in the whole genome 
sequence of Tohama-I strain (Parkhill et al., 2003), it should perhaps be regarded as the 
prototype sequence. However, amongst all the UK isolates and vaccine strains studied, 
no variation was found in the immunodominant region (Fig. 2.4.1). To my knowledge 
this is the first report of cyaA variation (Packard et aL, 2004).
Adenylate cyclase toxiu protein is of interest because it has been shovm to be protective 
against B. pertussis infection in the mouse (Hormozi et al, 1999; Guiso et al, 1991; 
MacDonald-Fyall, 2002) but is not included in any ACV preparation at present. Acellular 
vaccines have been investigated for their protective efBcacy in field trials and some have 
had their efficacy compared to that of WCVs. The vaccines may contain one to five 
components consisting of detoxified PTX, Prn, FHA, Fim2 or Fim3. It was concluded 
fiom these trials that the greater the number of components an ACV contains, the greater 
protection afforded (Hewlett, 1997b). One five-component ACV was found to have 
efficacy equivalent to the WCV that it was compared with (Olin et aL, 1997). Such 
vaccines are less reactogenic than WCVs and are used as pre-school boosters in the UK 
or for the primary vaccination series in some other countries. These vaccines may be 
used in the future for routine boosting of adults and adolescents. The genes that encode 
some of these antigens have demonstrated sequence variation. King et aL (2001) 
demonstrated that the Dutch WCV expressing prnA{\) afforded less protection against 
B. pertussis strains expressing prnA{2) or prnA(3), at least in the mouse, and the 
introduction of AC Vs may effect shifts in the B. pertussis population further resulting in 
the predominance of more non-vaccine sequence types. The CyaA protein has been 
shown to be protective, at least in mice, and its irnmunodominant region has been 
demonstrated to be stable which would make this antigen suitable as a component in any 
new generation of ACVs. However, countries that have currently licensed ACVs and
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included them in their immunisation programmes may not be amenable to the 
incorporation of an extra component, such as CyaA as this would be expensive and time- 
consuming. However, CyaA has other potential in vaccine formulations. Its lack of 
variation in the immunodominant region and overall stability, together with its cell- 
mvasive activity make it suitable for delivery of foreign epitopes to antigen-presenting 
cells. The molecule has been used as a non-repUcative anti-viral vaccine. Recombinant 
adenylate cyclase toxin containing the lymphocytic choriomeningitis vkus nucleoprotein 
CD8  ^epitope inserted in the AC domain between residues 224 and 225, protected mice 
against challenge with the virus (Saron et aL, 1997). Recombinant CyaA could therefore 
be used as a multivalent vaccine, boosting the immune response to pertussis ACV and, at 
the same time, delivering protective epitopes against other infections.
The immunodominant region of CyaA has been sequenced previously in B, parapertussis 
(AJ249835, BX470249) and B. bronchiseptica isolates (Betsou et aL, 1995b). The 
immunodominant region in cyaA of B. bronchiseptica exhibited much greater variation 
than in B. pertussis with 11 sequence types for this region having been deposited in the 
GenBank database. No further variation has been reported for B. parapertussis cyaA as 
there are only two GenBank entries, one of which is the genome sequence. Using the 
alignment tool BLAST no differences were found between these two GenBank entries. 
Greater variation in B. bronchiseptica isolates is not surprising as it has been shown by 
MLEE to be the most diverse of the Bordetella species whereas B. pertussis and B. 
parapertussis were shown to be clonM (Musser et aL, 1986). It is also thought that B. 
pertussis and B. parapertussis have evolved from B. bronchiseptica farily recently, 
explaining this lack of variation. However the genome data described by Parkhill et al. 
(2003) suggest that the genetic uniformity in B. pertussis reflects a recent bottleneck 
rather than recent descent from B. bronchiseptica.
4.1,6 Outer-membrane protein Q gene, virulence-activated gene 8, bordetella 
autotransporter protein C gene and bordetella resistance to killing protein A gene
A total of 42 UK B. pertussis isolates from the pre-vaccination (1920, 1941-1956), post­
vaccination era (1963-1985) and recent (1998-1999, 2002) time periods were 
investigated for allelic variation in ompQ. Fourteen UK isolates from the pre-vaccination 
era (1920, 1941-1950), post-vaccination era (1964-1983) and recent (1998-1999) time 
periods were mvestigated for brkA, vagS and bapC variation. Variation was found only
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between the type strain and the other isolates in ompQ, vag8 and bapC. The variation 
found in ompQ was a single non-silent nucleotide difference, for vag8 it was three single 
nucleotide differences, one of which was non-silent, and for bapC it was a single silent 
nucleotide difference. No variation was found in brkA in any of the strains examined by 
van Loo et aL (2002) and present data were concordant with this findmg. However, a 
difference in serum resistance has been described between the type stram 18323^ and 
BP338 (Fernandez and Weiss, 1998). The type strain was foimd to be more serum 
sensitive than BP338 despite both expressing BrkA as shown by Western blotting. The 
reason for increased sensitivity of strain 18323^ is not known, but may be related to 
differences in the level of BrkA expression. Alternatively, sequence variation in brkA 
might have been expected, creating differences in serum resistance. As NCTC 10739^ is, 
in many respects, an atypical strain of B. pertussis, the ompQ(2) and vag8(2) sequences, 
which are also present in the genome sequence of the Tohama-I strain (ParkliUl et aL
2003), should perhaps be regarded as the prototype sequences. This would not apply to 
bapC as the deposited GenBank sequence was designated as the allele bapC{V) and was 
found in all isolates except the type strain.
4.2 MLST TRENDS IN THE UK AND GLOBAL TRENDS
4.2.1 MLST trends
Previous studies have reported variation or lack of variation in the genes coding for five 
of the acellular vaccine components iprnA, ptxA-E, fha, fim2, firnS), and other surface- 
associated proteins, including tcfA, in isolates firom The Netherlands, Finland, Italy, 
Japan, and the United States (van Loo et aL, 2002). The MLST scheme described by van 
Loo et aL (2002) is based on the allelic variation of three genes, ptxA, ptxC  and tcfA, 
Van Loo et al (2002) reported nine MLST types. This MLST scheme was applied to 
data firom UK isolates in the present study to allow direct comparison between countries. 
Multilocus sequence type trends fi*om the pre-vaccination era up to recent isolates have 
been reported only for Dutch and US R pertussis isolates, whereas MLSTs for recent 
isolates have been reported only for Japan, Italy and Finland (van Loo et aL, 2002). The 
sequence type of vaccine strains has been reported only for The Netherlands.
A shift in MLST types in the UK R  pertussis population was found in the present study. 
Figure. 4.2.1.1a is a duplicate of the MLST data depicted in the results (Fig. 3.2.1.1), to 
allow ease of comparison between trends in the UK and other countries. During the UK
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pre-vaccination era, MLST-2, MLST-3 and MLST-11 were present. Vaccination with 
UK WCVs was introduced in the 1950s and the MLST types of the vaccine strains were 
MLST-2 and MLST-3. MLST-2 and -3 were found in post-vaccination isolates and, 
during the decrease in UK vaccination rates in the 1970s, there was the appearance of 
unusual MLST types, MLST-6 and -10. A non-vaccine MLST type, MLST-5, was 
found to predominate in recent isolates (tliis study).
During the pre-vaccination era in the UK, US and The Netherlands different MLST types 
were found. In the Dutch B. pertussis population, MLST-1 and MLST-2 isolates were 
present (Fig. 4.2.1.1b; van Loo et ah, 2002), in the US population MLST-1, MLST-2 
and MLST-9 were present (Fig. 4.2.1.1c; van Loo et ah, 2002) whereas the UK had 
MLST-2, -3 and the novel MLST-11 present (Fig. 4.2.1.1a; this study). All countries 
had MLST-2 as the predominating type in this period. Whole-cell vaccination was 
introduced and the four UK vaccine strains contained MLST-2 and MLST-3, whereas 
the Dutch vaccine strains contained MLST-1 and MLST-2. Multilocus sequence type 
data for B. pertussis strains isolated immediately after the introduction of whole-cell 
vaccination is only available for UK and The Netherlands and both populations contained 
MLST-2 and MLST-3 with the latter type predominating (Figs 4.2.1.1a and 4.2.1.1b). 
However, during 1977-1983 there was the appearance of unusual MLST types, MLST-6 
and -10, in the UK and this coincided with the decrease in vaccination uptake.
Recent isolates from 1990-1999 have been investigated for Dutch, US, Finnish, Italian 
and Japanese populations (van Loo et aL, 2002). Each country differed in the MLST 
frequencies present during this time period (Fig. 4.2.1.1b-f). In the UK, MLST-3 and -5 
predominated with MLST-4 and -6  present in very low ftequencies. The Dutch isolates 
from the 1990s also contained similar MLST types but at different frequencies. The 
Dutch vaccine MLST types, MLST-1 and MLST-2, were present in Dutch isolates but at 
very low frequencies, 1 and 4%, respectively (van Loo et aL, 2002). MLST-3 was 
present, but at a lower fr equency than that of UK isolates, 25% versus 49% for UK. 
MLST-4 and -5 were present at a greater frequency. Only 4% of recent UK isolates 
were MLST-4, whereas 31.8% of recent Dutch isolates were MLST-4 (Fig. 4.2.1.1a and 
b). The frequency of the non-vaccine MLST type, MLST-5, isolates in the UK and 
Dutch B. pertussis populations were similar, 42% and 38% respectively. With regard to 
US B. pertussis isolates from 1990-1999, MLST-5, an MLST type not found in the pre-
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Figure 4.2.1.1a: Temporal trends in multilocus sequence types (MLSTs) in the UK B.
pertussis population (this study). MLSTs of current UK whole-cell vaccine strains: B  O
Key (For Figures 4.2.1.1a-f ):
MLST-1 ■
MLST-2 ■
MLST-3 □
MLST-4 □
MLST-5 ■
MLST-6 B
MLST-7 □
MLST-8 Q
MLST-9 □
MLST-10 □
MLST-11 ■
Figure 4.2.1.1b: Tenporal trends in multilocus sequence types (MLSTs) in the The 
Netherlands B. pertussis population (van Loo et aL, 2002). MLSTs of current Dutch whole­
cell vaccine strains: □  ■
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Figure 4.2.1.1c: Temporal trends in multilocus sequence types (MLSTs) in the United
States B. pertussis population (van Loo et aL, 2002).
Figure 4.2.1.1d: Multilocus sequence types in the Japanese B. pertussis population (1990- 
1999) (van Loo et aL, 2002).
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Figure 4.2.1.1e: Multilocus sequence types in the Italian B. pertussis population (1990- 
1999) (van Loo et aL, 2002).
Figure 4.2.1.11: Multilocus sequence types in the Finnish B. pertussis population (1990- 
1999) (van Loo et aL, 2002).
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vaccination era, was the predominating type, found in 60% of isolates (Fig. 4.2,1.1c) 
(van Loo et al., 2002). This frequency of MLST-5 is slightly higher than that found for 
UK and Dutch isolates. MLST-2, -3, -7 and -8  were found in much lower frequencies 
(Fig. 4.2.1.1c). The latter two types were not found in recent UK or Dutch isolates.
Information for Japanese, Italian and Finnish B, pertussis isolates is incomplete as 
MLST types are only known for recent isolates from 1990-1999 (van Loo et aL, 2002). 
The Japanese isolates differ from other coimtries in that the predominating MLST type, 
MLST-2, found in about 69% of isolates (Fig. 4.2,1. Id; van Loo et aL, 2002), was found 
to predominate in other countries only during the pre-vaccination era. MLST-3 and 
MLST-5 were present equally but lower frequencies, 15%, and the MLST-5 frequency 
was lower than that seen for UK, Dutch and US isolates from the same time period. The 
recent Italian and Finnish isolates had only two MLST types, MLST-3 and MLST-4 
(Fig. 4.2.L ie  and f) (van Loo et aL, 2002). These recent isolates differ markedly from 
those described for other countries as no MLST-5 isolates were found. Recent Italian 
isolates had a gieater predominance of MLST-4 (60%) in contrast to the frequencies 
found in The Netherlands and UK. Finnish isolates showed a predominance of MLST-3 
and had the greatest frequency of MLST-3 compared to other B. pertussis populations.
Van Loo et aL (2002) have noted that the resurgence of pertussis in The Netherlands 
since 1996 has coincided with the appearance of the new MLST types, MLST-4 and 
MLST-5. The US has also reported increasing levels of pertussis since the 1980s and, 
during 1990-1999, MLST-5 became predominant in its B. pertussis population. In the 
UK, MLST-4 and MLST-5 were detected from 1999 onwards. Although only two UK 
MLST-4 isolates were found, MLST-5 was the predominant type in the most recent time 
period (2002), which is similar to that reported for The Netherlands and US. In contrast 
to The Netherlands and US, there has been no resurgence of pertussis in the UK (Mooi 
et aL, 1998; Cassiday et aL, 2000; Fry et aL, 2001) and therefore no evidence that 
vaccine efficacy has been compromised by change in the antigenic make-up of circulating 
strains.
4.2.2 MLST and pertactin type
A significant correlation between MLST and prnA type was previously demonstrated by 
van Loo et aL (2002), although prnA was not included as a gene target in the MLST
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scheme described by these authors. The reason given was that variation in the prnA gene 
occurs as a result of insertion and deletion of repeat units and this process is expected to 
occur relatively frequently and is reversible (van Loo et al, 2002). However, they foimd 
a non-random association between the MLST of recent isolates from 1990-1999 and the 
prnA type for Dutch, Finnish, Italian, Japanese and US isolates. Recent Dutch MLST-2 
isolates were all associated with prnA{\). The MLST-3 and -5 recent Dutch isolates 
were associated with the three prnA alleles, prnA{\yprnAQ), but the majority of recent 
Dutch MLST-3 and-5 isolates, 61% and 93% respectively, were associated with prnA(2) 
(van Loo et aL, 2002). All MLST-4 isolates were associated withprnAQ). American B. 
pertussis isolates from 1990-1999 that were MLST-5 were all prnAil). The recent 
Japanese B. pertussis MLST-2 isolates were wither prnA{\) o rprnA(2) but the majority, 
89%, were associated withprnA{l). Recent Finnish isolates differed from recent Dutch 
isolates in that there were four prnA alleles, prnA(\)-prnA{4), present. Its MLST-3 
isolates were associated with all four alleles but prnA{2) predominated (84%). Similar to 
the Dutch isolates, all Finnish MLST-4 and Italian MLST-4 isolates wereprnA(3).
During this study it was considered important to determine whether similar correlations 
existed between UK MLST and prnA types in recent isolates. UK MLST-3 isolates from 
1998-1999 were associated with three prnA alleles, prnA(iyprnA(3). The majority of 
MLST-3 isolates (90%) from this period were prnA(l) and tliis differs from Dutch and 
Finnish MLST-3 isolates (1990-1999) that were mainly associated withprnA(2). The UK 
MLST-4 isolates (both from 1999) were different from the previously reported MLST-4 
isolates as they were prnAÇL) or prnA(3). UK MLST-5 isolates were mainly prnA{2) 
(96%) and no UK MLST-5 isolates were prnA{l). There are some similmities between 
B. pertussis populations and their MLST and prnA types but there are also some 
differences such as the correlation between MLST-3 and prnA type for UK, Dutch and 
Finnish isolates. This difference can be related to when the shift in prnA type from 
prnA{\) to non- prnA{\) alleles occurred and this shift to predominating non-pmAiX) 
alleles has occurred later in the UK (Mooi et aL, 1998; 1999; Fry et aL, 2001).
4.3 FIMBRIAL ANTIGEN 2 AS A VIRULENCE MARKER
The fim2  allele, y?w2(2), was seen only in UK B. pertussis isolates from 1998 and 1999. 
Isolates from any other time period were all fim2(\). In 1998, 9 of 18 isolates were 
fim2{2) and in 1999, 11 of 26 isolates were Jim2(2). This differs from the fim2 vaiiation
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that has been described for the Dutch B. pertussis population. The fim2{2) allele was 
only apparent in The Netherlands during the pre-vaccination era and not in any recent 
isolates (van Loo et al., 2002). Using a larger sample size, it would be possible to 
investigate whether fim2(T) is a potential marker for virulence. In the present study, 
there was an apparent 100% linkage between isolates that were fim2(2) and serotype 
1,2. B. pertussis isolates that are serotype 1,2 have been linked to more severe cases of 
pertussis (van Buynder et al., 1999). It has been reported that in UK B. pertussis isolates 
the proportion of those that were serotype 1,3 decreased steadily over the years 1995- 
1997 with a concomitant increase in proportion of isolates that were serotype 1,2 but, in 
2002, the majority of isolates were serotype 1,3 (J. Duncan, personal communication). 
Serotype 1,2 was also related to the increase in rates of hospital admissions and 
complications associated with pertussis (van Buynder et al., 1999). Those that were 
infected with isolates that were serotype 1,2 were twice as likely to be admitted to 
hospital as serotype 1,3 and seven times as likely as those with serotype 1,2,3. However, 
during 1998-1999 there was no overall increase in the number of pertussis cases in the 
UK (Fig. 4). Information regarding vaccination status of individuals from whom isolates 
were recovered was available only for those from 1998-1999. There was no relationship 
between vaccination status and fim2 allele, but the sample size for 1998-1999 was small 
and it should be expanded to investigate a greater number of isolates to determine 
whether such a relationship existed. The allele fim2{2) has the potential to be used as a 
virulence marker for isolates. Using Pyro sequencing technology it would be possible to 
rapidly determine which isolates were Jim2(2) and might indicate which patients will 
have more severe disease.
4.4 MLST LINK WITH VIRULENCE
A Hnk with pertussis toxin promoter sequence variation and MLST type has been 
reported by Prof F. Mooi (Mooi, 2003). Multilocus sequence types are distinguished by 
allelic variation ofptxA,ptxC  and tcfA genes. There has been the 'appearance' of MLST- 
5 (ptxAiX), ptxC(2), tcfA(2)) in the Dutch B. pertussis population during the 1990s and 
this was found to be the predominating type. Prior to this the predominating MLST type 
was MLST-3 iptxA{\), ptxC{\), tcfA(2)). Since 1990 in The Netherlands, the frequency 
of MLST-5 has been increasing and this increase coincided with the epidemic that 
occurred in 1996 as well as the overall increase of pertussis. The difference between the 
two knownptxC alleles, ptxC{\) andptxC{2), is only a single süent nucleotide difference
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and this had led to the speculation that there may be other, unknown variation in 
virulence genes that has allowed MLST-5 strains to be more successful than other MLST 
types. An investigation of ptx promoter sequence variation amongst Dutch B. pertussis 
isolates led to the discovery of eleven ptx promoter alleles, ptxpl-ptxpW, and this 
variation occurred within the regulatory region of the promoter (Mooi, 2003). There was 
100% linkage between ptxp3 and the ptxC(2) allele. It was also found that the frequency 
of the ptxp3 allele has increased from 1997 onwards and the allele ptxpl had decreased 
during this time, Mooi and colleagues constructed isogenic strains to compare the two 
ptxp alleles in mouse respiratory studies (Mooi, 2003). The studies showed that B. 
pertussis isolates containing the ptxp3 allele were better colonisers of mice than isolates 
that were ptxpX. B. pertussis isolates with the ptxp3 aUele appeared therefore to be more 
virulent than those with the pixpl allele and/or are transmitted more efficiently. It was 
also reported that isolates containing the ptxp3 allele occurred in the other countries 
(The Netherlands, Finland and Sweden) known to have the ptxC(2) alleles in their B. 
pertussis populations. However, Italian B. pertussis isolates did not have this ptx 
promoter allele, but these isolates were not ptxC(2). It would be informative to expand 
the current sequencing study of UK B. pertussis isolates to include the ptx promoter to 
determine if a similar link between MLST-5 isolates and ptxpS allele exists in the UK. If 
this ptx promoter allele does not exist in UK isolates that ai e ptxC(2) then it may partly 
explain why the UK pertussis levels are not increasing. However, if UK B. pertussis 
isolates have this pertussis toxin promoter allele in recent isolates it would conflict with 
the suggestion that recent Dutch isolates are potentially more virulent, thus leading to 
increases in pertussis levels. It would also emphasise the flaws associated with the 
published MLST scheme and indicate that other virulence target genes should be 
included to gather more information on isolates.
4.5 ADVANTAGES AND DISADVANTAGES OF THE B, pertussis MLST 
SCHEME
Characterisation of strains by nucleotide sequence analysis has allowed epidemiological 
tracking of shifts in the circulating population of B. pertussis of several countries. The 
MLST scheme devised by van Loo et aL (2002) based on the allelic variation of ptxA, 
ptxC and tcfA is not the one that is traditionally used which would be based on the allelic 
variation of an organism’s housekeeping genes. This is because of the clonal nature of B. 
pertussis. However, the term MLST for the B. pertussis sequence typing scheme
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described by van Loo et al. (2002) should perhaps be altered to prevent confusion 
between this scheme and the MLST scheme based on variation of an organism’s 
housekeeping genes described by Maiden et al. (1998).
Although the MLST scheme by van Loo et al. (2002) has provided useful information 
about the changes in the B. pertussis populations of different countries with time, it does 
have its limitations as it is based on only tliree genes. Thus, there is no guarantee that an 
MLST-5 isolate in the UK is genotypically or phenotypically the same as an MLST-5 
isolate from another country. There may be differences in other gene sequences and/or 
gene expression. The inclusion of fiirther genes in this scheme would provide greater 
discrimination and potentially would be more informative. Such targets that have 
demonstrated sequence variation are prnA and The addition of the prnA and jim2 
alleles described here would increase the number of possible B. pertussis sequence types. 
The other genes, cyaA, bapC, vag8, brkA, ompQ, that were investigated for sequence 
variation revealed no polymorphism in UK isolates which precludes them from use as 
epidemiological markers.
Sequence typing schemes such as the van Loo et al. (2002) MLST scheme has allowed 
the comparison of data from different countries. This is useful to determine the shift in 
the pertussis population world-wide and whether, potentially, this relates to each 
country’s vaccines and vaccination schedules. Acellular vaccines are increasingly being 
used as booster vaccines in children of school age or in place of the traditional WCVs for 
primary immunisation in some countries. Such vaccines are composed of a limited 
number (1-5) of specific antigens from B. pertussis. Vaccination schedules may differ, as 
well as the number of components in the ACVs. The component antigens wiU also be of 
particular amino acid sequence types. Typing schemes such as MLST are important as 
they will be a powerful tool in determining whether vaccination with ACVs will have an 
effect on the circulating B. pertussis population. The efficacy of the UK WCVs has not 
been hampered by the shift that has occurred within its B. pertussis population. With 
further monitoring it would be possible to find if ACVs cause further shifts and if this 
affects their efficacy.
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4.6 MULTILOCÜS VIRULENCE GENE SEQUENCE TYPING (MVGST) 
SCHEMES
It was mentioned in sections 3.2.2 and 3.3 that two other genes, fm 2  and prnA, had 
demonstrated variation suitable for inclusion in a gene typing scheme. Allelic variation of 
prnA had been used previously for sequence typing of B. pertussis isolates but was not 
considered suitable for the MLST scheme developed by van Loo et al. (2002). The fim2 
gene had also shown variation amongst Dutch isolates but the two flm2 alleles were only 
found together during the pre-vaccination era and, for this reason, were not included in 
the MLST scheme by van Loo et al. (2002). In contrast, UK B. pertussis isolates had 
exhibited fim2 allelic variation amongst recent isolates from 1998-1999. By inclusion of 
these genes in a multilocus virulence gene sequence typing (MVGST) scheme of ptxA, 
ptxC, tcfA, prnA and fim2, it was hoped to gain further information on UK B. pertussis 
isolates by providing more discriminatory power. Three different combinations, (l)-(3), 
of gene targets for this sequencing scheme were compared: MVGST(l) ptxA, ptxC, tcfA 
and prnA', MVGST(2) ptxA,ptxC, tcfA and fim2', and MVGST(3) ptxA,ptxC, tcfA, prnA 
and fim2. There was one problem in comparing these three techniques in that prnA 
variation had been investigated for a greater number of UK B. pertussis isolates than for 
fim2. Therefore the number of sequence types achieved with each scheme differed, due 
to differences in strain numbers. Seven MLST types from 136 strains, eleven MVGST(l) 
types from 136 strams, six MVGST(2) from 80 strains and ten MVGST(3) types from 
80 strains were found amongst the UK B. pertussis population from 1920-2002, An 
equivalent number of UK B. pertussis isolates should be investigated for fim2 variation 
to determine whether the number of MVGST(2) types would increase significantly. 
However, by the inclusion o f prnA (MVGST(l)) or prnA and fim2  (MVGTS(3)) m the 
original MLST scheme, the number of sequence types present in recent isolates from 
1982 onwards increased compared to those found using the earlier MLST scheme. Six 
MVGST(l) types were found amongst 17 isolates from 1982-1985 compared to four 
MLST types found during this time period. Four MLST types and seven MVGST(l) 
types were found amongst 51 UK isolates from 1998-1999. During 2002 three 
MVGST(l) types were found amongst 31 UK isolates compared to two MLST types. 
With the MVGST(3) scheme, eight MVGST types were found amongst 33 isolates from 
1998-1999 compared to four MLST types.
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4.7 VARIATION IN cyaA PROMOTER REGION OF & pertussis AND ITS 
EFFECT ON VIRULENCE
Although little variation was found in the irnmunodominant region of CyaA, three alleles 
were identified m a region of cyaA between bases 686-695 (Fig. 3.5.1.1). This cyaA 
promoter region was amplified with primers CyaAl and CyaA6, targeting bases 287- 
1165 (Y00545), and used to study the expression of cyaA (section 3.9). The allele 
cyaApr{\) was found in the B. pertussis type strain NCTC10739^. When this sequence 
was compared to that of the cyaA GenBank sequence, Y00545, there was a single 
nucleotide difference at position 840. The strain source of Y00545 was B. pertussis 
18323^ and this strain is considered to be identical to NCTC10739^. However, these 
strains may have been separated many years previously and could have evolved by 
mutation, which may explain this difference in cyaA sequence. Another explanation for 
this discrepancy is that there was a sequencing error due to old sequencing technology at 
position 840 in the previously deposited sequence, Y00545. This region for 
NCTC10739^ was sequenced again and the data were found to agree with the nucleotide 
difference at position 840. The second allele, cyaAprfl), was found amongst the majority 
of UK B. pertussis isolates. Of the 46 B. pertussis isolates examined only 99K45 and 
PICU475 were cyaApr{3). These two strains also differed jfrom other isolates as they 
were the only two MLST-4 strains in the UK collection. It has been suggested that there 
is a 100% link between a particular pertussis toxin promoter allele and the ptxCÇL) allele 
(Mooi, 2003). Therefore there was further investigation to determine if there was a 
100% linkage between isolates that had tcfAQ) (MLST-4) and the 6 bp insertion 
between the cyaA and cyaC genes. B. pertussis isolates that were known to have the 
tcfA(3) allele were requested from Prof F. Mooi and sequenced for the cyaA promoter 
variation. Sequencing results indicated that there was no such linkage. This emphasises 
the problems that are currently associated with the MLST scheme for typing B. pertussis 
isolates. An isolate that is MLST-4 fi^ om the selected UK panel is not necessarily the 
same as an MLST-4 strain fiom elsewhere. Even so, these two isolates, 99K45 and 
PICU475, were known to be epidemiologically unrelated because they had different 
IS1002 RFLP profiles (Neal, 2004).
The effect that the 6 bp insertion might have on enzymic or cytotoxic activity of CyaA 
was determined by phenotypic investigation of strains 99K45 and PICU475. Their AC 
enzymic activity was investigated initially with bacterial cell suspensions lysed by Triton
197
X-100 as a som’ce of AC activity and compared to lysed cells of B. pertussis BP338. 
These assays showed that 99K45 had greater AC enzymic activity compared to 
PICU475 and BP338. Their tangents of the progress curves from the conductimetiy 
assay were 48, 21 and 23, respectively. It was found that PICU475 did not grow as well 
as the other B. pertussis isolates in SS liquid medium and therefore it was not used for 
AC and cytotoxic activity measurements, due to the need to prepare urea extracts from 
stationary growth phase cells. The urea extract of 99K45 had a similar AC enzymic 
activity to that of strain BP338; both were determined to have an activity of 1.5 lU mg‘‘ 
protein. The urea extracts of strain 99K45 and BP338 were used for further comparison. 
99K45 had slightly higher killing activity than BP338 in the MTT assay. Each sample 
was tested in duplicate but the cytotoxicity assay was carried out only once. These assays 
should be repeated with an improved urea extraction protocol using a larger culture 
volume (1 1 in instead o f250 ml) and it should be investigated whether purified CyaA can 
be prepared rather than a crude extract to determine if this 6 bp insertion has a true effect 
on increasing the cytotoxic activities of CyaA. However with only one strain containing 
this 6 bp insertion able to grow well, it may be difficult to draw definitive conclusions. 
To prove linkage between the insertion and increased cytotoxic activity, several more B. 
pertussis isolates with this particular genotype would have to be investigated to 
determine if this 6 bp insertion had an effect.
The 6 bp insertion is situated upstream (position 692) from the RNA polymerase binding 
sites and the phosphorylated BvgA binding sites of cyaA (Fig. 3.9.1.1). The sequence of 
the 6 bp insertion was checked to ensure that it was not an extra BvgA binding site but 
the sequence was not similar to that of the BvgA binding site consensus sequence 
[TTTC(C/G)TA] (Cotter and Jones, 2003). When the region between cyaA and cyaC is 
viewed using the program Artemis (www.sanger.ac.uk) the 6 bp insertion is situated very 
close to the start of the cyaC gene (Fig. 3.9.1.1).
4.8 COMPARISON OF TECHNIQUES USED TO DETECT SEQUENCE 
VARIATION
There were three techniques (sequencing by dideoxy method, Pyrosequencing and 
melting curve analysis with LightCycler) used to determine sequence variation for the 
genes described in results sections 3.1 and 3.3. Conventional, dideoxy sequencing was 
used routinely for investigation of genotypic variation of cyaA, tcfA, brkA, vag8 and
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bapC. Pyrosequencing was used for the investigation of single nucleotide polymorphisms 
in ompQ, fim2 and ptxC. Lastly, melting curve analysis was used for screening isolates 
for cyaA promoter variation. The main advantage of using LightCycler assays and 
Pyrosequencing over conventional sequencing is the fact that they aie much more rapid.
For example, with Pyrosequencing of a 96-well plate containing a sample in each well for 
determining single nucleotide polymorphisms, the time taken from the purification of 
PCR products to determining the allelic variation of the samples using the software 
supplied with the equipment is approximately 2.5 h - 3 h. This differs from conventional 
sequencing, which requires one day from the purification of PCR products to receiving 
chromatograms for sequence analyses. The analysis of chromatograms requires further 
time. The LightCycler assay takes approximately one hour but fewer samples (maximum 
32) can be analysed in one assay. Analysis of LightCycler melting curve results takes 
little time using the software supplied with the equipment. The advantage that 
conventional sequencing has over both of these techniques is related to the size of the 
region that can be sequenced.
Only single nucleotide polymorphisms were investigated using Pyrosequencing thus 
potentially missing any other variation that may have been present outside the known 
polymorphic site. This drawback also applies to the LightCycler as only a limited region 
is covered by hybridisation of specifically-designed probes. Targets that were used for 
LightCycler and Pyrosequencing were investigated initially by sequencing using the 
dideoxy sequencing method to determine polymorphic sites and to ensure that results 
would be concordant between methods. LightCycler and Pyrosequencing provide a 
powerfiil tool for screening hundreds of samples in a relatively short time.
4.9 CONDUCTIMETRY
4.9,1 Conductimetiy assay as a tool to study rCyaA activity
The conductimetry assay was developed as a rapid and convenient method to determine 
the AC enzymic activity of different forms of rCyaA in studies to characterise theft 
potential as immunogens and immunomodulators. This is an easy and rapid assay to 
detect the AC activity of rCyaA preparations. The detection limit of the conductimetry 
assay was determined in this study and found to be low, at approximately 1 ng protein 
(526 lU mg'  ^ protein) in a 2 ml volume fti the conductimetry cell. The conductimetry
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assay has several advantages over the radioisotopic assays that have been developed; for 
example it is more rapid, cheaper and teclinically less demanding. However, it is accepted 
that the radioactive assay can achieve a lower limit of detection (Lawrence et al., 2002), 
Adenylate cyclase toxin is an unstable enzyme/toxin that aggregates and loses activity in 
aqueous solution. It is normally purified by a stepwise procedure involving ion-exchange 
and hydrophobic interaction chromatography in presence of a high concentration of urea. 
The conductimetry assay is convenient in that it allows the AC activity of rCyaA 
preparations to be determined quickly at each stage of puiification. Different CyaA 
preparations at the same protein concentration can be compared, to determine which 
purification method is optimal. The method can also be used to determine the enzymic 
activity of different mutated forms of CyaA for use in immunogenicity studies.
It was found during this study that there was inter-assay variation of AC activity of the 
same rCyaA preparation at the same protein concentration. Thus without the inclusion of 
an internal standard, it would be difficult to compare the AC activity of one rCyaA 
preparation with that of another preparation on a different day. The assay was therefore 
standardised between conductimetry runs by including the same positive control of a 
known concentration and specific activity in every assay. It was also apparent that when 
the standard preparation of rCyaA was diluted in distilled water and freeze-thawed once, 
it lost approximately 50% of its AC activity. Therefore, dilutions of the stock preparation 
of rCyaA were prepared immediately prior to use in the conductimetry assay.
The eight glass cells within the conductimetiy machine were suspended over a spinning 
magnet. Cell number 5 was positioned veiy close to the rotor and sometimes the spinning 
magnet within this cell would jump and not spin properly which resulted in unreliability 
of the AC activity of the sample in this cell. The magnets of the individual cells would 
occassionally not spin correctly and would have to be adjusted to allow correct spinning 
of the magnet. The machine that was used was an early design of apparatus by Dr A 
Lawrence (Division of Infection and Immunity, University of Glasgow). Further versions 
of equipment have been developed since and they may overcome the problem of the 
conductimetry cell 5 position in relation to the rotor and the potential ‘jumping’ of 
magnetic fleas.
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4.10 CONDUCTIMETRY OF NATIVE CyaA
4.10.1 Conductimetry as a diagnostic tool
Currently there are several diagnostic tests for pertussis (see section 1.10). Of these PGR 
diagnostics is becoming one of the main tests, but it is suggested that it should be used 
alongside culture and serology. Routine PGR testing is a costly process. Thus, there is a 
need for a sensitive, specific, inexpensive diagnostic assay for laboratories that cannot 
afibrd to routinely use PGR assays. The presence of AG enzymic activity in clinical 
specimens from pertussis-infected individuals has been suggested for use in diagnosis of 
pertussis (von Koenig et al, 1989; Confer et al, 1990; Schefiel et al, 1992). It was 
reported that there was a 100% correlation between AG positive samples and B. 
pertussis culture-positive patients (Schefiel et al, 1992). However, these assays use 
radioisotopes and are technically demanding. Use of the novel conductimetric assay, that 
is simple, rapid and inexpensive, to detect AG enzymic activity was investigated for its 
diagnostic potential. Initially a method for lysing the B. pertussis cells had to be 
developed as whole cells, freshly grown on BG agar, did not exhibit much AG activity.
A small proportion of B. pertussis GyaA is known to be secreted into the culture medium 
but a large proportion (about 80%) is cell-associated (Hewlett et a/., 1976; Brownlie et 
al., 1985). Urea and various non-ionic detergents were chosen as potential lysis agents to 
optimise the detection of AG activity from B. pertussis cells. Two commercial reagents 
and urea solution were found to cause inhibition at higher concentrations. Solubilisation 
of membranes involves hydrophobic interactions between surfactant chains and the 
lipid/protein content. Synthetic nonionic detergents offer a wide range of 
hydrophilic/lipophilic balance (HUB) values and are non-denaturing. Maximum 
membrane solubilisation occurs using a surfactant with an HLB of about 12.5 (Jones, 
1999). Six of the seven nonionic detergents used in the present study had their HLB 
values listed by Jones (1999). The seven non-ionic detergents, Triton X-100, -114, Brij- 
35, Brij-58, Tween-20, Tween-80 and NP40, were found not to cause inliibition of AG 
activity in the conductimetry assay within a range of final concentrations of 0.05%-1.5% 
(v/v). Different numbers of B. pertussis BP348pRMBl cells were lysed with the non­
ionic detergents and were analysed to determine which would provide the best source of 
AG activity for conductimetry. It was found that the greater the number of cells used, the 
greater the AG activity detected, as would be expected. Four detergents, Triton X-100, - 
114, Brij-35 and NP40, which appeared to optimally lyse BP348pRMBl cells, were also
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used to lyse the type strain 18323^. These four detergents, except Brij-58, had an HLB 
value close to 12.5. B. pertussis cells lysed with Triton X-100 were found to exhibit the 
greatest activity. Therefore, Triton X-100 with an HLB value of 13.5 gave optimal lysis 
of B. pertussis cells, for use in conductimetry.
The data indicated that the conductimetry assay was probably not sensitive enough to 
detect AC activity from B. pertussis cells lysed with Triton X-100 if tliis was to be done 
directly from a clinical sample. This was due to the fact that the lowest number of cells 
that the assay could detect was about 10  ^ per conductimetiy cell. Tins value is 
considerably higher than the detection level reported for the conventional radioactive 
assay described by von Koenig et al. (1989), which was determined to be 3-6 x lO'^  cfu 
m f\
The specificity of the conductimetry assay for detecting AC activity from lysed B. 
pertussis cells was also investigated. In reactions that did not contain the reagent CaM, 
some AC activity was still apparent in the conductimetry assay. However, reactions that 
did not contain the reagent ATP were negative and the progress curve remained at the 
baseline. Therefore, lysed B. pertussis cells provide a good source of AC activity but 
there are either background reactions occurring that are ATP dependent, AC in the 
absence of CaM has some basal activity, or a molecule in B. pertussis lysate is able to 
substitute for CaM to some extent. In fact a CaM-like protein has been reported in B. 
pertussis and this CaM-like protein was determined to activate B. pertussis CyaA (Nagai 
et al., 1994). Unlike the conductimetry assay that specifically detects AC activity from 
rCyaA that is CaM dependent, this has been demonstrated by this study (section 3.6,4), 
this assay may not be completely specific for detecting native CyaA AC activity from B. 
pertussis cells. Reactions of enzymic activity from rCyaA that did not contain CaM gave 
very low progress curves almost at baseline level.
4.10.2 Conductimetry screening for Bordetella spp.
The conductimetry assay has potential application as a tool for detecting gene expression 
in B. pertussis, B. parapertussis and B. bronchiseptica. Tu et al. (2001) developed a 
mini~Tn5 transposon derivative containing cyaA' encoding the N-terminal 400 amino 
acids of CyaA wlfich provided the CyaA enzymic activity. This transposon was able to 
randomly insert the reporter gene cyaA' into the B. bronchiseptica chiomosome.
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However, the authors reported difficulty in screening B. bronchiseptica mutants 
containing the reporter using a radioactive assay. It would be beneficial for such 
screening to use the conductimetric assay, which would allow multiple isolates to be 
screened quickly, inexpensively and without the use of radioactive reagents.
B. bronchiseptica is known to express the 6vg-repressed protein urease when grown in 
modulating conditions. Friedman et a l  (2001) described the phenotypic evaluation of B. 
bronchiseptica cultures by urease activity and Congo red affinity. The conductimetry 
assay could be adapted to detect urease because the reactions of the enzyme produces 
ammonia from urea with the release of free ions. Urease in B, bronchiseptica has been 
found to be cell-associated and not detected in the culture supemates (McMillan et al., 
1996). Therefore, there is no need to take into account that some activity may not be 
present due to secretion into the culture medium as is the case with CyaA. Use of the 
conductimetiy assay would allow the discrimination of Bvg^ and Bvg‘ strains of B. 
bronchiseptica. The ability to rapidly identify Bvg^ strains would aid in the production of 
effective veterinary vaccines where the known virulence factor antigens need to be 
expressed in the Bvg^ phase. The conductimetry assay could be further explored by 
determining if Bvg' isolates can be detected with a modified urease or CyaA assay.
4.11 STUDY OF cyaA EXPRESSION WITH lux AND gfp REPORTER GENES
It was considered important to study the expression of the cyaA gene in B. pertussis to 
determine how this is affected by different growth conditions and during the different 
phases of growth. Constructs containing a promoterless reporter gene, lux or gfp, with 
the cyaA promoter region (cyaAl-6 or cyaA 1-8) inserted upstream, were developed for 
determining the level of cyaA expression. The lux plasmid, pSB395, containing the 
cyaAl-6 insert was successfully introduced into B. pertussis by plate-mating. However, 
tins transfer was never achieved with the gfp plasmid containing the cyaAl-6 insert. 
Studying cyaA expression using the lux operon is potentially useful as expression could 
be monitored in a real-time fashion using a luminometer, such as Lucy-1 machine.
The bioluminescence studies undertaken to investigate the expression of cyaA with the 
lux reporter gene found no light production. PCR analysis of the bacterial cells used for 
these studies revealed that the cyaAl-6 insert in the plasmid was not present, suggesting 
that the plasmid was unstable. The primers that were used to amplify the cyaA fragments
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containing the promoter region contained several restriction sites within the sequence. 
The CyaAl primer contained Kpnl, HindlU and Pstl restriction sites, whereas CyaA6 
and CyaA8 hoth contained BgBl restriction sites. B. bronchiseptica contains a restriction 
enzyme called Bbrl {Hinàlll) which recognises the sequence AAGCTT (Roberts, 1980). 
B. pertussis as well as B. bronchiseptica has a Hinàlll restriction system (Greenaway, 
1980). Weiss and Falkow (1982) reported that they were not able to obtain B. pertussis 
transformants with plasmid DNA isolated from E. coli, but when using B. pertussis was 
used as the donor in conjugation experiments, the transfer frequency increased. 
Therefore, it was suggested that B. pertussis may also modify the iTmdlll site. The 
plasmid used in this study was known to contain a single Ffmdlll site and this was 
isolated from B. pertussis and E. coli then digested with ///«dlll and RawHI (included as 
a control enzyme to demonstrate that other enzymes can digest B. pertussis DNA). 
When the resulting digest profiles were compared, the digested plasmid profile from E. 
coli contained one more fragment than that from B. pertussis, consistent with the 
plasmid DNA isolated from B. pertussis not being cleaved at the HinâüW site, thus 
indicating that the latter organism had modified the site. The reporter gene gfp does not 
have any Hindlll sites, however the vector pPROBE-AT' contains a single HindlU 
restriction site. Further investigation revealed that the lux operon contains three HindlU 
restriction sites. This indicates that the lux reporter may not be useful for studying B. 
pertussis cyaA expression and suggests why there appears to have been the loss of 
plasmid from B. pertussis even though it was successfully transferred. The B. 
bronchiseptica lux construct containing cyaAl-8, insert designed by Dr M. Lynch, was 
also unstable. Only B. bronchiseptica colonies resulting directly from the plate-mating 
were light-emittmg, but not when taken from glycerol stocks of the transconjugants (Dr 
M. Lynch).
There are several possibilties to overcome this problem of the restriction/modification 
system in B. pertussis and B. bronchiseptica. It would be valuable to find out from other 
B. pertussis research groups if there is a strain that has had this system mutated, thereby 
allowing the use of the lux operon that contains HindlU sites. Weingart et al. (1999) 
used gfp labelling of live B. pertussis to study phagocytosis of opsonised and 
nonopsonised bacteria. For this study, a construct containing gfp under the control of a 
constitutive promoter was developed. The resulting vector pGBSPl consisted of 
pBBRlMCS-2 with the gfp mutant 2 gene cloned in as a BamUl and EcdBA fragment.
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A Sau3A fragment encoding a constitutive B. pertussis promoter was cloned upstream of 
the gfp gene to control its expression. Tins vector was successfully introduced into B. 
pertussis by electroporation. The vector was requested and provided by Prof A, Weiss, 
University of Cincinnati. However, the constitutive promoter is a Sau3A fragment and 
this site is known to exist within the fragment amplified by CyaAl and CyaA6 primers 
used for cyaA cloning. The vector could be manipulated for future use as a plasmid for 
studying gfp expression in B. pertussis.
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4.12 CONCLUSIONS
The investigation of polymorphism in several virulence-related genes amongst UK B. 
pertussis isolates from 1920-2002 has given insight into the trends within the UK population 
and has allowed the comparison of UK B. pertussis isolates with those from other countries. 
Only three of the eight genes (ptxC, tcfA and fhn2) investigated were found to exhibit 
polymorphism suitable for use as markers to study these trends. Polymorphism was already 
known to exist in prnA and ptxA in the UK (Fry et a l, 2001) and other countries (Mooi et 
a l, 1998). There has been a sliift in predominating sequence types in the UK population 
relating to ptxC and prnA types. The predominating alleles found in recent isolates were not 
seen in pre-vaccination era isolates or from the era just after the introduction of the pertussis 
whole-cell vaccine (WCV). For example, the ptxC{2) allele was not apparent until the 1998 
and is now the predominant ptxC  allele. Variation was shown within tcfA and fim2 genes but 
was restricted to certain time periods and, there has been no clear shift in tcfA or fîm2 alleles. 
There was one dominant tcfA allele with other alleles present in very low frequencies. 
However, during the drop in UK vaccination uptake between 1974 and 1983, novel or 
unusual tcfA alleles were apparent but these have not been seen (except one tcfA{A) allele in 
1999) since vaccination uptake returned to normal levels. Amongst UK i s o l a t e s , a l l e l i c  
variation was apparent only amongst isolates from 1998-1999. The reason for tliis is 
unknown as vaccination uptake was normal and pertussis levels were low at this time. Other 
coimtries have reported increases in the incidence of pertussis and this has been attributed to 
genetic shifts in the B. pertussis populations. However, the UK has experienced similar' 
shifts but no increase in pertussis levels has been noted. In fact, pertussis levels m the UK 
are historically low. Such increases in pertussis elsewhere may be related to differences in 
efficacy of WCV preparations and vaccination programmes in different countries. 
Surveillance of isolates should continue, to monitor for sequence variation of virulence- 
related genes and, if possible, more historical isolates should be investigated. An acellular’ 
pertussis vaccine (ACV) composed of a small number of antigen components has recently 
been introduced to the UK as a pre-school booster. This may lead to further genetic and, 
possibly, antigenic shifts in the B. pertussis population thus potentially compromising the 
efficacy of the ACV.
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During the sequence investigations, a 6 bp insertion was found situated between the gene 
that codes for the CyaA protoxin, cyaA, and its accessory gene, cyaC, in two recent B. 
pertussis isolates. Further investigation revealed that these were the only two such strains 
from a panel of 46 isolates. Due to the position of this insertion, it was of interest to 
determine the enzymic and cytotoxicity activities of the isolates but results of these 
phenotypic analyses were not conclusive. Further analysis regarding these two stiains should 
be carried to determine whether this sequence variation has an effect on the biological 
activity of CyaA and how this relates to virulence of B. pertussis.
The novel conductimetry assay could not be made sufficiently sensitive for use as a 
diagnostic test for pertussis, but this assay was found to be a useful laboratory test. 
Individuals in the Division of Infection and Immunity and in other institutions ar e currently 
investigating the immunogenic and adjuvant properties of different forms of CyaA and this 
assay provides a quick and easy method of determining the AC activity of crude and purified 
preparations of CyaA. It has other potential applications such as determining the phenotypic 
phase of B. pertussis, B. parapertussis and B. bronchiseptica cultures and the Hkelihood of 
whether or not other virulence-related properties of the Bvg^ or the Bvg" phase are being 
expressed.
The development of lux or gfp reporter genes with the cyaA promoter inserted upstream of 
the genes would have provided important information regarding the expression of the cyaA 
gene. However, problems were experienced with the stability of plasmid constructs in B. 
pertussis. This may be due to the modification and restriction system present in B. pertussis 
wliich targets the /fr’wdlll recognition sequence.
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Appendices
APPENDICES
Appendix 1: Media
1.1 Bordet-Gengou (BG) agar
Bordet-Gengou agar base (Difco) g
1% (v/v) glycerol
15% (v/v) defibrinated horse blood  ^ ^
(E and O laboratories, Scotland)
Made to 1 litre in distilled water, then autoclaved.
1.2 Stainer Scholte (SS) liquid medium 
Solution A
L-glutamate ^
L-proline ^
Sodium chloride SPotassium di-hydrogen orthophosphate 0.5 g
Potassium chloride 0-2 g
Magnesium chloride.7H2O 0.1 g
Calcium chloride 0.02 g
Tris 0.1 g
Made to 1 litre in distilled water. Solution is prepared to pH 7.6 then autoclaved. 
Solution B
L-cysteine 0-04 g
Iron sulphate.7H20 0.01 g
Ascorbic acid 0.02 g
Nicotinic acid 0.004 g
Glutathione 0.1 g
Solution B was made to 10 ml in distilled water, sterile-filtered then added to 1 1 of 
solution A.
1.3 Cyclodextrin Liquid (CL) medium
For CL medium, prepared solution A as described above and supplemented with 
casamino acids (lOg) (Difco) and methyl-p-cyclodextrin 0.25 g. Autoclaved and 
added solution B as above.
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1.4 Casamino acids (CAA) solution
Casein hydrolysate 10 g
Magnesium chloride 0.1 g
Calcium chloride 0.016 g
Sodium chloride 5 g
Made to 1 litre in distilled water, pH to 7.1, then autoclaved. Used for preparation of 
Bordetella glycerol stocks.
1.5 Luria Bertrani (LB) broth
Tiyptone (Duchefa biochemie. The Netherlands) 10 g
Yeast (Duchefa biochemie. The Netherlands) 5 g
Sodium chloride 10 g
Add 1% (w/v) agar for solid media
Made up to 1 litre in distilled water, then autoclaved.
Appendix 2: DNA solutions
2.1 Loading buffer
20% glycerol 4 ml
5 X TBE (see below) 5 ml
Add bromophenol blue to coloui*.
Made to 20 ml in sterile filtered distilled water.
2.2 10 X TBE
Tris (Sigma) 108 g
Boric Acid 55 g
0.5M EDTApH8.0 40 ml
Made to 1 litre in distilled water, used 1 x TBE for electrophoresis.
Appendix 3: Urea extraction
3.1 Buffer
100 mM Tricine pH 8 1 ml
0.5MEDTA 10 pi
0.5MEGTA 10 pi
8 M urea 5 ml
1 OOmM PMSF(dissolved in ethanol) 100 pi
Made to 10 ml in deionised distilled water.
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Appendix 4: Protein analysis solutions
4.1 7.5% acrylamide
30% Acrylamide-Bis (Bio-Rad) 1.25 ml
IM Tris pH 8.8 1.875 ml
10% (w/v) SDS (Fisher Scientific) 50 pi
10% (w/v) APS (Riedel de Haen, distributed by Sigma-Aldrich) 50 pi
TEMED 5 pi
Made to 5 ml in distilled water
4.2 4% stacking gel
30% Acrylamide-Bis 0.67 ml
IM Tris pH 8.8 1.875 ml
10% (w/v) SDS 50 pi
10% (w/v) APS 50 pi
TEMED 5 pi
Made to 5 ml in distilled water.
4.3 2 X loading buffer
Glycerol 8 ml
20% (w/v) SDS 16 ml
2-p-mercaptoethanol 4 ml
0.5 M Tris-HCl pH 6.8 10 ml
0.05% (w/v) bromophenol blue 2 ml
Made to 40 ml with distilled water.
4.4 Coomassie blue stain
Methanol 400 ml
Acetic acid 100 ml
Brilliant blue R (Sigma) 0.5 g
Made to 500 ml with distilled water.
4.5 Destain
Made according to that described for coomassie blue stain without the addition of 
Brilliant blue R.
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4.6 10 X Electrode buffer
Tris 30 g
Glycine 144 g
SDS 10 g
Made to 1 litre with distilled water, used 1 x electrode buffer for electrophoresis.
Appendix 5: Conductimetry solution
5.1 Bicine buffer
100 mM Bicine pH 8 25 ml
100 mM Magnesium acetate 3.75 ml
lOOmM ATP pH 7 1.25 ml (0.5mM)/
2.5 ml (ImM)
Made to 250 ml in deionised distilled water.
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2. Packard E. R., R. Parton, J. G. Coote, and N. K. Fry. 2004. Sequence variation 
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